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Chapter 1 
In this chapter, an overview of intranasal delivery systems for proteins and 
peptides will be presented. The use of chitosan-based polymers in the 
pharmaceutical field will be summarized. Additionally, polyelectrolyte-protein 
complexes as a new drug delivery carrier will be discussed. 
 
1.1 Intranasal delivery of proteins and peptides 
Since oral absorption of proteins and peptides is severely hampered by the 
high metabolic activity and low permeability of intestinal epithelial membranes 
(1), several mucosal surfaces such as the nasal, pulmonary and peroral mucosae 
are being extensively investigated as alternative routes for the systemic 
administration of macromolecular drugs (2). The nasal mucosa is receiving 
particular attention due to the successful introduction of several nasal peptide 
drug formulations such as buserelin and desmopressin to the market (Table 1) 
(3,4). All of these peptides are inactive after oral administration and nasal 
delivery is regarded as an attractive alternative to chronic injection therapy.  
 
Table 1. Nasal delivery of peptides and proteins (4) 
Drug substances Status 
Calcitonin salmon (MiacalcinTM )  
Desmopressin (DDAVPTM )       
Buserelin (SuprefactTM )         
Nafarelin (SynarelTM )           
PTH (parathyroid hormone)       
Leuprolide             
Insulin               
Interferon             
Influenza 
Diptheria & Tetanus 
Pertussis 
Marketed by Novartis  
Marketed by Ferring and partners 
Marketed by Aventis 
Marketed by Searle 
In clinical trials 
In clinical trials (utilize chitosan delivery system)
In clinical trials 
In clinical trials 
In clinical trials 
In clinical trials 
Preclinical 
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The nasal passage, spanning from the nostril to the nasopharynx, has a 
length of approximately 12-14 cm (5). The total volume is 15 ml and total 
surface area is 150 cm2. The nasal cavity itself is covered by 2 to 4 mm thick 
mucosa composed primarily of ciliated pseudostratified columnar epithelium 
covered by a layer of secreted mucus, which has a pH in the range of 5.5 to 6.5 
in adults, and from 5.0 to 6.5 in children (6,7). Compared to other 
non-parenteral routes, such as buccal, peroral, rectal, transdermal and vaginal, 
intranasal administration has following advantages (8,9): 
 Rapid absorption comparable to intramuscular injections due to highly 
vascularized mucosal surface. 
 Comparatively high bioavailability. 
 Bypass of first-pass hepatic metabolism. 
 Patient compliance, particularly suitable for self-medication. 
 Bypass of the blood brain barrier (BBB) and targeting of the central 
nervous system (CNS), reducing systemic exposure and thus systemic 
side effects. 
Due to these pronounced advantages, both macromolecules and small 
molecules are extensively studied for nasal delivery, as listed in Table 2 (9). 
Recently, Illum reviewed the possibilities of nasal drug delivery and discussed 
the problems and solutions (4). 
 
1.2 Insulin administration: current status 
Insulin is a protein composed of 2 polypeptide chains, A-chain (21 amino 
acids) and B-chain (30 amino acids), which are covalently bound to one another 
by disulfide bonds between cysteine residues. Its molecular weight is about 
6000. The primary structure of human insulin is shown in Figure 1. The charge 
of the insulin molecule depends upon pH. Below its isoelectronic point (pI, 
5.3-5.35), insulin has a net positive charge and is soluble at pH < 4.5. Above the 
pI insulin has a net negative charge and is soluble at pH > 6.3. Insulin forms 
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high molecular weight aggregates, i.e., hexamers and octamers at pH values 
close to its isoelectric point. 
 
    Table 2. Small molecules and macromolecules currently being studied for 
nasal delivery (9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chain A 
 GLY- ILE -VAL- GLU -GLN -CYS -CYS -THR- SER -ILE -CYS- SER -LEU - TYR -GLN -LEU -GLU -ASN -TYR -CYS -ASN    
PHE -VAL -ASN-GLN -HIS -LEU -CYS- GLY- ASP -HIS -LEU- VAL- GLU- ALA -LEU- TYR -LEU- VAL- CYS- GLY- GLU- ARG -GLY- 
PHE -PHE -TYR - THR -PRO -LYS -THR    
Chain B 
Figure 1. The primary structure of human insulin. 
 
Administrating insulin orally results in limited biological activity due to 
gastrointestinal proteolytic degradation of the peptide. Therefore, insulin is 
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generally administrated by subcutaneous injection. Whilst this route is 
satisfactory in terms of efficacy, severe reactions may occur after subcutaneous 
injections and many patients are reluctant to accept a regimen of daily injections 
(10). Other drawbacks include the possibility of inducing hyperinsulinemia, 
variations in the absorption of the peptide (up to 60%), and difficulty in 
simulating the fast release of endogenous insulin at mealtimes (11). Due to these 
problems, other delivery routes have been investigated such as oral, buccal, 
rectal, transdermal, intranasal and pulmonary (2). Among them, intranasal and 
pulmonary routes are the most promising. 
Interest in the nasal route has increased due to demonstrations that 
biologically active peptides show significant absorption across the nasal mucosa 
(Table 1). In fact, the nasal route has been recognized as an attractive alternative 
for the injection of insulin since 1922 (12). Additionally, intranasal 
administration of insulin potentially mimics the pulsatile endogenous secretion 
pattern of insulin (13). However, the efficacy of the nasal route for the 
absorption of insulin is low (14). Therefore, numerous attempts have been made 
to further improve the bioavailability of the intranasal administrated insulin. 
These include (15,16,17):  
 Protecting the peptide from enzymatic degradation by using 
antiproteolytic agents. 
 The use of a variety of different penetration enhancers. 
 Chemical modification of the peptide to improve stability. 
 Bioadhesive delivery systems to encourage prolonged contact 
between the drug and mucus membrane. 
 Carrier systems such as microspheres and nanoparticles. 
Amongst these, penetration enhancers appeared to have the most 
prominent effect. However, when they were used at appropriate concentrations 
for absorption, mucosal damage occured (18,19). Recently, chitosan was 
demonstrated to be an effective penetration enhancer without causing mucosal 
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damage. Additionally, it is mucoadhesive and nanoparticles can be obtained 
with this polymer. Therefore, it is anticipated that chitosan-based derivatives 
may considerably improve insulin absorption. The properties of chitosan and its 
potential application are described in the following section. 
 
1.3 Chitosan: its use in the pharmaceutical field 
Chitosan (poly[ β -(1-4)-2-amino-2-deoxy-D-glucopyranose]) is a 
biodegradable cationic polysaccharide produced by partial deacetylation of 
chitin derived from naturally occurring crustacean shells. The molecular 
formula is C6H11O4N and its structure is shown in Figure 2. The polymer is 
comprised of copolymers of glucosamine and N-acetyl glucosamine. The term 
chitosan embraces a series of polymers that vary in molecular weight (from 
approximately 10,000 to 1 million Dalton) and degree of deacetylation (in the 
range of 50-95%). Since chitosan displays mucoadhesive properties, strong 
permeation enhancing capabilities for hydrophilic compounds and a safe 
toxicity profile (20), it has received considerable attention as a novel excipient 
in drug delivery system and has been included in the European Pharmacopoeia 
since 2002. Its applications are summarized in Table 3. 
 
 
 Figure 2. Structure of chitosan. 
 
Despite its biocompatibility, the use of chitosan in biomedical fields are 
limited by its poor solubility in physiological media. Chitosan has an apparent  
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Table 3.  Applications of chitosan in the pharmaceutical field 
Conventional formulations                    Novel applications 
Direct compression tablets                    Bioadhesion 
Controlled release matrix tablets               Transmucosal drug transport 
Wet graduation                             Vaccine delivery 
Gels                                      Non-viral DNA delivery  
Films 
Emulsions 
Wetting agent 
Coating agent 
Microspheres and microcapsules 
Targeting 
 
pKa value between 5.5 and 6.5 and upon dissolution in acid media the amino 
groups of the polymer are protonated rendering the molecule positively charged. 
At neutral and alkaline pH, most chitosan molecules lose their charge and 
precipitate from solution. To improve the poor water-solubility of chitosan at 
physiological pH, several derivatives have been studied, For example, the 
modification of chitosan by quaternization of the amino groups (21, 22), 
N-carboxymethylation (23) and PEGylation (24, 25) have been reported. 
Additionally, other derivatizations of the amine functionalities of chitosan were 
performed to obtain polymers with a range of properties, as listed in Table 4. 
Moreover, chitosan was used to modify the surface of poly (D, L-lactic acid) 
(PDLLA) in order to enhance its cell affinity (37).  
 
Absorption enhancer. Numerous studies have demonstrated that 
chitosan and their derivatives are effective and safe absorption enhancers to 
improve mucosa delivery of hydrophilic macromolecules such as peptides and 
protein drugs (41). The degree of deacetylation and molecular weight of  
 7
Chapter 1 
 
Table 4. Studies using chitosan based delivery systems for hydrophilic 
macromolecular drugs* 
Polymers Delivery system/purpose Reference 
Chitosan Nanoparticle [26,27] 
 Microparticles [28,29] 
 DNA complex  [30] 
N-Trimethyl chitosan Absorption enhancer  [31,32] 
Mono-N-carboxymethylated chitosan Absorption enhancer [33]  
N-Alkylated chitosan DNA complex [34] 
N-Acetylated chitosan DNA complex [35] 
Galactosylated chitosan-graft-PEG DNA complex  [36] 
Deoxycholic acid-modified chitosan DNA complex [37] 
Chitosan-EDTA conjugates Peroral peptide delivery [38,39] 
Chitosan-coated liposomes  Insulin enteral absorption [40] 
PEG-g-chitosan Increase solubility  [24,25] 
* This is not a comprehensive list, but serves as an illustration of the broad scope of chitosan 
delivery systems. 
 
chitosan determine their absorption enhancing and cytotoxic properties (42,43). 
Chitosans with a high degree of deacetylation (DD) (85 to 99%) promote drug 
absorption at both low and high molecular weights but also show clear 
dose-dependent toxicity. On the other hand, chitosans with DDs of 51 to 65% 
only increase the absorption of drugs with high molecular weights and display 
low toxicity. Chitosan-based formulations can greatly improve the absorption of 
drugs from the nasal cavity, and products for the treatment of migraine and 
cancer pain have reached PhaseⅡ clinical evaluation (44). A Japanese patent 
reported that a nasal composition containing salmon calcitonin and chitosan 
(particle size 30-60 µm) was administered to normal human subjects to 
determine pharmacokinetics, and good bioavailability was obtained. A nasal 
solution formulation of chitosan greatly enhanced the absorption of insulin 
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across the nasal mucosa of rat and sheep (45). This effect was concentration 
dependent, with the optimal efficacy obtained for concentrations > 0.2% and 
0.5% in rats and sheep, respectively (45).  
Luessen et al. reported a plateau effect when chitosan glutamate was used 
as an absorption promoter (46). They reported that a maximum transport rate 
was reached at 0.4% (w/v). This observation was in agreement with results 
obtained with chitosan glutamate at pH values ranging between 4.9 and 6.0, 
where a plateau level in Papp (apparent permeability coefficient) was reached at 
polymer concentrations of 0.25 and 0.5% (w/v) (47). Such a plateau effect has 
also been found for nasal insulin absorption in sheep, where at a pH value of 4.4, 
chitosan glutamate in concentrations exceeding 0.4% (w/v) did not result in a 
stronger reduction of glucose levels (45). This is because, at an appropriate 
concentration of chitosan, the viscosity and the degree of mucoadhesion may 
have been sufficient to reach and maintain the required deposition 
characteristics in the nasal cavity (45). 
 It has also been demonstrated that the use of chitosan to promote the 
transport of drugs across the nasal membrane can be enhanced by employing 
chitosan powder formulations rather than solution formulations (48). Gamma 
scintigraphy demonstrated nasal clearance half times in the order of 25, 40 and 
80 minutes for a control solution, a chitosan solution and a chitosan powder, 
respectively (49). This is due to the fact that a delivery device such as a nasal 
spray or a nasal insufflator (powder administration device) will normally 
deposit the formulation in the anterior part of the nasal cavity, a region largely 
devoid of ciliated cells. The formulation will then be cleared to the back of the 
throat by the mucociliary clearance mechanism. Therefore, a bioadhesive 
system that can slow down the process of mucociliary clearance, thereby 
allowing a prolonged period of contact between the formulation and the nasal 
tissues is advantageous. Soane et al. described the clearance characteristics of 
two bioadhesive nasal delivery systems in the form of chitosan microspheres 
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and chitosan solution from the nasal cavity of conscious sheep (50). The data 
showed the control was cleared rapidly from the sheep nasal cavity, with a 
half-time of approximately 15 min. The bioadhesive chitosan delivery systems 
were cleared at a slower rate, with half times of clearance of 43 min and 115 
min, for the solution and microsphere formulations respectively. Consequently, 
chitosan delivery systems have the ability to increase the residence time of drug 
formulations in the nasal cavity, thereby providing the potential for improved 
systemic medication. Vila et al. coated PLGA nanoparticles with the 
mucoadhesive polymer chitosan and reported improved stability of the particles 
in the presence of lysozyme and enhanced nasal transport of the encapsulated 
tetanus toxoid; nanoparticles made solely of chitosan were also stable upon 
incubation with lysozyme and were particularly efficient in improving the nasal 
absorption of insulin (51).  
Mechanism. The absorption promoting effect of chitosan has been 
found to be a combination of mucoadhesion and a transient opening of the tight 
junctions in the mucosal cell membrane, as shown in Figure 3. The 
mucoadhesive properties of chitosan are a consequence of an interaction 
between the positively charged chitosan and negatively charged sialic acid 
groups on the mucin. Such interactions encourage prolonged contact time 
between the drug substance and the absorptive surface, thereby permitting the 
absorption of drug molecules via the paracellular (Figure 3a, 1), transcellular 
pathway (Figure 3a, 3), or through endo- and transcytosis (Figure 3a, 2). 
Generally, only small, hydrophilic molecules with a molecular weight below 
500 g/mol are able to penetrate via a paracellular pathway through the tight 
junction. Most compounds are absorbed via a transcellular pathway through the 
cell membrane of the epithelial cells due to the high surface area. Endo- and 
transcytosis is characterized by the engulfment of the extracellular material, 
followed by the pinching of the membrane vesicles from the plasma membrane 
(Figure 3a, 2). Adsorptive endocytosis of chitosan nanoparticles has previously  
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Figure 3.  Schematic overview of the mechanism of chitosan as a 
permeation enhancer. 
A. Mucoadhesion.  
B. Opening the tight junction. 
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been demonstrated (52).  
Tight junctions are located between apical and basolateral domains in 
epithelial cells, and appear as a continuous apical belt around the cell periphery. 
They regulate the passage of molecules across these natural barriers. Large 
molecular weight drugs need to pass through these tissue barriers in order to 
reach their targeted sites. As part of the body’s normal activity, tight junctions 
selectively open and close in response to various signals both inside and outside 
the cells. This permits the passage of large molecules across the tight junction 
barrier. On a molecular level, tight junctions consist of proteins, for example, 
claudins, occludins and junctional adhesion molecules. Such molecules are 
anchored in the membranes of two adjacent cells and interact with one other to 
hold the cells together, preventing other molecules from passing between them. 
In intact tight junctions, these proteins are strongly associated with the plasma 
membrane (53). However under conditions precluding tight junction formation, 
these proteins appear to be relocated from the membrane into other cellular 
compartments (Figure 3B). It has been shown in both cell culture (Caco-2) and 
animal models that chitosan is able to induce a transient opening of tight 
junctions, thus increasing membrane permeability particularly to polar drugs, 
including peptides and proteins (53). The opening of the tight junctions has been 
demonstrated by a loss of ZO-1 proteins and occludins from the cytosolic and 
membrane fractions into the cytoskeletal fraction (42, 54).  
Toxicity.  Although a number of investigations have been performed to 
elucidate the cytotoxicity of chitosan, the results were controversial. A series of 
toxicity studies indicated that chitosan was toxic, with the extent of toxicity 
being dependent upon the molecular weight, degree of deacetylation and salt 
form (55,56). By contrast, other investigations have suggested that the toxicity 
of chitosan is negligible, with experiments investigating the effects on cilia beat 
frequency (CBF) in guinea pigs after 28 days application, effect on mucociliary 
clearance rates on human nasal tissue and effect on nasal membranes in rats 
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(57-59). A ten-day acute toxicity study in rabbits showed neither macroscopic 
nor microscopic effects on organs or tissues, and oral toxicity of chitosan was 
reported to be 16 g/kg body weight (LD50) (49). The mucociliary clearance rate 
in man, measured by a saccharine clearance test, was found to be unaffected 
after daily nasal application of chitosan (49). 
 
1.4 Complexation between polyelectrolytes and proteins. 
In recent years, nanoparticles have increasingly been investigated as 
potential carriers for hydrophilic macromolecules such as proteins and vaccines. 
They are known to improve protein stability, and permit administration through 
non-parenteral routes (60-62). However, traditional methods for nanoparticle 
preparation require organic solvents or sonication, which may inactivate the 
proteins or cause the burst release effect. However, complexes formed by 
self-assembly between proteins and natural or synthetic polyelectrolytes do not 
require such harsh preparation methods, and have been the focus of many recent 
studies (63). In fact, protein-polyelectrolyte complexes (PEC) are not new, and 
have been used extensively in biology over many years for protein purification, 
immobilization and stabilization of enzymes (64). However, only recently has it 
been used as a drug carrier, especially for DNA condensation and complexation. 
Lee et al. reported that self-aggregated nanoparticles, prepared from 
hydrophobically modified chitosan, could find a potential application as a gene 
delivery vehicle due to the controlled complex formation with plasmid DNA 
(65). Chitosan and its derivatives are cationic polymers, and insulin was 
negatively charged at pH < pI, therefore complexes were formed at appropriate 
conditions and a new insulin carrier was obtained. 
    Until now, numerous techniques have been applied to the characterization 
of PEC, including turbidimetry, viscometry, analytical ultracentrifugation, 
size-exclusion chromatography, fluorescence spectroscopy, electrophoretic light 
scattering (ELS), static light scattering, electron-spin resonance, circular 
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dichroism, and dynamic light scattering (66). Parameters affecting the complex 
formation process have been described in detail in the literature (66). 
    
Aim and Scope 
   In this dissertation, the potential of PEGylated trimethyl chitosan block 
copolymers as intranasal delivery carriers of insulin will be investigated 
systematically. 
   The successful application of chitosan as an absorption enhancer for 
macromolecules and as gene delivery vehicle is dependent on the molecular 
weight, therefore, in Chapter 2, factors affecting the oxidative 
depolymerization of chitosan were investigated, and physicochemical properties 
of the resulting polymer fractions including their cytotoxicity were 
characterized. However, as an absorption enhancer, chitosan is only effective at 
pH < 6.5. In order to improve its solubility at physiological pH, trimethyl 
chitosan (TMC) of varying molecular weights were synthesized using the 
chitosan fragments from chapter 2 as starting materials in order to investigate 
the effect of TMC molecular weight on its absorption ability. Unfortunately, 
using the MTT assay, it was shown that TMC was toxic and its cytotoxicity was 
MW and dose dependent. To improve the biocompatibility of TMC, PEGylated 
trimethyl chitosan block copolymers were synthesized and characterized by 
nuclear magnetic resonance and infrared spectroscopy (Chapter 3). Using the 
MTT assay and LDH assay, the cytotoxicity of PEGylated TMC copolymers 
was studied and compared with that of TMC in Chapter 4. PEGylation 
considerably decreased the cytotoxicity of TMC, and several copolymers were 
selected for further studies. It is well known that nanoparticles are a promising 
delivery system for peptides and proteins. To overcome the disadvantage of the 
traditional method for nanoparticle preparation, self-assembled insulin 
nanocomplexes were prepared with chitosan derivatives, the mechanism for 
complex formation was elucidated, and the process parameters were optimized 
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(Chapter 5). To investigate the potential of the polymer-insulin nanocomplexes 
as intranasal delivery carriers, uptake and transport studies of the complexes in 
Caco-2 monolayers were performed and the effect of polymer structure, 
polymer molecular weight, and charge density was evaluated. Moreover, the 
complex-uptake mechanism was investigated in detail and further demonstrated 
by confocal laser scanning microscopy (Chapter 6). A summary and prospects 
for further investigations is presented in the last chapter. 
 
References  
[1]  A.N. Fischer, The effect of molecular size on the nasal absorption of water soluble 
compounds in the albino rat,  J. Pharm. Pharmacol. 39 (1987) 357-362. 
[2]  D.R. Owens, B. Zinman, G. Bolli, Alterative routes of insulin delivery, Diabetic 
Medicine 20 (2003) 886-898. 
[3]  C.R. Behl, H.K. Pimplaskar, A.P. Sileno, W.J. Xia, J.C. Gries and V.D. Romeo, 
Optimization of systemic nasal drug delivery with pharmaceutical excipients, Adv. 
Drug Del. Rev. 29 (1998) 117-133. 
[4]  L. Illum, Nasal drug delivery-possibilities, problems and solutions, J. Controlled Rel. 
87 (2003) 187-198. 
[5] Y.V. Prasad, Intranasal drug delivery systems: an overview, Indian Journal of 
Pharmaceutical Science 58 (1996) 1-8. 
[6]  S.S. Hehar, J.D.T. Mason, A.B. Stephen, N. Washington, N.S. Jones, S.J. Jackson, 
Twenty four hour ambulatory nasal pH monitoring, Clin. Otolaryngol. 24 (1999) 
24-25. 
[7]  A.E. Pontiroli, Intranasal drug delivery: potential advantages and limitations from a 
clinical pharmacokinetic perspective, Clinical Pharmacokinetics 17 (1989) 299-307. 
[8]  P. Edman, E. Björk and L. Rydén, Microspheres as a nasal delivery system for peptide 
drugs,  J. Controlled Rel. 21 (1992) 165-172. 
[9]  S. Talegaonkar, P.R. Mishra, Intranasal delivery: an approach to bypass the blood brain 
barrier, Indian J. Pharmacol. 36 (2004) 140-147. 
[10]  A.E. Pontiroli, Insulin given intranasally induces hypoglycemia in normal and diabetic 
subjects, Br. Med. J. 284 (1982) 303-306.  
[11]  N.F. Farraj, Nasal administration of insulin using bioadhesive microspheres as a 
 15
Chapter 1 
delivery system, J. Controlled Rel. 13 (1990) 253-261. 
[12]  R.T. Woodyatt, The clinical use of insulin, J. Metab. Res. 2 (1922) 793. 
[13]  L. Illum and S. Davis, Intranasal insulin, Clinical pharmacokinetics 23 (1992) 30-41. 
[14]  A.E. Pontiroli, Intranasal administration of calcitonin and of other peptides: Studies 
with different promoters,  J. Controlled Rel. 13 (1990) 247-251.  
[15]  F.W.H.M. Merkus, N.G. M Schipper, J.C. Verhoef, The influence of absorption 
enhancers on intranasal insulin absorption in normal and diabetic subjects, J. 
Controlled Rel. 41 (1996) 69-75.  
[16]  V.H.L. Lee, Protease inhibitors and penetration enhancers as approaches to modify 
peptide absorption,  J. Controlled Rel. 13 (1990) 213-223. 
[17]  L. Rydén and P. Edman, Effect of polymers and microspheres on the nasal 
absorption of insulin in rats,  Int. J. Pharm. 83 (1992) 1-10.  
[18]  L. Jian and A. Li Wan Po, Effects of insulin and nasal absorption enhancers on 
ciliary activity,  Int. J. Pharm. 95 (1993) 101-104. 
[19]  N.G. M. Schipper, J. Verhoef, S.G. Romeijn and F.W.H.M. Merkus, Absorption 
enhancers in nasal insulin delivery and their influence on nasal ciliary functioning,  J. 
Controlled Rel. 21 (1992) 173-186. 
[20]  A.K. Singla, M. Chawla, Chitosan: some pharmaceutical and biological aspects-an 
update, J. Pharm. Pharmacol. 53 (2001) 1047-1067. 
[21]  A.B. Sieval, M. Thanou, A.F. Kotze,  J.C. Verhoef, J. Brussee, H.E. Junginger, 
Preparation and NMR characterization of highly substituted N-trimethyl chitosan 
chloride, Carbohydrate Polymers 36 (1998) 157-165. 
[22]  P. Le Dung, M. Milas, M. Rinando, J. Desbrieres, Water soluble derivatives obtained 
by controlled chemical modification of chitosans, Carbohydrate Polymers 24 (1994) 
209-214. 
[23]  R.A.A. Muzzarelli, F. Tanfani, and M. Emanuelli, N- (carboxymethylidene) chitosans 
and N-(carboxymethyl) chitosans: novel chelating polyampholytes obtained from 
chitosan glyoxylate, Carbohydr. Res. 107 (1982) 199-214. 
[24]  H. Saito, X. Wu, J. Harris, A. Hoffman, Graft copolymers of poly (ethylene 
glycol)(PEG) and chitosan, Macromol. Rapid Commun. 18 (1997) 547-550. 
[25]  Y. Ohya, R. Cai, H. Nishizawa, K. Hara and T. Ouchi, Preparation of PEG-grafted 
chitosan nanoparticles as peptide drug carriers, S.T.P. Pharma. Science 10 (2000) 
77-82. 
[26]  Y. Xu, Y. Du, Effect of molecular structure of chitosan on protein delivery properties 
 16
Introduction  
of chitosan nanoparticles,  Int. J. Pharm. 250 (2003) 215-226. 
[27]  R. Fernández-Urrusuno, P. Calvo, C. Remuñán-López, J. L. Vila-Jato, M.J. Alonso, 
Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm. Res. 
16 (1999) 1576-1581. 
[28]  V.R. Sinha, A.K. Singla, S. Wadhawan, R. Kaushik, R. Kumria, K. Bansal, S. 
Dhawan, Chitosan microspheres as a potential carrier for drugs. Int. J. Pharm. 274 
(2004) 1-33. 
[29]  S. Özba -Turan, J. Akbu a, C. Aral, Controlled release of interleukin-2 from chitosan 
microspheres, J. Pharm. Sci. 91 (2002) 1245-1251. 
[30]  S. Gao, J. Chen, X. Xu, Z. Ding, Y. Yang, Z. Hua, J. Zhang, Galactosylated low 
molecular weight chitosan as DNA carrier for hepatocyte-targeting, Int. J. Pharm. 255 
(2003) 57-68. 
[31]  A.R. Kotzé, H.L. Lueβen, B.J. de Leeuw, Bert G. de Boer, J.C. Verhoef, H.E. 
Junginger, N-Trimethyl chitosan chloride as a potential absorption enhancer across 
mucosal surfaces: In vitro evaluation in intestinal epithelial cells (Caco-2), Pharm. 
Res.  14 (1997) 1197-1202. 
[32]  J.H. Hamman, M. Stander, A.F. Kotzé, Effect of the degree of quaternisation of 
N-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat 
nasal epithelia, Int. J. Pharm. 232 (2002) 235-242. 
[33] M. Thanou, M.T. Nihot, M. Jansen, J.C. Verhoef, H.E. Junginger, 
Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, 
enhances the intestinal absorption of low molecular weight heparin across intestinal 
epithelia in vitro and in vivo, J. Pharm. Sci. 90 (2001) 38-46. 
[34]  W. Liu, X. Zhang, S. Sun, G. Sun, K. De Yao, D. Liang, G. Guo, and J. Zhang, 
N-Alkylated chitosan as a potential nonviral vector for gene transfection, 
Bioconjugate Chem. 14 (2003) 782-789. 
[35]  E. Kai,  T. Ochiya, A method for oral DNA delivery with N-Acetylated chitosan, 
Pharm. Res. 21 (2004) 838-843. 
[36]  I.K. Park, T.H. Kim, Y.H. Park, B.A. Shin, E.S. Choi, E.H. Chowdhury, T. Akaike, 
C.S. Cho, Galactosylated chitosan-graft-poly (ethylene glycol) as 
hepatocyte-targeting DNA carrier, J. Controlled Rel. 76 (2001) 349-362. 
[37]  K. Cai, K. Yao, Y. Cui, S. Lin, Z. Yang, X. Li, H. Xie, T. Qing, J. Luo, Surface 
modification of poly (D,L-lactic acid) with chitosan and its effects on the culture of 
osteoblasts in vitro, J. Biomed. Mater. Res. 60 (2002) 398-404.  
 17
Chapter 1 
[38]  A. Bernkop-Schnürch, M.E. Krajicek, Mucoadhesive polymers as platforms for 
peroral peptide delivery and absorption: synthesis and evaluation of different 
chitosan–EDTA conjugates, J. Controlled Rel. 50 (1998) 215-223. 
[39]  A. Bernkop-Schnürch, A. Scerbe-Saiko, Synthesis and in vitro evaluation of 
chitosan-EDTA-protease-inhibitor conjugates which might be useful in oral delivery 
of peptides and proteins, Pharm. Res. 15 (1998) 263-269. 
[40]  H. Takeuchi, H. Yamamoto, T. Niwa, T. Hino, Y. Kawashima, Enteral absorption of 
insulin in rats from mucoadhesive chitosan-coated liposomes, Pharm. Res. 13 (1996) 
896-901. 
[41]  M. Thanou, J.C. Verhoef, H.E. Junginger, Oral drug absorption enhancement by 
chitosan and its derivatives, Adv. Drug Deliv. Rev. 52 (2001) 117-26.  
[42]  N.G. M. Schipper, S. Olsson, J.A. Hoogstraate, A.G. deBoer, K.M. Vårum, Per 
Artursson, Chitosans as absorption enhancers for poorly absorbable drugs 2: 
Mechanism of absorption enhancement, Pharm. Res. 14 (1997) 923-929.  
[43]  N.G. M. Schipper, K.M. Vårum, Per Artursson, Chitosans as absorption enhancers for 
poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation 
on drug transport across human intestinal epithelial (Caco-2) cells, Pharm. Res. 13 
(1996) 1686-1692. 
[44]  L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A.N. Fisher and S.S. Davis, Chitosan as a 
novel nasal delivery system for vaccines, Adv. Drug Delivery Rev. 51 (2001) 81-96. 
[45]  L. Illum, N.F. Farraj, S. S. Davis, Chitosan as a novel nasal delivery system for 
peptide drugs, Pharm. Res. 11 (1994) 1186-1189. 
[46]  H.L. Lueβen, C.O. Rentel, A.F. Kotzé, C.M. Lehr, A.G. de Boer, J.C. Verhoef, H.E. 
Junginger, Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil 
and chitosan are potent enhancers of peptide transport across intestinal mucosae in 
vitro, J. Controlled Rel. 45 (1997) 15-23. 
[47]  P. Artursson, T. Lindmark, S. S. Davis, L. Illum, Effect of chitosan on the 
permeability of monolayers of intestinal epithelial cells (Caco-2), Pharm. Res. 11 
(1994) 1358-1361. 
[48]  L. Illum, Chitosan and its use as a pharmaceutical excipient, Pharm. Res. 15 (1998) 
1326-1331. 
[49]  R.J. Soane, M. Frier, A.C. Perkins, N.S. Jones, S.S. Davis, L. Illum, Evaluation of the 
clearance characteristics of bioadhesive systems in humans, Int. J. Pharm. 178 (1999) 
55-65. 
 18
Introduction  
[50]  R.J. Soane, M. Hinchcliffe, S.S. Davis, L. Illum, Clearance characteristics of 
chitosan based formulations in the sheep nasal cavity,  Int. J. Pharm. 217 (2001) 
183-91. 
[51]  A.Vila, A. Sánchez, M. Tobío, P. Calvo, M.J. Alonso, Design of biodegradable 
particles for protein delivery, J. Controlled Rel. 78 (2002) 15-24. 
[52]  M. Huang, Z. Ma, E. Khor, L. Lim, Uptake of FITC-chitosan nanoparticles by A549 
cells,  Pharm. Res. 19 (1999) 1488-1494. 
[53]  V. Dodane, M. Amin Khan, J. R. Merwin, Effect of chitosan on epithelial 
permeability and structure, Int. J. Pharm. 182 (1999) 21-32. 
[54]  J. Smith, E. Wood, M. Dornish, Effect of chitosan on epithelial cell tight junctions, 
Pharm. Res. 21 (2004) 43-49. 
 [55]  D. Sgouras and R. Duncan, Methods for the evaluation of biocompatibility of soluble 
synthetic polymers which have potential for biomedical use. 1 Use of the 
tretazolium-based colorimetric assay (MTT) as a preliminary screen for evaluation of 
in vitro cytotoxicity, J. Mater. Sci. Mater. Med. 1 (1990) 61-68. 
[56]  B. Carreño-Gómez, R. Duncan, Evaluation of the biological properties of soluble 
chitosan and chitosan microspheres. Int. J. Pharm. 148 (1997) 231-240. 
[57]  T. Aspden, L. Illum and φ. Skaugrud, Chitosan as a nasal delivery system: 
Evaluation of insulin absorption enhancement and effect on nasal membrane 
integrity using rat models, Eur. J. Pharm. Sci. 4 (1996) 23-31. 
[58]  T. Aspden, J.D.T. Mason, N.S. Jones, J. Lowe, φ. Skaugrud, L. Illum, Chitosan as a 
nasal delivery system: The effect of chitosan solutions on in vitro and in vivo 
muco-ciliary transport rates in human turbinates and volunteers, J. Pharm. Sci. 86 
(1997) 509-513. 
[59]  T. Aspden, L. Illum and φ. Skaugrud, The effect of chronic nasal application of 
chitosan solution on cilia beat frequency in guinea pigs, Int. J. Pharm. 153 (1997) 
137-146. 
[60]  M. Tobío, R. Gref, A. Sánchez, R. Langer, M. J. Alonso, Stealth PLA-PEG 
nanoparticles as protein carriers for nasal administration, Pharm. Res. 15 (1998) 
270-275.  
[61]  Z. Cui, R.J. Mumper, Microparticles and nanoparticles as delivery systems for DNA 
vaccines, Crit. Rev. Ther. Drug Carrier Syst. 20 (2003) 103-137. 
[62]  S. Sakuma, M. Hayashi, M. Akashi, Design of nanoparticles composed of graft 
 19
Chapter 1 
copolymers for oral peptide delivery, Adv. Drug Deliv. Rev. 47 (2001) 21-37. 
[63]  H. Mao, K. Roy, Vu L. Troung-Le, K.A. Janes, K.Y. Lin, Y. Wang, J. T. August, K.W. 
Leong, Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization 
and transfection efficiency, J. Controlled Rel. 70 (2001) 399-421. 
[64]  Y. Wen and P. L. Dubin, Potentiometric studies of the interaction of bovine serum 
albumin and poly (dimethyldiallylammonium chloride), Macromolecules 30 (1997) 
7856-7861. 
[65]  K.Y. Lee, I.C. Kwon, Y.H. Kim, W.H. Jo, S.Y. Jeong, Preparation of chitosan 
self-aggregates as a gene delivery system, J. Controlled Rel. 51(1998) 213-220. 
[66]  P. Dubin, J. Bock, R. Davis, D.N. Schulz, C. Thies, Macromolecular complexes in 
chemistry and biology, Springer-Verlag Berlin Heidelberg (1994) 119-324. 
 
 20
  
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
The depolymerization of chitosan: Effects on 
physicochemical and biological properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
International Journal of Pharmaceutics 2004, 281(1-2), 45-54 
 
Chapter 2 
Abstract 
Chitosan has been extensively used as an absorption enhancer for 
macromolecules and as gene delivery vehicle. Both properties are molecular 
weight dependent. Here we investigate factors affecting the oxidative 
depolymerization of chitosan and physicochemical properties of the resulting 
polymer fractions including their cytotoxicity. The molecular weight of the 
depolymerized chitosan was influenced by the initial concentration and the 
source of chitosan. At constant initial concentrations, the molecular weight 
decreased linearly with the chitosan/NaNO2 ratio and was a function of 
logarithm of the reaction time. Chitosan with larger molecular weight was more 
sensitive to depolymerization. No structural change was observed during the 
depolymerization process by infrared and proton nuclear magnetic resonance 
spectroscopy. In addition, thermal properties of chitosan fragments were studied 
by thermal gravimetric analysis and it was found that the decomposition 
temperature was molecular weight dependent. Furthermore, the solubility of 
different molecular weight chitosan was assayed as a function of pH and it 
increased with decreasing molecular weight. The cytotoxicity of chitosan was 
concentration dependent but almost molecular weight independent according to 
MTT assay using L929 cell line recommended by USP 26. In summary, low 
molecular weight fractions of chitosan may potentially useful for the design of 
drug delivery systems due to the improved solubility properties. 
  
1. Introduction 
Chitosan (poly[ β -(1-4)-2-amino-2-deoxy-D-glucopyranose]) is a 
non-toxic and biocompatible cationic polysaccharide produced by partial 
deacetylation of chitin isolated from naturally occurring crustacean shells. Due 
to its specific properties, chitosan has found a number of applications in drug 
delivery including that of as an absorption enhancer of hydrophilic 
macromolecular drugs (Artursson et al., 1994; Illum et al., 1994; Lueßen et al., 
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1996; Singla et al., 2001) and as gene delivery system (Erbacher et al., 1998; 
Richardson Simon et al., 1999). 
The term chitosan embraces a series of polymers, which vary in 
molecular weight (MW) and degree of deacetylation (DD). Although a number 
of investigations have been performed to elucidate the relationship between 
MW and cytotoxicity, the results were controversial. A series of toxicity studies 
indicated that chitosan was toxic and the toxicity was dependent upon their 
molecular weight, degree of deacetylation and salt form (Sgouras et al., 1990; 
Heller et al., 1996; Carrecuno-Gomez et al., 1997). By contrast, other 
investigations suggested that the toxicity of chitosan was negligible (Aspden et 
al., 1995, 1996, 1997a, 1997b). Additionally, the transfection efficiency of 
chitosan with molecular weight >100 kDa was reduced compared to 15 and 52 
kDa and chitosans of 10-50 kDa seem to be promising as gene transfer reagents 
(Sato et al., 2001). Lee et al. (2001) indicated that low molecular weight 
chitosan (molecular weight of 22 kDa) showed higher transfection efficiency 
than poly-L-lysine. 
     However, most commercially available chitosans possess quite large 
MWs. Due to promising properties of low molecular weight chitosans in the 
pharmaceutical field, it is essential to establish a reproducible and 
straightforward method for generating low MW chitosans. Generally, low 
molecular weight chitosans can be prepared from high molecular weight 
chitosan by depolymerization using enzymatic degradation (Chang et al., 1998), 
oxidative degradation (Li et al., 1999), acidic cleavage and ultrasonic 
degradation (Chen et al., 2000). The rate of molecular weight degradation was 
irregular during the time course of ultrasound treatment. Liu studied the 
depolymerization of chitosan using NaNO2, H2O2, and HCl. They found that 
NaNO2 showed the best performance (Liu et al., 1997). These results were 
recently confirmed, but no detailed experimental information was provided 
(Janes et al., 2003).  
 23
Chapter 2 
     The purpose of this paper, therefore, is to study the factors affecting the 
depolymerization process of chitosan using sodium nitrite and to clarify the 
relationship between chitosan MW and cytotoxicity. Using intrinsic viscosity 
measurements, these factors were investigated systematically and the structure 
identification of chitosan during depolymerization was performed with IR and 
1H NMR methods. In addition, the solubility of different chitosans was 
characterized as a function of pH value. The cytotoxicity of chitosans was 
characterized by MTT assay using L929 fibroblast cell line.  
 
2. Materials and methods 
2.1 Materials 
Three different commercially available chitosans F-LMW (150 kDa), 
F-MMW (400 kDa), F-HMW (600 kDa), with a nominal degree of 
deacetylation of 84.5%, 84.7%, and 85.0% respectively, were purchased from 
Fluka (Neu-Ulm, Germany).  Acetic acid (HAc), sodium acetate (NaAc), 
sodium hydroxide (NaOH) and sodium nitrite (NaNO2) were of analytical grade. 
Dulbecco’s modified Eagle’s medium (DMEM) was obtained from Gibco 
(Eggenstein, Germany). 3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium 
bromide (MTT) was purchased from Sigma (Deisenhofen, Germany), 
dimethylsulfoxide (DMSO) was from Merck (Darmstadt, Germany). 
The chitosans selected for this study had similar degrees of deacetylation, 
but differed markedly in their molecular weights. The degrees of deacetylation, 
viscosity average molecular weights, and moisture contents of the commercial 
chitosans used in this study were determined experimentally and compared with 
the values reported by the supplier, as listed in Table 1.  
 
2.2 Depolymerization of chitosan 
The low molecular weight chitosans were prepared by oxidative 
degradation with NaNO2 at room temperature. Briefly, 1% (W/W) chitosan was 
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dissolved in 1% acetic acid solution under magnetic stirring. When chitosan was 
completely dissolved, the appropriate amount of 0.1 M NaNO2 , as indicated 
below, was added dropwise and the reaction was performed at room temperature 
for 3 h unless indicated otherwise. The reaction mixture was subsequently 
neutralized with 1N NaOH to pH 8.0 to precipitate chitosan. The precipitated 
chitosan was recovered by centrifugation, washed several times with deionized 
water, and dried by lyophilisation.  
 
Table 1. Characteristics of chitosans used in this study 
Degree of deacetylation (%) Molecular weight (kDa) Moisture content (%) Chitosan 
Labeleda Determinedb Labeleda Determinedc Labeleda Determinedd
F-LMW 84.5 83.0 150   225 ≤10% 10.0 
F-MMW 84.7 85.1 400 540 ≤10% 10.4 
F-HMW 85.0 84.9 600 610 ≤10% 10.3 
a Values supplied by the supplier. 
b Determined by 1H NMR. 
c Calculated from the intrinsic viscosity using the classical Mark-Houwink equation  
[η] = K (Mv)a , where the constants K = 1.38*10-5 and a = 0.85. 
d Calculated from TGA measurement. 
 
2.3 Characterization of chitosan  
    Fourier Transformed Infrared Spectroscopy (FTIR) was conducted on a 
FT-IR 510P spectrometer (Nicolet) in the range between 4000 and 400 cm-1, 
with a resolution of 2 cm-1. All powder samples were compressed into KBr 
disks for the FTIR measurement. 
Thermogravimetric Analysis (TGA) was performed on a 
thermogravimetric analyser TGA 7 with a thermal analysis controller TAC 
7/DX from Perkin-Elmer using an approximately 5 mg polymer sample. The 
scanning rate was 20℃/min, and the thermograms were recorded within the 
temperature range 30-550℃. Analysis was performed under a nitrogen gas 
atmosphere in platinum crucibles. 
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2.4 Determination of intrinsic viscosity 
Intrinsic viscosity of chitosans in 2% HAc/0.2M NaAc were measured 
using an automated Ubbelohde capillary viscometer (Model Schott AVS-360, 
Germany) in a constant-temperature water bath at 25±0.01℃ in triplicate. The 
capillary diameter used was 0.63 mm. Solution concentrations were adjusted 
based on the viscosity of the samples and the flow through time was kept in the 
range of 100-150 s. Six different concentrations were tested for each sample. 
The intrinsic viscosity was determined by the common intercept of both 
Huggins (ηsp/C~C) and Kraemer (ηinh~C) plots on the ordinate at C=0. As a 
representative example, the intrinsic viscosity calculation method of HMW 
chitosan was shown in Figure 1. 
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Figure 1.   A representative plot for intrinsic viscosity calculation (HMW chitosan). Bothη
sp/C andηinh are plotted on the same graph and the common intercept of the plots 
on the ordinate at C=0 is the intrinsic viscosity. 
 
While reduced viscosity of polymers is defined as: 
   
Ct
tt
Csp ⋅
−=
0
0η  
and inherent viscosity is defined as: 
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C
tt
inh
)ln( 0=η  
where t0 is the flow time for solvent and t is the flow time for tested solution. 
Bothηsp/C andη inh are plotted on the same graph in Figure 1. The 
common intercept of the plots on the ordinate at C=0 gives: 
  [η] = (ηsp/C) c=0  = (ηinh) c=0 = 1.168 L/g 
The viscosity average molecular weights of chitosans were calculated 
using the classical Mark-Houwink equation: 
[η] = K (Mv)a 
where [η] is the intrinsic viscosity of the depolymerized chitosan, K and a are 
constants for given solute-solvent system and temperature. For chitosan, they 
are influenced by the degree of deacetylation, pH, and ionic strength of the 
solvent (Kasaai et al., 2000). As to the chitosans with a DD value of 85%, the 
constants K=1.38*10-5 and a=0.85 were reported (Gamzazade et al., 1985). The 
viscosity-average molecular weight of the HMW chitosan was therefore 
calculated as follows: 
        610)
1038.1
168.1( 85.0/15 ≈×= −vM kDa 
 
2.5 Determination of degree of deacetylation (DD) 
In order to assess any structure modification occurred during the 
depolymerization process, the structure of original chitosans and the 
depolymerized chitosans were determined by 1H NMR spectroscopy and 
infrared spectrum. 1H NMR spectra were recorded on a FT-NMR spectrometer 
(AMX500, 500 MHz, Bruker) at 80℃ using D2O containing 5% CD3COOD as 
the solvent. The NMR experiment was performed at higher temperatures in 
order to shift the signal of HOD to a higher field, which allowed quantifying the 
H1 signals of glucosamine residues. The samples were dissolved at a 
concentration of 10 mg/ml. The DD was determined from the integral of the 
 27
Chapter 2 
CH3 signal at 1.97 ppm compared with that of H-1 signals of glucosamine and 
N-acetylglucosamine (Varum et al., 1991). 
 
2.6 Solubility testing 
   Solubility of various chitosans was measured at different pH values. Briefly, 
chitosans were dissolved in 0.25% HAC solution (2 mg/ml), the pH of the 
solution was adjusted by the addition of 1N NaOH solution and the 
transmittance of the solution at 600 nm as a function of pH value was recorded 
on a UV/Vis spectrophotometer (UV-160, Shimadzu) (Park et al., 2003). Cloud 
point pH values, which are defined as the pH when the transmittance was no 
less than 98%, were determined at the same time (Anderson et al., 2002) in 
triplicate.  
 
2.7 Cytotoxicity testing (MTT assay) 
A mouse connective tissue fibroblast cell line, L929 was selected to 
evaluate cytotoxicity as a direct contact test, as recommended by USP 26. The 
experiment was carried out according to the method described previously 
(Fischer et al., 1999). Briefly, L929 was cultured in DMEM supplemented with 
10% fetal calf serum and 2 mM glutamine without antibiotics. The cells were 
cultivated in an incubator at 37℃, 95% RH and 10% CO2 . Chitosan was first 
dissolved in 0.5% HAC solution, and then diluted with equal volume of double 
DMEM medium. The pH of this stock solution was adjusted to 6.5 for all the 
chitosans tested. Thereafter, DMEM (pH 6.5) was used to prepare serial 
dilutions of the polymer. L929 cells were seeded into 96-well microtiter plates 
at a density of 8000 cells/well. 24 hour later, culture medium was replaced with 
100 µl serial dilutions of chitosan (0.6-10 mg/ml) and cells were incubated for 
24 h. Subsequently, 20 µl MTT (5 mg/ml) was added to each well. After 4 h, 
unreacted dye was aspirated and the formazon crystals were dissolved in 200 
µl/well DMSO. Absorption was measured at 570 nm with a background 
 28
Depolymerization of chitosan 
correction at 690 nm using a Titertek Plus MS 212 ELISA reader (ICN, 
Eschwege, Germany). The relative cell viability compared to control cells 
containing cell culture medium (pH 6.5) without polymer was calculated by [A] 
test/[A] control (n = 7).   
 
2.8 Calculations and statistics 
Results are depicted as mean±SD from at least three measurements. 
Significance between the mean values was calculated using ANOVA one-way 
analysis (Origin 7.0 SRO, Northampton, MA, USA). Probability values P < 0.05 
were considered significant. 
 
3. Results and discussion 
3.1 Depolymerization of chitosan 
  The concentration of sodium nitrite could be expected to play a significant 
role in the depolymerization process. In order to facilitate the control of the 
molecular weight of chitosan fragment, keeping chitosan concentration at 1%, 
the depolymerization was carried out in a 1% acetic acid solution by varying 
chitosan / NaNO2 molar ratio, using three types of chitosan as original material. 
The relationship between chitosan / NaNO2 molar ratio and the MW of chitosan 
fragment is shown in Figure 2. 
Regression analysis of chitosan/NaNO2 molar ratio as a function of the 
molecular weight of chitosan fragment yielded an almost linear correlation with 
correlation coefficients of 0.98, 0.99 and 0.97 for chitosan LMW, MMW, HMW, 
respectively. Furthermore, from the slope of the profiles, one can conclude that 
HMW chitosan is more sensitive to NaNO2 degradation compared to LMW 
chitosan. This may be explained by larger molecular dimensions of HMW 
chitosan in solution, which increases the contact area with NaNO2.  
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Figure 2.   The relationship between chitosan/NaNO2 molar ratio and chitosan molecular 
weight. (◆) chitosan 150 kDa; (■) chitosan 400 kDa; (▲) chitosan 600 kDa. 
The measurements were carried out in triplicate and the results are expressed as 
mean±SD. Different molecular weight chitosans (1%) were degraded by sodium 
nitrite in 1% acetic acid solution for 3 h at room temperature. 
 
3.2 Effect of reaction time on the molecular weight of chitosan 
In order to investigate the effect of reaction time, keeping chitosan 
/NaNO2 molar ratio at 0.009, chitosan (1%) was degraded by NaNO2 in 1% 
acetic acid solution and the reaction was stopped at 1, 2, 3 and 6 h respectively, 
and the corresponding samples were processed in the same way as that 
described before. LMW and MMW chitosan were used as starting materials. 
The intrinsic viscosities of the samples were determined and the molecular 
weights were calculated according to the MHS equation. The results are 
illustrated in Figure 3. 
It was noted that the depolymerization occurred mainly in the first hour, 
and then slowed down significantly. This behavior was expected since the 
concentration of sodium nitrite decreased with the reaction time. Moreover, it 
could be deduced from the slope that MMW chitosan was more sensitive to 
NaNO2 degradation compared with that of LMW chitosan. In addition, the 
molecular weight of depolymerized chitosans was plotted versus the logarithm 
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of the reaction time, and a linear relationship was observed with correlation 
coefficients 0.9991 and 0.9985 respectively for LMW and MMW chitosan, 
indicating that the degradation process belongs to first-order kinetics.  
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Figure 3.   Effect of reaction time on the molecular weight of depolymerized chitosan. 
(■) low MW chitosan.  (◆) medium MW chitosan.  The measurements were 
carried out in triplicate and the results are expressed as mean±SD. Chitosan (1%) 
was degraded in 1% acetic acid solution with chitosan/NaNO2 molar ratio 0.009.  
 
3.3 Effect of chitosan initial concentration  
In order to investigate whether chitosan/NaNO2 molar ratio and reaction 
time were the only factors influencing the molecular weight of chitosan 
fragment, taking MMW chitosan as an example, the chitosan/NaNO2 molar 
ratio was kept at 0.009 and reaction time 3 hours, two different chitosan initial 
concentrations, 0.5% and 1% respectively, were studied. The results are shown 
in Figure 4, with regression coefficients of 0.99 and 0.97 respectively for 1% 
and 0.5% initial concentrations of chitosan. 
It seems that the depolymerization of chitosan was not only influenced 
by the ratio of chitosan/NaNO2, but also by the initial concentration of chitosan. 
When the concentration was low, chitosan was more sensitive to 
depolymerization despite of the same chitosan/NaNO2 ratio. This phenomenon 
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is related to the structure of chitosans in solution. Normally chitosans take the 
shape of an extended random coil in solution. When the concentration is high, 
due to the larger viscosity of the solution and strong intermolecular interactions, 
accessible chain segments can only stretch in a limited area, decreasing the 
contact probability with sodium nitrite, thus resulting in a lower degradation 
rate. In this case, low chitosan concentration would be preferred to yield very 
small molecular weight chitosan in a short time. 
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Figure 4.   Effect of MMW chitosan initial concentration on the molecular weight of  
chitosan fragments. (■) 0.5% , (◆) 1.0%.  The measurements were carried out 
in triplicate and the results are expressed as mean±SD. Medium molecular 
weight chitosans were degraded in 1% acetic acid solution with different 
chitosan/NaNO2 ratios for 3 h at room temperature. 
 
3.4 Investigation on the reproducibility of the degradation process 
While the reproducibility of a method is of extremely importance, 
chitosan samples of LMW and MMW were degraded in triplicate to test the 
deviation of this oxidative degradation method. The chitosan/NaNO2 molar ratio 
was adjusted based on the purposed molecular weight of chitosan. Briefly, 1% 
chitosan was degraded in 1% acetic acid solution for 3 h with chitosan/NaNO2 
molar ratio 0.004 and 0.009 respectively for LMW and MMW chitosans to get 
different molecular weight products. The resulting molecular weights were 2800
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±200 and 49000±3600 respectively. Coefficients of variation for both samples 
were approximately 7% and no significant difference was indicated by t-test in 
the same array. Consequently, it could be concluded that this method has a good 
reproducibility and can be used to prepare chitosans with desired molecular 
weight. 
 
3.5 Structure identification during the depolymerization process 
In order to investigate any structural changes during the 
depolymerization process, IR spectra of the depolymerized chitosans were 
recorded, as shown in Figure 5.  
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Figure 5.  IR spectra of chitosan fragment with different molecular weights.  
 
The IR spectrum clearly shows that the process has no significant influence 
on the structure. In case of great changes in the DD value, there should be some 
change in the absorption bands a (3253 cm-1) and b (3143 cm-1) which increase 
with decreasing DD. T
intermolecular C (21) NH
b indicates the reductio
  he decrease of peak a indicates the reduction of 
---O=C (73) hydrogen bonds, and the decrease of peak 
n of intermolecular C (61) OH---HOC (62) hydrogen 
33
Chapter 2 
bonds (Cho et al., 2000). To quantify the absorption intensity as an indirect 
indicator for the change of DD, the absorption ratios at 3253 cm-1 and 3143 cm-1 
compared with that of at 1551 cm-1 were calculated respectively and the results 
are shown in Table 2. Significance between different molecular weight samples 
was calculated using ANOVA one-way analysis (Origin 7.0 SRO, USA) and no 
statistically significant difference (P > 0.05) was indicated despite that the value 
was to some extent higher for chitosan 10 kDa and 50 kDa. 
While IR is a coarse method for DD determination, the DD values were 
further measured by 1H NMR and the results are listed in Table 2. It was 
consistent with the result from IR spectra and the DD values of different 
molecular weight samples had only a negligible difference. 
 
Table 2   Characteristics of different molecular weight chitosans prepared 
from MMW chitosan 
Mv (Da) 5000 10000 50000 100000 400000 
A3143/A1551a  0.6713 0.7049 0.7195 0.5100 0.5295 
A3259/A1551a 0.7946 0.8085 0.8456 0.6462 0.6928 
DD(%)b    85.42   86.27 89.93 85.39 85.11 
a Absorption ratios calculated by infrared spectroscopy. 
b Degree of deacetylation calculated by 1H NMR. 
 
3.6 Thermoanalytical characterization of different molecular weight chitosans     
     The thermal properties of chitosan were further characterized by TGA. 
Molecular weight dependent degradation behaviour was observed, as illustrated 
in Figure 6. Chitosan with MW of 250~500 kDa showed a maximum 
degradation temperature at about 280℃, low MW chitosan degraded at lower 
temperature, at 220, 180℃ for MW 25~100 and 2.5~5 kDa respectively. A 
similar MW dependent degradation behaviour was observed for 
polyethylenimine and polyethylene glycol (Peterson et al., 2002). 
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3.7 Solubility of different molecular weight chitosans 
     The water solubility of chitosan was assayed as a function of pH. A good 
correlation between pH and transmittance at 600 nm was established for all the 
chitosans investigated. pH50, which is defined as the pH value when the 
transmittance reached 50%, was calculated from the equation and was 
employed to express the solubility difference of different chitosans. pH50 and 
the cloud point pH of different molecular weight chitosans are shown in Figure 
7.  
 
 
(g) 
(f) 
(c)
(b)
(a)
(e)
(d)
Figure 6.  Degradation behavior of different molecular weight chitosans measured by 
thermal gravimetric analysis. 
          (a) MW 400 kDa; (b) MW 250 kDa; (c) MW 100 kDa; (d) MW 50 kDa; (e) MW 
25 kDa; (f) MW 5 kDa; (g) MW 2.5 kDa. Molecular weight dependent 
degradation behaviour was observed. 
 
We observed that pH50 and cloud point pH increased with decreasing 
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molecular weight. This was expected because, the presence of rigid crystalline 
domains, formed by intra- and/or intermolecular hydrogen bonding, was 
considered to be responsible for the poor solubility of chitosan in high pH 
solutions (Nishimura et al., 1991). The hydrogen bonding will be disturbed 
during the depolymerization process, resulting in the improved solubility. It 
should be noted that these tests were only carried out at one concentration and 
were simply used to verify that the solubility of chitosan could be improved by 
decreasing molecular weight. 
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Figure 7. Solubility properties of different molecular weight chitosans. (■) pH50,  (□) 
critical pH.  pH50 is defined as the pH value when the transmittance of the solution 
at 600 nm reached 50%. Cloud pH is defined as the pH when the transmittance at 
600 nm was no less than 98%. 
 
3.8 Biocompatibility studies 
  While chitosan is considered as a degradable polymer due to its 
susceptibility to various enzymes (Zhang et al., 2001), we performed in this 
work a cytotoxicity study to clarify the relationship between molecular weight 
and toxicity.  
Generally, the determination of cell viability is an ordinary assay to 
evaluate the in vitro cytotoxicity of biomaterials. Common methods for 
determining cell viability depend upon membrane integrity (e.g. trypan blue 
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exclusion), or incorporation of nucleotides during cell proliferation (e.g. BrdU 
or 3H-thymidine). However, these methods are limited by the impracticality of 
processing large number of samples, or by the requirement for handling 
hazardous materials. The MTT Assay, in contrast, provides a rapid and versatile 
method for assessing cell viability (Mosmann, 1983). This test is a quantitative 
colorimetric method to determine cell proliferation and it utilizes the yellow 
tetrazolium salt [3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide] 
which is metabolized by mitochondrial succinic dehydrogenase activity of 
proliferating cells to yield a purple formazan reaction product which is largely 
impermeable to cell membranes, thus resulting in its accumulation within 
healthy cells. Solubilization of the cells results in the liberation of the product 
that can readily be detected using a simple colorimetric assay. The ability of 
cells to reduce MTT provides an indication of the mitochondrial integrity and 
activity, which, in turn, may be interpreted as a measure of viability and/or cell 
number. Comparison of results between control and test cultures provides an 
indication of the cytotoxic effect of test compounds. 
The results are described in Figure 8. The cytotoxicity of chitosan was 
concentration dependent, as expected, but all the chitosans tested were relatively 
non-toxic at concentration up to 1 mg/ml. Chitosan 400 kDa showed an IC50 of 
4200 µg/ml, whereas approximately 5000 µg/ml were found for chitosan 100-5 
kDa. Taking the deviation of this method into account, it is reasonable to 
conclude that the cytotoxicity of chitosan was molecular weight independent 
although it was not in agreement with the result of Sgouras (Sgouras et al., 
1990), who found a molecular weight dependence of the cytotoxicity. This 
difference can be attributed to different cell lines used in those experiments. The 
L929 fibroblast cell line used in our experiments is recommended by USP and 
several other pharmacopoeias as a standard method for cytotoxicity testing. 
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Figure 8. Cell viability upon incubation with increasing concentrations of chitosans for 24 h, 
as demonstrated by MTT assay with L929 cells. Values shown are mean±SD (n = 
7).   CH 400 kDa (◆); CH 100 kDa (■); CH 50 kDa (▲); CH 10 kDa (×); CH 5 
kDa (*). 
 
4. Conclusions 
     The depolymerization of chitosan could be carried out by oxidative 
degradation using sodium nitrite. A large series of chitosans with desired 
molecular weights could be obtained by changing chitosan/NaNO2 molar ratio, 
chitosan initial concentration and reaction time. The molecular weight of the 
depolymerized chitosan was linear with chitosan/NaNO2 ratio, and decreased as 
a function of the logarithm of reaction time. Chitosan with larger molecular 
weight was more sensitive to depolymerization. IR spectrum and 1H NMR 
spectroscopy demonstrated that there was no structure change during 
depolymerization process. The reproducibility of this method was fairly good. 
The decomposition temperature of chitosan was molecular weight dependent 
and the solubility of chitosan increased with decreasing molecular weight. The 
cytotoxicity of chitosan was almost molecular weight independent according to 
MTT assay using L929 cell line. Chitosan was nontoxic when the concentration 
was as high as 1mg/ml. 
In summary, using the oxidative depolymerization of chitosan, low 
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molecular weight fragments can be easily and reproducibly obtained.  
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ABSTRACT   
PEGylated trimethyl chitosan copolymers were synthesized in an attempt 
to both increase the solubility of chitosan in water, and improve the 
biocompatibility of trimethyl chitosan (TMC). A series of copolymers with 
different degrees of substitution were obtained by grafting the activated PEG of 
different MW onto TMC via primary amino groups. Structure of the copolymers 
was characterized using FT-IR, 1H and 13C NMR spectroscopies. Solubility 
experiments demonstrated that PEG-g-TMC(400) copolymers were completely 
water-soluble over the entire pH range of 1-14 regardless of the PEG MW, even 
when the graft density was as low as 10%. Cytotoxicity of the copolymers and 
corresponding insulin complexes was studied using a MTT assay. We found that 
PEGylation with PEG 5 kDa and PEG 20 kDa significantly decreased the 
cytotoxicity of TMC 400 kDa, and complex formation with insulin led to further 
increases in IC50. Properties of PEG-g-TMC copolymer insulin complexes were 
further investigated to gain an insight into the effect of the copolymer 
composition on the complex properties. All complexes investigated had a 
particle size in the range of 150-300 nm and were positively charged, ξ
–potentials were shown to decrease with increasing graft density. Association 
efficiency increased with PEG graft ratio, and extremely high association 
efficiency, that is, 96.22%, was obtained with PEG(5k)679-g-TMC(400) 
copolymer. To conclude, the degree of PEGylation and the MW of PEG were 
found to strongly influence the biocompability of TMC 400 kDa and properties 
of the corresponding insulin complexes. These complexes merit further 
investigations in animal studies. 
 
1. Introduction 
Chitosan (poly(β-(1-4)-2-amino-2-deoxy-D-glucopyranose)), a non-toxic 
and biocompatible cationic polysaccharide, is produced by partial deacetylation 
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of chitin derived from naturally occurring crustacean shells. Due to its specific 
structure and properties, chitosan has found a number of applications in drug 
delivery including as an absorption enhancer for hydrophilic macromolecular 
drugs and as a gene delivery system [1]. The applications of chitosan in the 
biomedical field are limited, however, by its poor solubility in physiological 
media. Chitosan is only soluble in aqueous acidic solutions below pH 6.5, in 
which the primary amino groups of chitosan are protonated. To improve the 
poor water-solubility of chitosan, several derivatives have been proposed.  For 
example, the modification of chitosan by quaternization of the amino groups 
[2,3], N-carboxymethylation [4] and PEGylation [5,6] have been reported.  
However, these efforts were only partially successful in the case of 
PEG(5k)-g-chitosan, which was prepared via reacting chitosan (degree of 
deacetylation 70%, MW 70 kDa) with methoxy-PEG(5k)-g-nitrophenyl 
carbonate [6]. With a graft density of 78.5% (calculated as a weight ratio of 
PEG 5 kDa in the graft copolymer, the same below), PEG(5k)-g-chitosan 
copolymer solutions became cloudy at pH 6.8, which is suggestive of polymer 
precipitation. Even at graft densities as high as 92.7%, the copolymer solution 
became cloudy [5] and formed aggregates [6] when the pH was > 7.0. It is 
noteworthy that phase separation appeared at pH 6.5 or higher for unmodified 
chitosan, depending on the molecular weight [7]. This indicates that PEGylation 
can only marginally improve the solubility of chitosan in a very limited range 
(pH 6.5-7.0), even with high graft densities. Accordingly, the objective of the 
present study was to design chitosan derivatives with superior solubility and 
biocompatibility.  
Another possible approach involves trimethyl chitosan (TMC). TMC is a 
permanently quaternized chitosan derivative, which has been proven to be 
highly soluble over a wide pH range (pH 1 to 9) up to 10% (w/v) concentration. 
Moreover, TMC is capable of opening tight junctions of intestinal epithelial 
cells at physiological pH values, thus increasing paracellular permeability of 
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intestinal epithelia [8], whereas chitosan itself is insoluble and thus ineffective 
in this role. Moreover, TMC seems to be an efficient gene delivery system [9]. 
However, in contrast to chitosan, TMC was shown to be cytotoxic in L929 
mouse fibroblast cells as indicated by MTT assay in our laboratory (data shown 
below). Kotze et al. also indicated that reversibility of the effect of 0.5% 
concentrations of TMC with different degree of quaternization could not be 
demonstrated at pH 6.2 and 7.4 in Caco-2 cells [10]. Therefore, further 
improvement of the biocompatibility of TMC is desirable. 
As a water soluble, biocompatible, non-toxic and non-immunogenic 
material, PEG can not only enhance biocompatibility but also favorably affect 
pharmacokinetics and tissue distribution. Conjugation of PEG to proteins is well 
known to enhance the in vivo half-life of the encapsulated drugs, assist 
penetration into the cell membrane, alter pharmacological properties and 
increase biocompatibility [11,12]. Therefore, PEGylated TMC copolymers 
could possibly provide further biological functionality, in addition to improving 
solubility and decreasing cytotoxicity. Here we described the synthesis and 
physico-chemical characterization of PEGylated trimethyl chitosan in an effort 
to improve both solubility and biocompatibility. Additionally, the feasibility of 
the copolymers as insulin carriers is investigated. 
 
2. Materials and methods 
2.1 Materials  
Chitosan (MW~400 kDa, degree of deacetylation 84.7%) was purchased 
from Fluka (Steinheim, Germany). Methoxypoly (ethylene glycol) (Mn 550 and 
5000 Da), water free toluene (99.9%), dichloromethane (99.9%), dimethyl 
sulfoxide (DMSO) (99.9%), diethyl ether (99.9%), maleic anhydride, 
N-hydroxysuccinimide (NHS) and dicyclohexylcarbodiimide (DCC) were 
obtained from Aldrich (Steinheim, Germany) and used as received. Human 
recombinant insulin powder (26.2 IU/mg) was purchased from Sigma 
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(Steinheim, Germany). All other chemicals and solvents were of analytical 
grade. Activated PEG 20 kDa (α-Methoxy-ω-NHS ester) was purchased from 
RAPP Polymer GmbH (Tuebingen, Germany). 
 
2.2 Activation of mPEG    
The monohydroxy-terminated PEGs were converted to a 
carboxyl-terminated intermediate by esterification with cyclic aliphatic 
anhydride according to the literature report [13]. Briefly, in a 50 ml 
round-bottomed flask equipped with a reflux condenser and an oil bubbler, 5 g 
(0.0091 mol) of pre-dried mPEG 550 Da was dissolved in 20 ml of water free 
toluene, 4.457 g maleic anhydride (0.04545 mol, 1:5 molar ratio vs PEG) was 
added under the protection of argon. The reaction mixture was stirred at 70℃ 
for 48 h under an argon atmosphere. After the esterification process, toluene and 
the excess maleic anhydride were eliminated by distillation and sublimation at 
40℃ under vacuum.   
Subsequently, the intermediate mentioned above (0.54 mmol) together with 
NHS (2.7 mmol) (1:5 in molar ratio) were dissolved in 20 ml dichloromethane 
(DCM) in a flask equipped with a magnetic stirring bar. The flask was then 
cooled in an ice-water bath and DCC (0.54 mmol) was added under argon. The 
reaction mixture was sealed under argon and stirred for 1 h at 0℃, and a further 
24 h at room temperature. The precipitated 1, 3-dicyclohexylurea (DCU) was 
removed by filtration. The filtrate was added to diethyl ether (50 ml) and cooled 
at 4℃ for 2 h. The precipitated product was then redissolved in DCM and 
reprecipitated with diethyl ether. This procedure was repeated at least three 
times to completely remove excess NHS. Finally, the product was dried under 
vacuum and stored at room temperature under argon. mPEG 5 kDa was 
activated in the same manner. 
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2.3 Preparation of trimethyl chitosan (TMC)  
TMC was prepared according to a two-step method previously described 
by Sieval et al. to obtain TMC with a quaternization degree of approximately 
40% [2]. This degree of quaternization has been demonstrated to have improved 
permeation enhancing properties [14]. TMC 400 kDa used throughout this study 
was characterized by 1H NMR and its composition is as follows: N+ (CH3) 3 
group 46.41%, N (CH3) 2 group 12.44%, 3-OCH3 group 6.14%, 6-OCH3 8.04%, 
NHCOCH3 10.32%, free amino group 30.83%. 
 
2.4 Coupling of activated mPEGs onto TMC  
A predetermined quantity of TMC was dissolved in purified water at a 
concentration of 10 mg/ml. NHS-mPEG was dissolved in DMSO (50 mg/ml) 
solution. Subsequently, the TMC solution was added to the NHS-mPEG 
solution and the mixture was stirred at room temperature for 24 h. Weight ratios 
of TMC to NHS-mPEG were varied in order to achieve the optimal PEGylation 
level. After 24 h of stirring, the solution was purified by ultra filtration with an 
Amicon system equipped with a 10 000 MW cut-off membrane. The 
concentrated solution was diluted and ultrafiltrated again. This procedure was 
repeated at least 3 times and the dialyzed solution was finally freeze-dried. The 
graft ratio (wt %) of PEG was calculated from integral values of the 
characteristic peaks of PEG block at ~3.35 ppm (-OCH3) and TMC blocks at ~ 
3.0 ppm (-N (CH3) 2) and  ~ 3.3 ppm (-N+ (CH3) 3) obtained in the 1H NMR 
spectra, using the known molecular weight of mPEG. This method of comparing 
integration of 1H NMR peaks has been widely implemented [13, 15].  
PEGylated chitosans were prepared in the same manner for the purpose of 
comparison. However, due to its higher viscosity, concentration of chitosan 400 
kDa was 0.2% instead of 1% for TMC 400 kDa. 
 
2.5 Characterization of copolymers  
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Fourier Transformed Infrared (FTIR) spectral studies were conducted on a 
FT-IR 510 P spectrometer in the range of 4000 and 400 cm-1, with a resolution 
of 2 cm-1. All powder samples were compressed into KBr disks for the FTIR 
measurement. 
   Nuclear Magnetic Resonance Spectroscopy (NMR).  1H NMR and 13C 
NMR spectra were recorded on a JEOL GX 400 D spectrometer operating at 
400 MHz at room temperature. Samples were dissolved in D2O or CDCl3. 
   Gel permeation chromatography (GPC) was carried out using a 
Supremamax 3000 column (Polymer Standard Service, Mainz, Germany) with 
0.3 M acetic acid and 0.2 M sodium acetate as an eluent (1 ml/min). 40 µl 
samples were injected with a Merck Hitachi autosampler AS-2000A. The 
samples were analyzed with a differential refractive index (RI) detector RI-71 
from Merck.   
   Differential Scanning Calorimetry (DSC).  DSC measurements were 
performed on a Perkin-Elmer differential scanning calorimeter (DSC-7) at a 
heating rate of 20℃/min. The sample (approximately 5 mg) was first heated 
from –100℃ to 170 ℃. It was then quenched to -120℃ with liquid nitrogen, 
and heated again to 170 ℃. The melting temperature (Tm) was determined from 
the endothermic peak of the DSC curve recorded in the first heating scan. 
 Thermogravimetric Analysis (TGA) was carried out on a 
thermogravimetric analyser TGA 7 with a thermal analysis controller TAC 
7/DX from Perkin-Elmer using a sample weighing approximately 5 mg. 
Thermograms were recorded within the temperature range of 30-550℃ at a 
scanning rate of 20℃/min. All experiments were performed under nitrogen in 
platinum crucibles. 
 
2.6 Water Solubility Testing  
Solubility of the various copolymers was measured at different pH values 
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at room temperature. Briefly, the copolymers were dissolved in a 0.25% acetic 
acid solution (2 mg/ml), the pH value of the solution was adjusted using 1N 
NaOH and transmittance of the solution at 600 nm as a function of pH was 
recorded on an UV/Vis spectrophotometer (UV-160, Shimadzu, Japan). The 
copolymers were considered insoluble when the transmittance was less than 
90%, compared to that of distilled water.  
 
2.7 Formation of copolymer-insulin complexes and characterization 
The complexes were prepared via self-assembling process using the 
electrostatic interaction between the polymers and insulin, and the process 
parameters were optimised (chapter 5). Briefly, insulin (1 mg/ml) and 
appropriate quantity of copolymer (based on the ratio with insulin, as indicated 
in Table 3) were dissolved in 0.1 N Tris buffer solution pH 7.4. Complexes were 
prepared by mixing equal volumes of insulin and polymer solution under gentle 
magnetic stirring, and incubating for further 20 min at room temperature.  
Dynamic light scattering determination (DLS). Complex size 
measurements were performed with a Zetasizer 3000 HS from Malvern 
Instruments, Herrenberg, Germany (10 mW HeNe laser, 633 nm). Scattering 
light was detected at a 90o angle through a 400 micron pin hole at a temperature 
of 25℃. For data analysis, the viscosity ( 0.88 mPa•s) and the refractive index 
(1.33) of distilled water at 25℃ were used. The instrument was routinely 
checked using Standard Reference latex particles (AZ 55 Electrophoresis 
Standard Kit, Malvern Instruments). Measurements were analysed using the 
CONTIN algorithm. Values given are mean±SD (n = 10).  
Laser Doppler Anemometry (LDA). Theξ- potential measurements of the 
complexes were carried out in the standard capillary electrophoresis cell of the 
Zetasizer 3000 HS from Malvern Instruments at 25℃. Values given are mean 
± SD (n = 10). 
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Insulin association efficiency of the complexes. The amount of insulin 
encapsulated in the complexes was calculated by measuring the difference 
between the total amount of insulin added and the quantity of non-associated 
insulin remaining in the aqueous medium after the self-aggregation process. For 
this purpose, prepared insulin complexes were centrifuged at 14000 rpm/min at 
room temperature for 30 min. The quantity of insulin in the supernatant was 
measured using a Merck HPLC system equipped with a fluorescence 
spectrophotometer ( F-1050) and a LiChrospher 100 RP-18e column ( 5 µm, 4.6
×250mm ). A sample of 20 µl was injected on each occasion. The mobile phase 
comprised eluent A (ultrapure water with 0.1% trifluoroacetic acid (TFA)) and 
eluent B (acetonitril: water: TFA 89.9: 10: 0.1) 65: 35. The flow rate was 1.0 
ml/min and an emission wavelength 600 nm together with an excitation 
wavelength 280 nm was employed. Insulin content was quantified by peak area 
measurement. The insulin association efficiency was then calculated using the 
following relationship:  
%100×−=
insulinofamountTotal
insulinFreeinsulinofamountTotalefficiencynAssociatio  
 
2.8 Cytotoxicity of the complexes  
In vitro cytotoxicity of both the copolymers and the complexes was 
evaluated using a MTT assay with L929 fibroblast cell line, as described 
previously [16]. Briefly, L929 cells were seeded into 96-well microtiter plates at 
a density of 8000 cells/well. After 24 h, the culture medium was replaced with 
100 µl serial dilutions of polymer/complex and cells were incubated for a 
further 24 h. Subsequently, 20 µl MTT (5 mg/ml) was added to each well. After 
4 h incubation, unreacted dye was aspirated and the formazon crystals were 
dissolved in 200 µl/well DMSO. Absorption was measured at 570 nm with a 
background correction of 690 nm using a Titertek Plus MS 212 ELISA reader 
(ICN, Eschwege, Germany). The relative cell viability compared to control cells 
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containing cell culture medium (pH 6.5) without polymer was calculated by [A] 
test /[A] control. 
3. Results and discussion 
3.1 Copolymer preparation and characterization  
Hydroxyl-terminated PEGs were converted to carboxyl-terminated 
intermediates by esterification with cyclic aliphatic anhydride. Maleic 
anhydride was chosen in the present study to activate PEG in preference to 
succinic anhydride [17] because it has been demonstrated to be more reactive to 
PEG hydroxyl group, and is straightforward to eliminate via sublimation after 
the esterification process [13]. After activation, PEGs were coupled to the 
amino groups of TMC, forming a graft copolymer, i.e., PEG-g-TMC. The 
synthetic route is shown in Scheme 1.  
We investigated the influence of polymer solution pH on the final graft 
ratios, with no significant difference being observed at polymer pH 5.0, 7.0, 8.5 
respectively. Therefore all copolymers were prepared at a constant polymer 
solution pH of 7.0. The effect of feed ratios was investigated and the graft ratios 
of the copolymers, calculated from 1H NMR spectra based on the MW of the 
polymer provided by the supplier, are listed in Table 1. We used the following 
abbreviated nomenclature for the copolymers: PEG(X)n -g-TMC(400), where X 
denotes the MW of PEG in Da and the subscript n represents the average 
number of PEG chains per TMC 400 kDa macromolecule. The average number 
of free amino groups in the copolymer was measured using fluorescamine assay 
[18]. 
Obviously, the graft ratios increased with feed ratio and a good linear 
correlation between NHS-mPEG/polymer ratio and graft density was found 
(Table 1). It is generally assumed that the activity of PEG is molecular weight- 
dependent, for example, mPEG 550 Da should be more reactive than mPEG 5 
kDa. This is the case for PEG-g-chitosan(400) copolymers, as shown in Table 1. 
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Scheme 1.  Synthetic route of PEGylated chitosan derivatives. 
 
However, the opposite is true for TMC 400 kDa, as indicated by the number of 
PEG chains per TMC molecule. For instance, when the NHS-mPEG/TMC 400 
kDa feed ratio was 3:1, only 83 PEG 550 Da molecules were coupled to TMC 
molecule compared to 298 mPEG 5 kDa molecules at the same feed ratio and 
prepared under the same conditions. The results were reproducible with 
different batches of activated PEG, as annotated in Table 1. Furthermore, 
copolymers were prepared with TMC 100 kDa (with the same substitution ratio 
as that of TMC 400 kDa) in the same manner and were found that the graft 
ratios of PEG(550)-g-TMC(100) copolymers were similar to that of PEG 
(550)-g-chitosan(100) in the same feed ratio (data not shown). Steric effect 
 52
Chapter 3 
could not be a cause for the low graft ratio of PEG(550)-g-TMC(400), because 
at the same feed ratio even higher graft ratio was obtained with 
PEG(5k)-g-TMC(400) (75.44%) compared to PEG(5k)-g-TMC(100) (68.25%) 
due to relative high amount of primary amino groups. Possible explanations are 
competitive reactions of activated PEG 550 Da with water. PEG-NHS is 
moisture-sensitive and can lose its reactivity by interacting with water. The 
shorter the PEG chains, more sensitive with water. Though that short PEG-NHS 
possesses the highest reactivity to amino groups, it also possesses the highest 
reactivity to water. Principally, reactivity with -NH2 is higher than with water. 
However, some substituted groups may shield part of -NH2 groups of TMC and 
thus grafting will become slow, requiring the PEG-NHS to maintain reactive 
over a longer period. 
 
Table 1. Properties of PEG-g-TMC(400) and PEG-g-chitosan(400) copolymers 
PEG(550)-g-TMC(400)    PEG(5k)-g-TMC(400)     PEG(550)-g-chitosan(400)    PEG(5k)-g-chitosan (400) Feeding ratio 
(PEG/polymer) 
(w/w) 
graft% PEG550a  free 
NH2b1  
graft% PEG5ka free 
NH2b1
graft%e  PEG550a free 
NH2b2  
graft%e PEG5ka free 
NH2b2 
3:1 10.3c 83 553 75.4d  298 250 43.7 564 1547 75.2 243 1868 
4:1 16.1 139 524 88.9 641   233  49.4 710 1401 82.8 386   1725 
5:1 17.1 148   341 89.4 679 168 55.1 892 1219 86.6 515 1596 
a Number of PEG chains per TMC 400 kDa molecule, calculation based on 1H NMR data. 
b1 Number of free amino groups per TMC 400 kDa molecule, calculation based on fluorescamine assay. 
   b2 Number of free amino groups per chitosan 400 kDa molecule, calculation based on the substitution of 
chitosan 400 kDa and the graft density of PEG. Fluorescamine assay is not feasible due to the solubility 
limitation of the copolymers. 
C Calculated as a weight ratio of PEG in the graft copolymer based on NMR analysis. Reproducibility of 
the copolymer preparation method with different batches of activated PEG 550 Da were investigated, 
the values were 8.93, 12.6, 10.3%, respectively, with SD of 1.85. 
d Reproducibility of the copolymer preparation method with different batches of activated PEG 5 kDa 
were investigated, the values were 78.83, 77.72, 75.44%, respectively, with SD of 1.73. 
e Calculated as a weight ratio of PEG in the graft copolymer. 
 
FTIR spectroscopy, which is known to be a particularly relevant technique 
for the investigation of specific intermolecular interactions [19, 20], was  
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Figure 1.  FTIR spectra of mPEG(550)-g-TMC(400) copolymers (A) and mPEG 
(550)-g-chitosan(400) copolymers (B). 
(A). (a) mPEG(550)-NHS, (b) PEG(550)21-g-TMC(400), (c) 
PEG(550)83-g-TMC(400), (d) PEG(550)139-g-TMC(400), (e) TMC 400 kDa. 
(B). (a) mPEG(550)-NHS, (b) PEG(550)564-g-chitosan(400), (c) 
PEG(550)892-g-chitosan (400), (d) PEG(550)1457-g-chitosan(400), (e) Chitosan 
400 kDa.  
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employed to characterize the block copolymers. The FT-IR spectra of 
mPEG(550)-g-TMC(400) copolymers in the carbonyl vibration region are 
displayed in Figure 1 as a function of mPEG 550 Da composition. Another 
copolymer, PEG(550)21-g-TMC(400), with a rather low graft density (2.9%) 
was utilized in this study to elucidate the signal evolution readily. For the 
mPEG(550)-g-TMC(400) copolymers studied here, the activated mPEG 550 Da 
contains a carboxyl group, yielding aυc=o stretching mode at ~1730 cm-1, 
whereas TMC shows no absorption in the carbonyl vibration region ranging 
from 1650 cm-1 to 1800 cm-1. Therefore, any change in the FTIR spectrum in 
this region can be directly attributed to a change in the carbonyl group 
environment, such as binding with other group. As shown in Figure 1(A), a new 
peak centered at ~1707 cm-1 appeared in the copolymer spectra and its intensity 
increased with PEG 550 Da content. A similar phenomenon was observed with 
PEG(550)-g-chitosan (Figure 1(B)). The amide band II at 1580 cm-1 decreased 
with increasing graft ratio. 
1H NMR spectra of a graft copolymer and corresponding intermediate 
prepolymers are shown in Figure 2A. 1H NMR resonance signals are assigned 
accordingly. NHS-terminated mPEG 550 Da (Figure 2A(b)) showed two 
resonance absorptions at ~6.2 and 6.6 ppm (doublet, -C (=O) CH=CHC (=O)-), 
which are not present in the spectrum of HO-terminated mPEG containing no 
maleic moiety (Figure 2A(a)). Only a signal peak at ~6.0 (C=C) was observed 
in the graft copolymer (Figure 2A(c)), implying the environment of the double 
bond has changed, and likely the proton shielding effect of local chemical 
environment to the two methine groups became closer. Additionally, the graft 
copolymer showed strong absorption at ~3.0 (N (CH3) 2) and ~3.3 (N+ (CH3) 3) 
ppm, which are from the TMC. The structure of the copolymers was further 
investigated with 13C NMR, as shown in Figure 2(B). These results are 
consistent with the expected chemical structure of the copolymer.  
GPC measurements were also employed to verify the successful synthesis  
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Figure 2. 1H (A) and 13C NMR (B) spectra of HO-terminated mPEG 550 Da (a), 
NHS-terminated mPEG 550 Da  in CDCl3 (b), and PEG(5k)42-g-TMC(400) 
copolymerin D2O (c). 
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of the graft copolymers. Copolymers showed unimodel molecular weight 
distribution in the GPC eluograms with increased molecular weight (data not 
shown), indicating that negligible PEG homopolymer was present in the 
copolymer products. 
 
3.2 Thermal properties  
The thermal properties of copolymers were studied with differential 
scanning calorimetry (DSC). DSC thermogram showed an endothermic peak at 
its melting temperature for PEG and a MW dependence was observed, Tm 14.6
℃ and 63℃ for PEG 550 Da and PEG 5 kDa, respectively. However, no glass 
transition temperature was detected, probably because PEG crystallized too 
rapidly. Additionally, no Tg and Tm were observed for both chitosan 400 kDa 
and trimethyl chitosan 400 kDa.  
The melting temperature of PEG 5 kDa decreased with increasing TMC 
content (Table 2). For instance, Tm of homo-PEG 5 kDa is 65.95℃ and only 
55.48℃ in the copolymer with a graft ratio of 75.44%, a decrease about 10℃. 
This implies the crystallization of PEG 5 kDa was greatly affected by TMC 400 
kDa. Considering that all the samples had the same thermal history, it is 
reasonable to conclude that PEG and TMC are at least partially miscible [21]. 
It is also noted that the decrease of Tm in PEG(5k)-g-chitosan(400) 
copolymers was larger than that in PEG(5k)-g-TMC(400) copolymers with 
similar PEG 5 kDa content (Table 2). The depression of Tm can be explained 
with the following equation [22]: 
)21(
LH
TT
f
eo
mm ∆−=
γ  
where γe is the free energy of chain folding at the surface of the lamellae, Δ
Hf is the heat of fusion of the lamellae, L is the thickness of the lamellae, and 
Tmo is the melting point of a 100% perfect polymer crystal. As we can see, the 
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reduction of the lamellar thickness can lead to a melting point depression. The 
interactions between different blocks is expected to have a dominant effect on 
reducing L in the diblock copolymer, leading to a decreased Tm. Therefore, it is 
reasonable to assume that the interaction between PEG and chitosan is stronger 
than that of PEG and trimethyl chitosan. This result can be used to explain the 
solubility difference of the copolymers. On the other hand, decreased Tm 
indicated that those two components are miscible and compatible. As to the 
small MW mPEG 550 Da, the Tm change was not so obvious, as summarized in 
Table 2.  
 
          Table 2.  Melting temperature of the copolymers 
Polymer Substitution %a Graft ratio (%)b Tm 
mPEG 550 Da   14.6 
mPEG 5000 Da   65.9 
Chitosan 400 kDa   -c 
TMC 400 kDa   -c 
mPEG(550)-g-chitosan(400) 26.8 
33.7 
42.4 
43.7 
49.4 
55.1 
-c 
-c 
12.2 
mPEG(550)-g-TMC(400) 3.9 10.3 13.6 
 6.6 16.1 12.1 
 7.0 17.1 13.2 
mPEG(5k)-g-chitosan (400) 11.6 75.2 54.1 
 18.4 82.8 53.1 
 24.5 86.6 54.2 
mPEG(5k)-g-TMC(400) 14.2 75.4 55.5 
 30.5 88.9 60.0 
 32.3 89.4 61.5 
a Calculated based on the primary amino group content in chitosan 400 kDa, 84.7%. 
b Calculated as a weight ratio of PEG in the graft copolymer. 
c Not detected. 
 
Tm of the pure mPEG 550 Da was observed at 14.63℃ and no Tm was observed 
in the PEG(550)-g-chitosan(400) copolymers when the content of mPEG 550 
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Da was less than 55.09%, implying that the crystallization of mPEG 550 Da 
was fully suppressed by chitosan 400 kDa, and a decreased Tm was identified 
only when PEG 550 Da content was above 60%. In contrast, a Tm decrease in all 
mPEG(550)-g-TMC(400) copolymers was found. This can probably be 
attributed to the stronger interaction between chitosan and PEG 550 Da, leading 
to improved miscibility. 
TGA measurements were also performed to investigate the thermal 
decomposition temperatures (Td) of mPEGs, chitosan, TMC and the copolymers. 
mPEG (Mn 550, 5000 Da) decomposed at 280-380℃, whilst chitosan 400 kDa 
decomposed at 280℃ . As for the TMC 400 kDa, two distinct thermal 
decomposition transitions were identified at 200℃and 270℃. These are due to 
a special composition with a quaternization degree of 40%. TGA thermograms 
of graft copolymers based on mPEG 5 kDa and chitosan/TMC are shown in 
Figure 3.  
Three-step Td’s are observed in the TGA thermograms of PEG-g-TMC 
copolymers, which we believe correspond to the Td’s of the TMC (two Td’s) and 
PEG segments, respectively. In all cases, chitosans/TMCs were degraded first, 
followed by PEG degradation at approximately 400℃, as demonstrated by the 
profiles of the homopolymers. However, it cannot be assumed that all of the 
chitosan/TMC is degraded when the first amount of PEG begins to degrade, as 
there is still 10% left in the end and PEG is known to be completely degradable 
at such a high temperature. In addition, it is noticed that only a single Td was 
found for PEG(5k)515-g-chitosan(400) copolymers. This can be explained by the 
miscibility enhancement observed in the block copolymer, leading to the 
identical component Td [23,24]. Indeed, enhanced miscibility was additionally 
verified by DSC measurements, as described above.  
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Figure 3. TGA thermograms of graft copolymers based on mPEG 5 kDa and chitosan/TMC  
(A) PEG(5k)-g-TMC(400) copolymers.   
(a) TMC 400 kDa, (b) PEG 5 kDa, (c) PEG(5k)298-g-TMC(400), (d) 
PEG(5k)641-g-TMC(400), (e) PEG(5k)679-g-TMC(400).   
(B) PEG(5k)-g-chitosan copolymers. 
(a) Chitosan 400 kDa, (b) PEG 5 kDa, (c) PEG(5k)243-g-chitosan(400), (d) 
PEG(5k)386-g-chitosan(400), (e) PEG(5k)515-g-chitosan(400). 
 
3.3 Water Solubility of Copolymers  
The primary aim of our present study is to improve the solubility of 
chitosan. As such, water solubility of the copolymers was evaluated under 
different pH conditions. Solutions of PEG-g-TMC copolymers remained 
transparent over the entire pH range irrespective of PEG MW even when the 
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graft density was as low as 10% and the concentration was as high as 50 mg/ml. 
The PEG moieties presented on the TMC chain increased the hydrophilicity of 
the copolymer, thus leading to improved solubility. In contrast, no clear 
solutions were observed with PEG grafted chitosan copolymers at pH 7, despite 
of high graft densities. This is due to the strong interaction between chitosan 
and PEG [5,6], as demonstrated by the significantly decreased Tm value in DSC 
experiments.  
 
3.4 Biocompatibility and properties of the complexes   
In addition to the solubility, biocompatibility is of particular importance 
when a polymer is to be used as a drug carrier. Generally, polycationic polymers 
are related to cytotoxicity as a consequence of their interaction with the 
negatively charged components on the cell membrane. Therefore, the 
cytotoxicity of these new synthesized copolymers was investigated, and the 
concentration of the copolymers resulting in 50% inhibition of cell growth, i.e. 
IC50 value, was calculated. Along with the increase of PEG 5 kDa substitution, 
the free amino groups on TMC 400 kDa chains decreased, which, together with 
the steric effect of PEG 5 kDa, led to considerably decreased cytotoxicity, as 
illustrated in Table 3.  
Moreover, complex formation leads to further increase of IC50. This can 
probably be attributed to the electrostatic interaction between the copolymers 
and insulin, which decreased the charge density of the copolymers, as 
demonstrated by the decreasedξ–potentials (Table 3). Another possibility is 
that complex formation embeds part of the free amino groups, preventing them 
from direct contact with the cells. It was noticed that with PEG 5 kDa coupling, 
cytotoxicity of TMC 400 kDa could be decreased more than 30 fold. 
PEG(20k)-g-TMC(400) copolymers were prepared in the same manner to 
investigate the influence of PEG MW on the properties of the copolymer and 
corresponding insulin complexes. Despite the low substitution ratio, 
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cytotoxicity of the copolymer was decreased remarkably after PEG 20 kDa 
coupling, and further after complexation, which can probably be explained by 
the steric effect of the PEG 20 kDa molecules leading to subdued interaction 
with cell membrane. However, theξ- potential of PEG (20k)10-g-TMC(400) 
insulin complex decreased only marginally compared to that of TMC 400 kDa 
in 6 mM Tris buffer, 18.7±1.7 versus 20.9±1.4. A similar phenomenon was 
observed with PEI(25k)-g-PEG(20k)1 compared to PEI 25 kDa [25]. 
 
Table 3.  Properties of the PEG(5k)-g-TMC(400) copolymers and 
corresponding insulin complexes  
IC50(µg/ml) (24 h)   Complex properties Polymer Substitution b 
(%) 
Graft 
ratioc 
(%) 
Pure 
polymer
Complexes
Mass 
ratiod Particle size 
(nm) 
Zeta-potential
   (mV) 
Association 
efficiency 
(%) 
TMC 400 kDa - - 15 50 0.3:1 256.3±0.8 20.9±1.4 78.6±4.9 
PEG(5k)298-g-TMC(400) 38.9 75.4 40   100 0.7:1  171.7±1.9 11.2±0.9 81.3±1.1 
PEG(5k)640-g-TMC(400) 83.5 88.9 >500a  > 500a 1:1   181.8±2.1 2.3±0.3 87.0±6.3 
PEG(5k)680-g-TMC(400) 88.7 89.5 >500a  > 500a 1.5:1 245.6±2.9 1.7±1.0   96.2±2.1 
PEG(20k)10-g-TMC(400) 1.3 33.3 100   500 0.7:1 220.8±4.7 18.7±1.7 71.9 ±2.9 
PEG(20k)20-g-TMC(400) 2.6   50.0    >500a > 500a 1:1  256.1±7.0  18.8±0.3   79.3 ±1.7 
a The highest concentration investigated. 
b Calculation based on the primary amino group content in TMC 400 kDa, 30.83%. 
c Calculated as a weight ratio of PEG in the graft copolymer. 
d Optimized polymer/insulin mass ratio for complex preparation. 
 
PEG 5 kDa and PEG 20 kDa grafted TMC copolymer insulin complexes 
were also investigated to gain insight into the effect of copolymer composition. 
Based on the preliminary experimental procedure, soluble insulin complexes 
were prepared at optimal polymer/insulin mass ratios, as listed in Table 3. 
Particle size, ξ–potentials and the association efficiency (AE) of various 
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insulin complexes were also investigated. The particle size was in the range of 
150-300 nm, and increased with graft ratio. No significant difference in particle 
size was observed for the two PEG(20k)-g-TMC(400) copolymer insulin 
complexes. All of the complexes investigated here were positively charged and 
ξ–potentials decreased with increasing graft density. This is consistent with the 
cytotoxicity results.  
There have been reports that insulin binds to polymers via its negative 
charge, i.e. adhesion being facilitated by the interaction between the positively 
charged polymers and the negatively charged insulin. Based on this hypothesis, 
a decreased AE of PEGylated copolymers would be expected compared to 
non-modified polymers. Surprisingly, AE values increased with PEG 5 kDa 
graft ratio and extremely high association efficiency, that is, 96.22%, was 
achieved with PEG(5k)679-g-TMC(400) copolymer. A similar result was found 
in PEG(2k)-g-chitosan DNA nanoparticles [26], and preferential partition of 
insulin into the PEG phase in PEG-dextran systems was also reported [27]. 
Previously, Prestwich et al. showed that insulin has a high affinity for PEG rich 
environement [28]. Furthermore, PEG chains have been shown to complex with 
protein and stabilize them [29,30]. Therefore it is reasonable to assume that a 
certain proportion of insulin was retained in the PEG moieties conjugated in the 
TMC matrix, resulting in a higher AE.  
Taking all the above results into consideration, PEGylation with PEG 5 
kDa is sufficient to increase the biocompatibility of TMC and the corresponding 
copolymers are promising insulin carriers.  
 
4. Conclusions 
PEGylated trimethyl chitosan 400 kDa copolymers with varying PEG 
molecular weight and graft ratios were successfully synthesized and 
demonstrated by FT-IR, 1H NMR, 13C NMR and GPC measurements. Decreased 
melting temperature of PEG in the copolymers indicated that the two blocks are 
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miscible and compatible. PEG-g-TMC(400) copolymers were completely 
water-soluble over the entire pH range, irrespective of PEG MW. Based on 
cytotoxicity results, the potential of PEG(5k)-g-TMC(400) and 
PEG(20k)-g-TMC(400) copolymers as insulin carriers was studied. The particle 
sizes were less than 300 nm andξ-potential decreased with increasing graft 
density, which was consistent with the decreased toxicity. Insulin association 
efficiency was PEG graft density dependent, and the value could be as high as 
96.22%. Based on the good solubility of the copolymers and the speciality of 
polyethylene glycol, we believe these copolymers could be used to enhance the 
therapeutic and biotechnological potentials of other macromolecules.  
 
References 
[1]  Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects-an update. 
J Pharm Pharmacol 2001; 53: 1047-1067. 
[2]  Sieval AB, Thanou M, Kotze AF, Verhoef JC, Brussee J, Junginger HE. Preparation and 
NMR characterization of highly substituted N-trimethyl chitosan chloride. 
Carbohydrate Polymers 1998; 36: 157-165. 
[3]  Le Dung P, Milas M, Rinando M, Desbrieres J. Water soluble derivatives obtained by 
controlled chemical modification of chitosans. Carbohydrate Polymers 1994; 24: 
209-214.  
[4]  Muzzarelli RAA, Tanfani F and Emanuelli M. N-(carboxymethylidene) chitosans and 
N-(carboxymethyl) chitosans: novel chelating polyampholytes obtained from chitosan 
glyoxylate. Carbohydr Res 1982; 107:199-214. 
[5]  Saito H, Wu X, Harris J, Hoffman A. Graft copolymers of poly (ethylene glycol)(PEG) 
and chitosan. Macromol Rapid Commun 1997; 18: 547-550. 
[6]  Ohya Y, Cai R, Nishizawa H, Hara K and Ouchi T. Preparation of PEG-grafted chitosan 
nanoparticles as peptide drug carriers. STP Pharma Science 2000; 10: 77-82. 
[7]  Mao S, Shuai X, Unger, F, Simon M, Bi D, Kissel T. The depolymerization of chitosan: 
Effects on physicochemical and biological properties. Int J Pharm 2004; 281: 45-54. 
[8]  Thanou MM, Kotze AF, Scharringhausen T, Lussen HL, de Boer AG, Verhoef JC, 
Junginger, HE. Effect of degree of quaterization of N-trimethyl chitosan chloride for 
 64
Chapter 3 
enhanced transport of hydrophilic compounds across intestinal Caco-2 cell monolayers. 
J Controlled Rel 2000; 64: 15-25.  
[9]  Thanou M, Florea BI, Geldof M, Junginger HE, Borchard G. Quaternized chitosan 
oligomers as novel gene delivery vectors in epithelial cell lines. Biomaterials 2002; 23: 
153-159. 
[10]  Kotzé AF, Thanou MM, Lueben HL, De Boer AG, Verhoef JC, Junginger HE. 
Enhancement of paracellular drug transport with highly quaternized N-trimethyl 
chitosan chloride in neutral environments: In vitro evaluation in intestinal epithelial 
cells (Caco-2). J Pharm Sci 1999; 88: 253-257. 
[11] Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E. PEGylated 
DNA/transferring-PEI complexes: reduced interaction with blood components, 
extended circulation in blood and potential for systemic gene delivery. Gene Therapy 
1999; 6: 595-605. 
[12]  Veronese FM.  Peptide and protein PEGylation: a review of problems and solutions. 
Biomaterials 2001; 22: 405-417. 
[13]  Shuai X, Jedlinski Z, Luo Q, Farhod N. Synthesis of novel block copolymers of poly 
(3-hydroxybutyric acid) with poly (ethylene glycol) through anionic polymerisation. 
Chinese J Polym Sci  2000; 18: 19-23. 
[14]  Hamman JH, Schultz CM, Kotze AF. N-trimethyl chitosan chloride: optimum degree 
of quaternization for drug absorption enhancement across epithelial cells. Drug Dev 
Ind Pharm 2003; 29: 161-172. 
[15]  Petersen H, Martin AL, Stolnik S, Roberts CJ, Davies MC, Kissel T. The macrostopper 
route: A new synthesis concept leading exclusively to diblock copolymers with 
enhanced DNA condensation potential. Macromolecules 2002; 35: 9854-9856. 
[16]  Fischer D, Bieber T, Li Y, Elsaesser H, Kissel T. A novel non-viral vector for DNA 
delivery based on low molecular weight, branched polyethylenimine. Effect of 
molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999; 16: 
1273-1279. 
[17]  Hermanson GT. Bioconjugate Techniques. Academic press, 1996. 
[18]  Read ML, Etrych T, Ulbrich K, Seymour LW. Characterisation of the binding 
interaction between poly (L-lysine) and DNA using the fluorescamine assay in the 
preparation of non-viral gene delivery vectors. FEBS Lett 1999; 461: 96-100. 
[19]  Shuai X, Merdan T, Unger F, Wittmar M, Kissel T. Novel Biodegradable ternary 
copolymers hy-PEI-g-PCL-b-PEG: Synthesis, characterization and potential as 
 65
Copolymer synthesis and characterization 
efficient nonviral gene delivery vectors. Macromolecules 2003; 36: 5751-5759. 
[20]  He Y, Asakawa, N, Inoue Y. Biodegradable blends of high molecular weight poly 
(ethylene oxide) with poly (3-hydroxypropionic acid) and poly (3-hydroxybutyric 
acid): a misbility study by DSC, DMTA and NMR spectroscopy. Polym Int 2000; 49: 
609-617. 
[21]  Zhang L, Goh SH, Lee SY. Miscibility and crystallization behaviour of poly 
(L-lactide)/poly (p-vinylphenol)blends. Polymer 1998; 39: 4841-4847. 
[22]  Wei M, Shuai X, Tonelli AE. Melting and crystallization behaviors of biodegradable 
polymers enzymatically coalesced from their cyclodextrin inclusion complexes.  
Biomacromolecules 2003; 4: 783-792.  
[23]  Shuai X, Porbeni FE, Wei M, Bullions T, Tonelli AE. Formation of inclusion 
complexes of poly (3-hydroxybutyrate)s with cyclodextrins. 1. Immobilization of 
atactic poly(R, S-3-hydroxybutyrate) and miscibility enhancement between poly(R, 
S-3-hydroxybutyrate) and poly ( -caprolactone). Macromolecules 2002; 35: 
3126-3133. 
[24]  Wei M, Tonelli AE. Compatiblization of polymers via coalescence from their common 
cyclodextrin inclusion compounds. Macromolecules 2001; 34: 4061-4065. 
[25]  Petersen H, Fechner PM, Martin AL, Kunath K, Stolnik S, Roberts CJ, Fischer D, 
Davies MC, Kissel T. Polyethylenimine-graft-poly (ethylene glycol) copolymers: 
influence of copolymer block structure on DNA complexation and biological 
activities as gene delivery system. Bioconjug Chem 2002; 13: 845-854. 
[26]  Mao H, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW. 
Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and 
transfection efficiency.  J Controlled Rel 2001; 70: 399-421. 
[27]  Moriyama K, Yui N. Regulated insulin release from biodegradable dextran hydrogels 
containing poly (ethylene glycol). J Controlled Rel 1996; 42: 237-248. 
[28]  Prestwich G, Luo Y, Kirker K. Crosslinked hyaluronic acid hydrogel films: new 
biomaterials for drug delivery. J Controlled Rel 2000; 69:169-184. 
[29]  Iwanaga K, Ono S, Narioka K, Morimoto K, Masawo K, Yamashita S, Nange M, Oku 
N. Oral delivery of insulin by using surface coating liposomes: Improvement of 
stability of insulin in GI tract. Int J Pharm 1997; 157: 73-80. 
[30]  Yeh M. The stability of insulin in biodegradable microspheres based on blends of 
lactide polymers and poly (ethylene glycol). J Microencapsul 2000; 17: 743-756. 
 
 66
  
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
In vitro cytotoxicity of biodegradable poly (ethylene 
glycol)-grafted trimethyl chitosan copolymers 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscript in preparation 
 
Chapter 4 
Abstract   
The purpose of this study was to evaluate the in vitro cytotoxicity of 
trimethyl chitosan (TMC) and PEGylated TMC copolymers. Using the methyl 
tetrazolium (MTT) assay, the effect of TMC molecular weight, PEGylation ratio, 
PEG and TMC molecular weight in the copolymers, and complexation with 
insulin on the cytotoxicity of TMC was examined, and IC50 values were 
calculated with L929 cell line. All polymers exhibited a time- and 
dose-dependent cytotoxic response that increased with molecular weight. 
PEGylation can decrease the cytotoxicity of TMC, to a great extent in the case 
of low molecular weight TMCs. According to the cytotoxicity results, PEG 5 
kDa is superior for PEGylation when compared to PEG 550 Da at similar graft 
ratios. Complexation with insulin further increased cell viability. In addition, 
LDH (Lactate dehydrogenase) assays were performed to quantify the 
membrane-damaging effects of the copolymers. These results indicated that 
after 3 h of incubation with 1 mg/ml copolymer solutions, less than 6% LDH 
release were measured for PEG(5k)40-g-TMC(100), PEG(5k)19-g-TMC(50) and 
PEG(550)228-g-TMC(100) copolymers, compared to approximately 50% for 
TMC 100 kDa, which is in line with the conclusion drawn from MTT assay. 
Moreover, the safety of the copolymers was corroborated by observing the 
morphological change of the cells with inverted phase contrast microscopy. 
 
1. Introduction 
Chitosan is a non-toxic and biocompatible cationic polysaccharide 
produced by partial deacetylation of chitin derived from naturally occurring 
crustacean shells. Due to its specific structure and properties, chitosan has found 
a number of applications in drug delivery including as an absorption enhancer 
for hydrophilic macromolecular drugs and as a gene delivery system [1]. The 
applications of chitosan in the biomedical field are limited, however, by its poor 
solubility in physiological media. Chitosan is only soluble in aqueous acidic 
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solutions below pH 6.5, at which the primary amino groups of chitosan are 
protonated. To overcome the poor solubility displayed by chitosan in 
physiologically-relevant environments, N-trimethyl chitosan chloride (TMC), a 
partially quaternized chitosan derivative, has been synthesized and proven to be 
soluble over a wide pH range (pH 1 to 9) up to 10% (w/v) concentration, even 
at very low degree of quaternization [2]. Moreover, TMC is capable of opening 
tight junctions of intestinal epithelial cells at physiological pH values, and 
highly quaternized TMC has been proven to be a potent absorption enhancer, 
especially at neutral pH [3], whereas chitosan itself is insoluble and therefore 
ineffective. Moreover, TMC seems to be an efficient gene delivery system [4].  
However, the biocompatibility of TMC needs to be taken into 
consideration, and the absence of cytotoxicity is of vital importance. Whilst 
Kotze et al. suggested that TMC was non-toxic using a number of techniques 
including trypan blue exclusion technique [2,3], nuclear staining in Caco-2 cell 
monolayers and ciliary beat frequency assay [5], the reversibility of 
transepithelial electrical resistance (TEER) of 0.5% TMC solutions with 
different degrees of quaternization could not be demonstrated at pH 6.2 and 7.4 
in Caco-2 cells [3]. TMC, like most cationic macromolecules such as protamine 
and polylysine, probably interacts with anionic components (sialic acid) of the 
glycoproteins on the surface of epithelial cells, causing cytotoxic effects. 
Changes in cell morphology have already been observed with 1.0 µg/ml 
polylysine [6].  
Recently, a number of different molecular weight (MW) TMCs were 
synthesized in our laboratory. Unfortunately, we found that TMC was cytotoxic 
in L929 mouse fibroblast cells by MTT (methyl tetrazolium) assay (data shown 
below), a cell line recommended by USP 26 and several other pharmacopoeias 
as a standard method for cytotoxicity testing [7].  
From a safety point of view, it must be guaranteed that polymers used as 
drug carriers are biocompatible and non-toxic. The cytotoxicity of various MW 
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chitosans has been systematically investigated in our lab, and they were proven 
to be non-toxic [8]. However, no such work has been performed with TMC and 
its derivatives so far, despite their promising applications in the field of drug 
delivery. In general, polycations are considered to be cytotoxic [9], with the 
mechanism of cytotoxicity being mediated by interactions of polycations with 
cell membranes [10]. As TMCs exhibit a high positive charge density, such an 
investigation is essential. To our knowledge, no study has systematically 
explored the influence of TMC MW on the physico-chemical and biological 
properties. Additionally, in order to further improve the biocompatibility of 
TMC, PEG-g-TMC copolymers were synthesized [11]. Conjugation of PEG 
(polyethylene glycol) to proteins is well known to enhance the in vivo half-life 
of the encapsulated drugs, assist penetration into the cell membrane, alter 
pharmacological properties and increase biocompatibility [12,13]. Since these 
polymers are positively charged, self-assembled insulin complexes were readily 
obtained at optimal conditions. The influence of complexation on cytotoxicity 
was further investigated in order to elucidate the correlation between polymer 
MW, polymer structure, complexation and cytotoxicity, providing experimental 
support for the development of drug carriers from such materials.  
 
2. Materials and methods 
2.1 Materials  
Chitosan (~ 400 kDa) was purchased from Fluka (Steinheim, Germany) 
with a degree of deacetylation (DD) value of 84.7% and depolymerized 
according to the method described previously [8] to obtain chitosans of different 
molecular weights. Human recombinant insulin powder (26.2 IU/mg) was a gift 
from Aventis Pharma AG (Germany). Dulbecco’s modified Eagle’s medium 
(DMEM) was obtained from PAA (Coelbe, Germany). MTT (3-(4, 
5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) was purchased 
from Sigma (Deisenhofen, Germany). Lactate dehydrogenase assay kit (Product 
 70
In vitro cytotoxicity 
No. LK 100) was obtained from Sigma (Taufkirchen, Germany). 
Dimethylsulfoxide (DMSO) analytical grade was from Merck (Darmstadt, 
Germany). 
 
2.2 Synthesis of TMC with different MW 
Different MW TMCs were prepared according to a two-step method 
described previously using depolymerized chitosans of appropriate MW as 
starting materials and were subsequently characterized by 1H NMR [14].  
Throughout, we used the abbreviation TMC 400 kDa to denote the polymer 
prepared from chitosan 400 kDa, and the same for the other polymers. Since the 
degree of quaternization of TMC plays an important role in opening the tight 
junctions and a higher degree of substitution had improved permeation 
enhancement [4,15], TMCs with a 40% degree of substitution were prepared.  
 
2.3 Copolymer preparation and characterization 
PEGylated TMC copolymers were synthesized as described elsewhere in 
detail [11]. The products were purified by ultrafiltration and lyophilized. The 
graft ratio (wt%) of PEG was calculated from integral values of the 
characteristic peaks of PEG block at ~3.35 ppm (-OCH3) and TMC block at 
~3.0 ppm (-N (CH3) 2) and ~3.3 ppm (-N+ (CH3) 3) obtained in the 1H NMR 
spectra, using the known molecular weight of mPEG.  
The following nomenclature for the copolymers was adopted: PEG(X)n 
-g-TMC(Y), where X denotes the MW of PEG in Da, Y denotes the MW of 
TMC in kDa, and the subscript n represents the average number of PEG chains 
per TMC macromolecule of Y kDa.   
 
2.4 Preparation and characterization of insulin complexes 
The complexes were prepared via self-aggregation using the electrostatic 
interaction between polymers and insulin. The process parameters were 
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optimized as described in chapter 5. Briefly, an appropriate quantity of 
copolymer and insulin (1 mg/ml) were dissolved in 0.1 N Tris buffer pH 7.4. 
Complexes were prepared by mixing equal volumes of insulin and polymer 
solution under gentle magnetic stirring, and incubating for a further 20 min at 
room temperature. The complexes were characterized by dynamic light 
scattering and laser doppler anemometry (LDA) measurements. Complex size 
measurements were carried out with a Zetasizer 3000 HS from Malvern 
Instruments, Herrenberg, Germany (10 mW HeNe laser, 633 nm). Scattering 
light was detected at 90o angle through a 400 micron pin hole at a temperature 
of 25℃. For data analysis, the viscosity ( 0.88 mPa•s) and the refractive index 
(1.33) of distilled water at 25℃ were used. Measurements were analysed using 
the CONTIN algorithm. The zeta potential measurements of the complexes 
were carried out in the standard capillary electrophoresis cell of the Zetasizer 
3000 HS from Malvern Instruments at 25℃ in 6 mM Tris buffer pH 7.4. Values 
given are mean ± SD (n =10).  
 
2.5 MTT assay 
A mouse connective tissue fibroblast cell line, L929, was selected to 
evaluate cytotoxicity as a direct contact test, as recommended by USP 26. The 
experiment was carried out according to the method described previously [7,16]. 
The relative cell viability compared to control cells containing cell culture 
medium without polymer was calculated by [A]test / [A]control. Polyethylene 600 
(1 mg/ml) and polyethylenimine (10 mg/ml) were used as positive and negative 
controls of the method, respectively. 
 
2.6 LDH assay 
50 000 L929 cells/well were seeded in 12-well cell culture plates. After 24 
h incubation, cells were washed with PBS (phosphate buffered solution) and 
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were then incubated with selected polymers (1 mg/ml) in 2 ml PBS. 100 µl 
/well samples were collected at predetermined points. The LDH content in these 
samples was assayed utilizing a commercial kit according to the manufacturer’s 
protocol, which spectrophotometrically determined the amount of reduced 
nicotinamide adenine dinucleotide (NAD) at 492 nm in the presence of lactate 
and LDH. Control experiments were performed with 0.1% (w/v) Triton X-100 
and set as 100% cytotoxicity. LDH release was calculated by the following 
equation: 
100
][][
][][
(%)
%100
×−
−=
medium
mediumsample
AA
AA
LDH  
where [A]sample, [A]medium, [A]100% denote the absorbance of the sample, medium 
control and Triton X-100 control, respectively. All experiments were run in 
triplicate. 
2.7 Calculations and Statistics 
Results are depicted as mean ± SD from at least three separate 
measurements. Significance between the mean values was calculated using 
ANOVA one-way analysis (Origin 7.0 SRO, Northampton, MA, USA). 
Probability values P < 0.05 were considered significant. 
 
3. Results 
3.1 Characterization of TMCs  
The compositions of TMCs after undergoing a two-step synthesis are listed 
in Table 1. No significant difference in the degree of quaternization was 
observed with different MW TMCs (P > 0.05). 
Characteristics of the intermediates of TMC 50 kDa, TMC 25 kDa, and 
TMC 5 kDa after undergoing a one-step reaction are described in Table 2. 
Comparing Table 1 and 2, it is evident that the degree of substitution of 
trimethylated amino groups was only about 20% after the one step reaction. 
However, the substitution degrees of dimethylated amino group were high.  
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Table 1.  Degrees of substitution of different trimethyl chitosans after second 
step reaction 
 
%* TMC 400 kDa TMC100 kDa TMC 50 kDa TMC 25 kDa TMC 5 kDa 
N+(CH3)3 42.4 39.2 39.6 40.4 38.8 
N(CH3)2 12.4 13.0 12.7 7.2 0.6 
3-OCH3 6.1 5.4 7.8 12.0 12.0 
6-OCH3 8.0 6.7 11.9 14.7 14.8 
NHCOCH3 10.3 10.7 7.4 8.7 5.9 
NH2 free 30.8 37.0 40.3 43.6 54.7 
* Calculation based on 1H NMR analysis. 
 
Table 2. Characteristics of trimethyl chitosan intermediates after first step 
reaction 
%* TMC 50 kDa TMC 25 kDa TMC 5 kDa 
N+(CH3)3 17.2 18.2 20.0 
N(CH3)2 35.8 32.8 21.5 
NHCOCH3 12.1 16.8 10.9 
NH2 free 34.9 43.6 47.5 
* Calculation based on 1H NMR analysis. 
 
Therefore, the two-step synthesis was essential to the preparation of TMC with 
a higher N+(CH3) 3 substitution degree. Additionally, when the molecular weight 
of chitosan was < 50 kDa, it was easier to convert the intermediate N (CH3) 2 to 
the N+(CH3) 3 form in a second step, as indicated by the significantly decreased 
degree of N (CH3) 2 substitution. However, it also resulted in O-methylation in 
the 3- and 6-position, and the degree of 3-OCH3 and 6-OCH3 substitutions 
increased considerably with TMC 25 kDa and TMC 5 kDa, which can be 
explained by the decreased steric hindrance of the low molecular weight 
polymers. On the other hand, the degree of deacetylation of chitosan decreased 
slightly due to the sodium hydroxide used in the process, and chitosans with 
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molecular weight < 50 kDa were more sensitive compared with the larger 
molecular weight polymers.  
FT-infrared spectroscopy was used to investigate the change in structure 
after substitution, as depicted in Figure 1.  
5 0 01 5 0 02 5 0 03 5 0 0
( a )
( b )
( c )
( d )
( e )
 
Figure 1.  IR spectra comparing of chitosan with trimethyl chitosan. (a) Chitosan 400 kDa, 
(b) TMC 400 kDa, (c) TMC 100 kDa, (d) TMC 50 kDa, (e) TMC 5 kDa. 
 
Pure chitosan 400 kDa shows a distinct amide Ⅱ band at 1580 cm-1(s,δ
NH ) and amide linkage at 1406 cm-1(υC-N ) [17], the area between 1000 and 
1150 cm-1 was saturated, maybe due to the presence of three distinct modes of 
C-O-C, C-OH, and C-C ring vibrations. N-H stretching and O-H stretching 
vibrations can be characterized by the broad signals in the region of 3200-3500 
cm-1. After preparation of TMC, the absorption at 1580 cm-1(δNH ) decreased 
significantly. Normally there should be no absorption in this area for pure 
tertiary amine. However, the TMC prepared with this method is a mixture of 
primary amine, secondary amine and trimethyl amine, hence a small signal 
remains at this wavelength. Comparing the spectra of TMCs with that of 
chitosan, the signals at 1453 cm-1(δasCH3 ) and 1337 cm-1(δsCH3 ) became 
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stronger due to the formation of N+(CH3)3 group. This is in good agreement with 
the structure of TMC. 
 
3.2 Effect of TMC MW on cytotoxicity 
MTT assays were performed to test the effects of polymer structure on the 
metabolic activity of cells. All the polymers showed a dose and MW dependent 
effect on cytotoxicity. Cell viabilities of different MW TMCs versus 
concentration were investigated, and the IC50 values, which represent 
concentration of the copolymers resulting in 50% inhibition of cell growth, were 
calculated. The results are summarized in Table 3.  
 
Table 3.  Properties and IC50 values of TMC and its derivatives (Mean±SD). 
Cell viability was quantified by MTT assay (n = 7). 
Polymer 
(kDa) 
Degree 
of 
substit
ution 
(%)a 
TMC 
content 
[%(w/w)]
Theoretical 
MW 
(g/mol) 
Dalton/
chargeb
IC50 of pure 
polymers (µg /ml) 
 
3 h         24 h 
Complexes 
Particle 
size 
(nm) 
Zeta 
potential  
(mv) 
TMC 400  - 100 400000 189.4 30 15 256.6±0.8 19.6±2.3 
TMC 100 - 100 100000 189.4 70 22 273.3±4.6 22.7±2.5 
TMC 50 - 100 50000 189.4 90 37 236.6±1.3 21.7±1.9 
TMC 25 - 100 25000 189.4 270 125   
TMC 5 - 100 5000 189.4 >1000 >1000   
PEG(5k)298-g-TMC(400) 12.0 22.7±1.7 1890000 1042 220 40   
PEG(5k)640-g-TMC(400) 25.7 11.1±2.1 3600000 2446 370 >500   
PEG(5k)680-g-TMC(400) 27.4 10.6±2.5 3800000 2655 380 >500   
PEG(5k)40-g-TMC(100) 6.44 32.8±1.0 300000 640 >500 >500   
PEG(5k)19-g-TMC(50) 6.13 34.2±0.9 145000 590 >500 >500   
PEG(550)228-g-TMC(100) 36.7 41.5±1.5 225000 750 >500 270   
PEG(550)116-g-TMC(50) 37.4 40.8±3.4 120000 930 >500 460   
a Calculated by 1H NMR measurement. 
b Denoted as Dalton per charge.  
 
With similar charge ratios, the cytotoxicity of TMCs increased with 
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increasing MW. TMC 400 kDa was especially toxic with an IC50 of 15 µg/ml. 
However, TMC 5 kDa was shown to be completely nontoxic with an IC50 > 1 
mg/ml. An exponential relationship between TMC MW and IC50 after 3 h 
incubation was established, as presented in Figure 2, which can be used to 
predict the cytotoxicy of different MW TMC.  
IC50 = 2195.2M-0.7349
R2 = 0.9225
0
50
100
150
200
250
300
0 100 200 300 400
TMC MW (kDa)
IC
50
 
Figure 2. Relationship between TMC MW and IC50 values. 
 
3.3 Cytotoxicity of PEG(5k)-g-TMC copolymers  
Taking the extremely toxic TMC 400 kDa as a model, the effect of 
PEGylation on cytotoxicity was assessed with MTT assay. The theoretical 
molecular weights and compositions were calculated from the degree of 
substitution based on 1H NMR spectra and listed in Table 3. Cell viabilities of 
the copolymers are also shown in Figure 3.  
Compared to the unmodified TMC, PEGylation decreased cytotoxicity 
significantly (P > 0.05) despite of the increased MW of the copolymers. The 
cytotoxicity decreased with an increase in PEG substitution degree. A linear 
correlation between substitution degree and IC50 value after 3 h incubation was 
found (Figure 3C). When the substitution degree reached 25%, the resulting 
decrease in toxicity slowed. Moreover, it was noted that for the copolymers with 
a substitution degree above 25%, the cell viabilities at 24 h were even higher 
than at 3 h, but no statistical difference (P > 0.05).  
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Figure 3. Cytotoxicity of PEG(5k)-g-TMC(400) copolymers measured by MTT assay with 
L929 cells. Each point represents the mean±SD of seven experiments. 
(a) 3 h incubation. 
(b) 24 h incubation.  
              (c) Correlation between degree of substitution of TMC and IC50 values after 3 h 
incubation with the L929 cells. 
 
3.4 Effect of TMC MW in PEG(5k)-g-TMC copolymers 
As demonstrated, cytotoxicity of TMC was MW dependent. However, 
whether PEGylation has the same influence with different MW TMCs remains 
unclear. Therefore, PEG(5k)-g-TMC copolymers were prepared with similar 
graft ratio but different TMC MW (TMC 400 kDa, 100 kDa and 50 kDa, 
respectively), and the cytotoxicity was evaluated. Results are shown in Figure 4. 
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Cytotoxic dependency on TMC MW was more obvious in the copolymers. The 
cytotoxicity of TMC 100 kDa and TMC 50 kDa was decreased more than 10 
fold after PEGylation with a substitution degree of approximately 6%, with 
more than 80% of the cells still viable after 24 h incubation with a 500 µg/ml 
polymer solution, which was considerably higher than the concentration applied 
in practice. In contrast, PEG(5k)298-g-TMC(400) was more toxic compared to 
PEG(5k)40-g-TMC(100) and PEG(5k)19-g-TMC(50) copolymers, despite its 
higher substitution degree (12.0% versus 6%) and lower TMC content. 
Additionally, for the copolymers PEG(5k)40-g-TMC(100) and 
PEG(5k)19-g-TMC(50), no apparent time and dose dependent cytotoxicity was 
observed, implying that they were non-toxic.  
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Figure 4.  Effect of TMC MW on the cytotoxicity of PEG(5k)-g-TMC copolymers measured 
by MTT assay after (a) 3 h and (b) 24 h incubation with L929 cells. Each point 
represents the mean±SD of seven experiments. 
 
3.5 Effect of PEG MW in the copolymers 
It is believed that PEG MW in the copolymers will influence the 
cytotoxicity to some extent. Therefore, taking TMC100 kDa as an example, 
PEG(5k)40-g-TMC(100) and PEG(550)228-g-TMC(100) copolymers, which have 
similar graft ratios, were synthesized and the cell viabilities were investigated 
with MTT assay. Results are shown in Figure 5.  
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After 3 h of incubation, no significant difference in cell viability was 
observed between the two copolymers according to two sample paired t-test (P 
> 0.05). However, the difference was significant in the concentration range of 
10-500 µg/ml after 24 h of incubation (P < 0.05). Higher cell viability, 
especially at concentrations of 500 µg/ml, was observed for 
PEG(5k)40-g-TMC(100) compared to that of PEG(550)228-g-TMC(100), despite 
the higher substitution degree of PEG(550)228-g-TMC(100) (36.7% versus 
6.4%).  
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Figure 5.  Effect of PEG MW on the cytotoxicity of PEG-g-TMC copolymers measured by 
MTT assay after (a) 3 h and (b) 24 h incubation with L929 cells.  Each point 
represents the mean±SD of seven experiments.  
 
3.6 Effect of complexation with insulin 
Based on the assumption that complexation may decrease the cytotoxicity 
of the polymers, the relatively toxic polymers TMC 400 kDa, 100 kDa, 50 kDa 
were used as examples. Polymer concentration was kept constant at 0.1 mg/ml. 
Complexes were prepared at optimized polymer/insulin mass ratio 0.3:1. All of 
the complexes are comparable in size and carry a positive charge (Table 3). 
Effects of complexation on cell viability are shown in Figure 6. After 3 h of 
incubation, the effect of complexation was only apparent with TMC 400 kDa. 
No significant differences were found with TMC 100 kDa and 50 kDa (P > 
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0.05). However, after 24 h incubation cell viabilities increased approximately 
two fold with the complexes for all TMCs investigated.  
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Figure 6.  Effect of complexation with insulin on the cytotoxicity of TMC (100 µg /ml) 
measured by MTT assay after (a) 3 h and (b) 24 h incubation with L929 cells. Each 
point represents the mean±SD of seven experiments. The complexes were 
prepared at polymer/insulin mass ratio 0.3:1. 
 
3.7 LDH assay  
Lactate dehydrogenase (LDH) is a stable cytosolic enzyme present in the 
cytosol that is released upon cell lysis. This assay permits the investigation of 
chemicals that may induce alternations in cell integrity. It was performed to 
measure the membrane-damaging effects of the copolymers via the quantity of 
LDH in the culture media at different time points. 
Based on MTT assay, PEG(5k)40-g-TMC(100), PEG(5k)19-g-TMC(50), and 
PEG(550)228-g-TMC(100) copolymers were parctically nontoxic, with IC50 > 
500 µg /ml after 24 h of incubation. In order to elucidate any 
membrane-damaging effect caused by the copolymers, their influence on LDH 
release was investigated using TMC 100 kDa as a positive control, as shown in 
Figure 7. After 3 h of incubation, the LDH released was less than 6% for the 
three copolymers investigated, compared to 50.5±3.1% for TMC100 kDa, 
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which is in agreement with the results of the MTT assay.  
-20 0 20 40 60 80 100 120 140 160 180
0
10
20
30
40
50
60
LD
H
 R
el
ea
se
 (%
)
Time (min)
 
Figure 7. Cytotoxicity of the TMC and its derivatives by LDH assay. Each point represents 
the mean ± SD of three experiments. ( ■ )TMC 100 kDa, ( ● ) 
PEG(5k)40-g-TMC(100), ( ▲ )PEG(550)228-g-TMC(100), 
(▼)PEG(5k)19-g-TMC(50). 
 
3.8 Microscopic observations 
After performing the LDH assay, changes in cell morphology were 
observed using a Nikon inverse phase contrast microscope (Nikon TMS, Nikon, 
Japan) equipped with an objective (Plan 10/0.30Dl/Ph1, Nikon, Japan) of 100× 
magnification. Figure 8 shows a selection of phase contrast microscopy images 
obtained after 3 h of incubation with 1 mg/ml polymer solutions, and compared 
with medium control (PBS solution). In general, L929 mouse fibroblasts are 
large, spindle-shaped, adherent cells that grow as a confluent monolayer (Figure 
8a). Complete cell death was observed using 0.1% Triton X-100 in PBS as a 
positive control (Figure 8b). The cells were grainy and lacked normal 
cytoplasma space, the open area between cells indicated cell lysis had occurred. 
In contrast, the fibroblast L929 cells incubated with copolymers 
PEG(5k)40-g-TMC(100), PEG(5k)19-g-TMC(50), and PEG(550)228-g-TMC(100) 
maintained a polygonal shape with stretched filapodia (Figure 8d, 8e, 8f), no 
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cell debris, no detachment from dish bottom was observed, which was 
comparable to that of the medium control. As a contrast, the boundary of the 
cells became blurry after incubation with TMC 100 kDa and spindle shape was 
lost (Figure 8c). These morphological observations were consistent with the 
results obtained from both the MTT and LDH assays. 
 
4. Discussion 
    In vitro cytotoxicity of TMC and PEGylated TMC copolymers were 
studied with the MTT and LDH assay in the current work. All the polymers 
exhibited a time- and dose-dependent cytotoxic response that increased with 
MW. PEGylation decreased the cytotoxicity and was substitution degree 
dependent. Complexation with insulin decreased the cytotoxicity after 24 h 
incubation.   
Using the ninhydrin complexation reaction, Sabnis et al. found that the 
reactivity of chitosan was inversely proportional to its MW [18]. However, in 
our study, degree of quaternization of different MW TMC was similar, implying 
that the activity of primary amino groups was chitosan MW independent. Our 
result is consistent with Flory’ s theory, which suggests the intrinsic activity of 
all functional groups on a polymer remains the same [19]. 
Generally, the determination of cell viability is an assay to evaluate the in 
vitro cytotoxicity of biomaterials. The predicative value of in vitro cytotoxicity 
tests is based on the concept that toxic chemicals affect the basic functions of 
cells. Such functions are common to all cells, and hence the toxicity can be 
measured by assessing cellular damage. MTT and LDH assays are two methods 
commonly used for this purpose. Normally an early indication of cellular 
damage is a reduction in metabolic activity and this is the principle of MTT 
a s s a y  [ 1 6 ] .  I t  u t i l i z e s  t h e  y e l l o w  t e t r a z o l i u m  s a l t  [ 3 - ( 4 , 
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium-bromide], which is 
metabolized by mitochondrial succinic dehydrogenase activity of proliferating 
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(d)(c) 
(b)(a) 
Figure 8. Phase contrast microscopy images of L929 cells after incubation with different 
polymers (1 mg/ml) for 3 h. (a) Medium control, (b) 100% cytotoxic control, (c) 
TMC 100 kDa, (d) PEG(5k)40-g-TMC(100), (e) PEG(5k)19-g-TMC(50), (f) 
PEG(550)228-g-TMC(100). All figures are of the same magnification (100×). 
 
cells to yield a purple formazan reaction product which is largely impermeable 
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to cell membranes, thus resulting in its accumulation within healthy cells. 
Solubilization of the cells results in the liberation of the product that can readily 
be detected using a simple colorimetric assay. The ability of cells to reduce 
MTT provides an indication of the mitochondrial integrity and activity, which, 
in turn, may be interpreted as a measure of viability and/or cell number. In 
contrast, LDH reflects the damage /leakage of plasma membranes. It has been 
shown that changes in metabolic activity are superior indicators of early cell 
injury, and effects on membrane integrity are indicative of more serious damage, 
leading to cell death [20]. Therefore, in this study, MTT assay was employed 
first to evaluate the correlation between polymer structure and toxicity, and 
LDH assay was used for corroboration. As indicated, MTT and LDH assay gave 
similar results. PEG(5k)40-g-TMC(100), PEG(5k)19-g-TMC(50), and 
PEG(550)228-g-TMC(100) copolymers did not induce a significant decrease in 
metabolic activity after 3 h incubation. Additionally, no considerable LDH 
release was measured. In contrast, a remarkable LDH release was observed with 
TMC 100 kDa, a toxic polymer indicated by MTT assay. However, using trypan 
blue exclusion assay, a direct measurement of cell number, Kotze et al. 
suggested that TMC was almost nontoxic [2,3]. This discrepancy could 
probably be attributed to the different method employed. Generally, trypan blue 
exclusion assay is a direct measurement of cell number, since dead cells 
normally detach from a culture plate, and are washed away from the medium, 
therefore, it cannot quantifiably differentiate between dead cells that may have 
been damaged. 
Generally, biocompatibility is influenced by different properties of the 
polymers such as MW, charge density and type of the cationic functionalities, 
structure and sequence (block, linear, branched), and conformational flexibility 
[7]. TMC 400 kDa was found to display the highest cytotoxicity, whilst TMC 
25 kDa and TMC 5 kDa were almost nontoxic. An increase in cytotoxicity as a 
function of MW, which was observed for TMC in this study, was also reported 
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for other polycations, such as DEAE-dextran [7] and PEI (polyethylenimine) 
[21]. Whilst it has been found that chitosan was nontoxic irrespective of the 
MW [8], the cytotoxicity of TMC can probably attributed to the positive charge 
carried by the polymer even in neutral environment, which can subsequently 
interact with the negatively charged cell membrane, resulting in membrane 
damage. PEGylation decreased the cytotoxicity of TMC considerably, the 
extent of which was substitution degree, TMC MW and PEG MW dependent. 
The effect of PEG can be explained by steric effects, which acts to shield a 
proportion of the positive charges present on TMC. This was particular 
relevant in the case of small MW TMC. However, since parts of the primary 
amino groups in TMCs were substituted by PEG , positive charge density 
decreased overall.  
High cytotoxicity of the PEG(5k)298-g-TMC(400) copolymer was 
observed, despite the high degree of substitution. This effect was probably 
related to the polymers high MW. Hence, a higher substitution degree is 
essential to decrease the cytotoxicity of TMC 400 kDa and 25% substitution 
was demonstrated to be sufficient. It should be noted here that a degree of 
substitution of > 40% is impossible to attain, since only primary amino function 
groups can participate in the reaction (Table 1). When considering the 
cytotoxicity, PEG 5 kDa is preferable to PEG 550 Da for PEGylation as its 
comparatively long chain structure probably shields the positive charges of 
TMC more efficiently.  
Complexation with insulin decreased the cytotoxicity of TMC after 24 h of 
incubation with cells. This phenomenon can be ascribed to the electrostatic 
interaction between TMC and insulin, which, decreased the interaction of the 
positively charged amino groups of TMC with the anionic components of the 
glycoproteins on the cell membrane, leading to higher cell viability. Kunath et al. 
reported similar results with PEI and galactosylated PEI [22]. 
Based on studies with modified PLL (poly-l-lysine), Ferruti et al. noted 
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that macromolecules with tertiary amine groups exhibit a lower toxicity than 
those with primary and secondary residues [23]. Dekie et al. found that the 
presence of primary amines had a significant toxic effect on red blood cells with 
poly l-glutamic acid derivatives [24]. However, TMC is toxic despite of its high 
tertiary amino group content (approximately 40%) and low primary amine 
groups (approximately 40%) compared to chitosan. In contrast, chitosan, despite 
its high primary amine group content, was biocompatible. Therefore, it is clear 
that both the type of amine groups and nature of the polymer influence the 
cytotoxicity.  
In summary, different MW TMCs have been synthesized and characterized. 
Cytotoxicity of TMC and its derivatives was investigated with the MTT and 
LDH assays, which allow the quantification of the cell metabolic activity and 
membrane integrity, respectively. Similar results were obtained with the two 
methods, which were in turn in agreement with observations from inverted 
phase contrast microscope images. MW dependent cytotoxicity was observed 
for TMC, and PEGylation led to increased biocompatibility. PEG 5 kDa is 
preferable to PEG 550 Da for efficacious PEGylation. Complexation with 
insulin decreased the toxicity of TMCs after 24 h incubation. These insights 
could be particular helpful due to the promising application of TMC as drug 
delivery vehicles.  
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Abstract 
Polyelectrolyte complexes (PEC) formed from chitosan derivatives and 
insulin were prepared and parameters influencing complex formation were 
characterized. Turbidimetric titration, in combination with dynamic light 
scattering (DLS) and laser doppler anemometry (LDA), were used to study the 
complexation process. The morphology of the PECs were determined using 
atomic force microscopy (AFM). PEC formation was predominantly pH 
dependent. Complexation with insulin occurred only above critical pH value 
(pHc) of 6.0 for all the chitosan derivatives investigated. Soluble PECs in the 
size range of 200-500 nm with spherical or sub-spherical morphology and 
smooth surface structure were obtained at optimized polymer/insulin charge 
ratios. Optimal conditions were obtained when the pH of PECs was in the range 
of 6.5-8.0, depending on polymer structure. The stability of PECs was 
influenced by polymer chain length. Only when the MW of the polymers was 
≥25 kDa PEC precipitation could be avoided. Increasing the ionic strength of 
the medium accelerated complex dissociation. Conversely, high temperatures 
facilitated PEC formation and compaction. Chitosan trimethylation and 
PEGylation significantly improved the stability of PECs. All of the complexes 
could be lyophilized without influencing the properties. On the basis of our 
results, we suggest that interactions involved in PEC formation were 
predominantly electrostatic in nature, involving the positively charged amino 
groups of chitosan and the negatively charged insulin above its isoelectric point. 
 
1. Introduction 
Recently, nanoparticles have increasingly been investigated as carriers for 
hydrophilic macromolecular drugs such as peptides, proteins, vaccines and 
DNA to improve stability and permit administration through non-parenteral 
routes (1).  Although a wide variety of techniques are available for producing 
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nanoparticles including solvent evaporation (2), interfacial polymerization (3) 
and emulsion polymerization methods (4), most of these approaches involve the 
use of organic solvents, heat or vigorous agitation, procedures which are 
potentially harmful to sensitive biomolecules. In recent years, self-assembly of 
proteins with natural or synthetic polyelectrolytes to form complexes 
(poly-electrolyte-complexes, PEC) with drug candidates has drawn increasing 
attention (5).  PEC formation leads to particles with dimensions on a colloidal 
level, generating optically homogeneous and stable nano-dispersions. 
Additionally, such methods have the advantage of not necessitating sonication 
and organic solvents during preparation, therefore minimizing possible damage 
to drug candidates during PEC formation. 
Chitosan is a non-toxic and biocompatible cationic polysaccharide 
produced by partial deacetylation of chitin that is isolated from naturally 
occurring crustacean shells. Due to its specific properties, chitosan has found a 
number of applications in drug delivery including that of an absorption 
enhancer of hydrophilic macromolecular drugs (6,7) and as gene delivery 
system (8,9). Additionally, it has been included in the European Pharmacopoeia 
2002 as an excipient. Moreover, enhancement of nasal absorption of insulin in 
rabbits and sheep was reported (10,11). In 1997, Calvo et al. prepared chitosan 
nanoparticles by ionotropic gelation of chitosan with tripolyphosphate 
counterions (12). Since this time, almost all chitosan nanoparticles have been 
prepared in this manner. Chitosan is positively charged at pH < 6.5 due to the 
protonation of the amino groups, and insulin is negatively charged at pH above 
its isoelectric point (apparent pI 6.4). Consequently, electrostatic interactions 
between both entities can be used as a driving force for PEC formation. 
The purpose of this investigation is to evaluate the feasibility of PEC 
formation between insulin and various chitosan derivatives by self-assembly 
through the electrostatic interaction in the absence of TPP. Although Dyer et al. 
mentioned this approach (13), this work has yet to be investigated 
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systematically to the best of our knowledge. In this paper, using turbidimetric 
titration and dynamic light scattering, the properties of soluble PECs between 
insulin and chitosan derivatives have been characterized, and various factors 
influencing the process were investigated in detail.   
   
2. Materials and methods  
2.1 Materials 
Chitosan (400 kDa) was purchased from Fluka (Steinheim, Germany) with 
a degree of deacetylation (DD) of 84.7%. Depolymerization was carried out as 
described previously to obtain chitosans of different molecular weights (14). 
Trimethyl chitosan (TMC) derivatives were synthesized in a two-step synthesis 
(15). Grafting of TMC with poly (ethylene glycol), PEG 5 kDa and PEG 550 Da 
was achieved to yield copolymers: PEG(5k)40-g-TMC(100) and 
PEG(550)228-g-TMC(100) as described elsewhere (16). The following 
nomenclature was adopted for the copolymers: PEG(X)n-g-TMC(100), where X 
denotes the MW of PEG in Da and the subscript n represents the average 
number of PEG chains per TMC macromolecule of 100 kDa. Human 
recombinant insulin powder (26.2 IU /mg) was a gift from Aventis Pharma AG 
(Germany).  
 
2.2 Preparation of insulin nanocomplexes 
Chitosan-insulin PEC can be obtained when both molecules oppositely 
charges. To facilitate this, the pH of chitosan solutions was adjusted to 5.5 (in 
this case, more than 90% of the amine groups are protonated), and pH of insulin 
solution was adjusted as required. Polymer solutions of appropriate 
concentration (as indicated below) were prepared by dissolving the dry polymer 
powder in 0.25% acetic acid solution under stirring and adjusting the pH to 5.5 
with 1 N NaOH. Insulin solution (1 mg/ml) was prepared by dissolving insulin 
powder in 87% (v/v) 0.01 N HCl. Subsequently, 13% (v/v) 0.1 N Tris 
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(hydroxymethyl) aminomethane solution was added, resulting in a clear insulin 
solution in Tris buffer at pH 7.4. The pH was further adjusted with 1 N HCl or 
1N NaOH as required. Due to the poor solubility of chitosan at neutral pH 
conditions, PECs were prepared by adding 1 ml polymer solution to an equal 
volume of insulin solution in a glass vial under gentle magnetic stirring, and 
incubating for a further 20 min at room temperature. All experiments were 
performed in triplicate at ambient temperature. Freshly prepared solutions were 
used in each experiment.  
 
2.3 Characterization of polymer-insulin complexes 
Dynamic Light Scattering (DLS). Complex size measurements were carried 
out with a Zetasizer 3000 HS from Malvern Instruments, Herrenberg, Germany 
(10 mW HeNe laser, 633 nm). Scattering light was detected at 90o angle through 
a 50 micron pin hole at a temperature of 25℃. For data analysis, the viscosity 
( 0.88 mPa•s) and the refractive index (1.33) of distilled water at 25℃ were 
used. Scattering data (Kilo counts per second, Kcps) were noted during the 
measurement. The instrument was routinely checked and calibrated using 
standard reference latex particles (AZ 55 Electrophoresis Standard Kit, Malvern 
Instruments). Measurements were analysed using the CONTIN algorithm. 
Particles sizes of PEC are given as mean ± SD (n = 10). 
Laser Doppler Anemometry (LDA). The zeta potential measurements of the 
complexes were carried out in the standard capillary electrophoresis cell of the 
Zetasizer 3000 HS from Malvern Instruments (Herrenberg, Germany) at 25℃ 
in 0.01 M Tris buffer pH 7.4. Average values of the zeta potential were 
calculated with the data from ten runs (± SD).  
Insulin loading of PEC.  The amount of insulin entrapped in PEC was 
calculated by measuring the difference between the total amount of insulin 
added to the solution, and the quantity of non-associated insulin remaining in 
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the aqueous supernatant after the PEC formation. For this purpose, PECs were 
centrifuged at 14000 rpm/min for 30 min at room temperature. The quantity of 
insulin in the supernatant was measured using a Merck HPLC (Hitachi, 
Darmstadt, Germany) system equipped with a fluorescence detector (F-1050) 
and a LiChrospher 100 RP- 18e column (5 µm, 4.6×250mm). Samples of 20 µl 
were injected with an automatic sampler (model As-200A). The mobile phase 
consisted of eluent A (ultra pure water with 0.1% trifluoroacetic acid (TFA)) and 
eluent B (acetonitrile: water: TFA 89.9: 10: 0.1) 65: 35. The flow rate was 1.0 
ml/min and an emission wavelength of 600 nm, together with an excitation 
wavelength of 280 nm was employed. Insulin content was quantified by peak 
integration and insulin association efficiency was calculated as follows:  
%100×−=
insulinofamountTotal
insulinFreeinsulinofamountTotalefficiencynAssociatio  
All samples were measured in triplicate. 
Morphology of the complexes.  Atomic force microscopy was employed 
to characterize the morphology of PECs using a Digital Nanoscope IV Bioscope 
(Veeco Instruments, Santa Barbara, CA, USA). All measurements were 
performed in tapping mode to avoid damage of the sample surface. Samples 
were freshly prepared in triplicate before the experiment.  
 
2.4 Turbidimetric Titration  
The simplicity and sensitivity of turbidimetric titration method as applied 
to protein-polyelectrolyte systems is based on the fact that turbidity is 
proportional to both the molecular weight and the concentration of particles in a 
system (17). Consequently, the interaction between polymer and insulin was 
studied with this method in our work. Briefly, insulin solution (1 mg/ml) was 
added stepwise to 1 ml polymer solutions. Transmittances at 460 nm and pH 
changes of the mixture were noted throughout (17). Transmittance was 
monitored with a UV/Vis spectrophotometer (UV-160, Shimadzu, Kyoto, Japan) 
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connected to a 1 cm path length optical probe and calibrated to 100% 
transmittance with ultra pure water. The turbidity was reported as 100 - %T, 
where %T was the average value of triplicate measurements. A pH meter with a 
combination electrode was used to monitor the solution pH (n = 3). 
 
2.5 Lyophilization 
Sucrose (Fluka, Steinheim, Germany) or mannitol (Fluka, Steinheim, 
Germany) was added to freshly prepared complex solutions. The content of 
lyoprotectant was expressed as the lyoprotectant / insulin ratio (w/w). Samples 
(600 µl ) were frozen at -80℃  in Eppendorf tubes. Freeze drying was 
performed using the lyophilizator Beta 1 (Crist, Osterode, Germany). Samples 
were dried for 48 h at a working pressure of 0.07 mbar corresponding to a 
condenser temperature of -46℃. Dried samples were resuspended in 600 µl of 
distilled water and characterized by dynamic light scattering. 
 
2.6 Calculations and statistics 
Results are depicted as mean±SD from at least three measurements. 
Significance between the mean values was calculated using ANOVA one-way 
analysis (Origin 7.0 SRO, Northampton, MA, USA). Probability values P < 0.05 
were considered significant. 
 
3. Results and Discussion 
3.1 Effect of the pH value of insulin solution 
   The effects of pH on PEC formation have previously been discussed, with 
increased pH values promoting the formation of protein-polycation complexes 
(18). Since complex formation between proteins and polyelectrolytes is 
primarily driven by coulombic interactions, the pH of the insulin solution will 
influence properties of the resulting PECs. Insulin solutions (1 mg/ml) of 
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differing pH values (7.0, 8.0, 8.5, and 9.0, respectively) were added to equal 
volumes (1 ml) of various concentrations of chitosan 100 kDa solutions at pH 
5.5 under gentle magnetic stirring. Figure 1 shows that the particle size of 
chitosan–insulin PECs is dependent on both the pH of the insulin solution and 
the chitosan concentration. Soluble insulin-PECs were formed when the final 
system pH was in the range of 6.5-7.0. By contrast, when the pH of insulin 
solution was 9.0, then the final system pH was > 7.5. Here, less than 10% of the 
amino groups of chitosan are positively charged and precipitation occurred. 
Additionally, extremely large particles were observed at pH 7.0 with increasing 
chitosan concentration, compared with these prepared at pH 8.0 and 8.5. This 
effect can be attributed to the increased electrostatic interaction with pH, 
resulting in PEC compaction. Insulin-PECs with particle sizes in the desired 
range of 200-500 nm could be formed when the chitosan concentration was in 
the range of 1.0-2.0 mg/ml and the pH value of insulin solutions was 8.0-8.5. 
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     Figure 1. Effect of insulin solution pH and chitosan 100 kDa concentration on the 
particle size of the PEC. The PEC was prepared by adding 1 ml insulin 
solution (1 mg/ml) of desired pH into chitosan 100 kDa solution (pH 5.5) 
dropwise under stirring.  
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3.2 Stoichiometric ratio of insulin and chitosan derivatives in PEC  
       It is well known that polymer/insulin ratio influences both the degree of 
interactions and the properties of PECs. Therefore, the stoichiometry was 
investigated in greater detail using turbidimetry and dynamic light scattering. 
Polymer solutions were titrated against insulin solutions, and the resulting 
particle size and Kcps values were measured. The points at which particle size 
began to increase dramatically, and the Kcps values reached a plateau were 
denoted as the endpoint of the titration, and the optimal [polymer]/ [insulin] 
charge ratio was calculated. Differently structured polymers, namely chitosan 
100 kDa, TMC 100 kDa, PEG(5k)40-g-TMC(100) and PEG(550)228-g-TMC(100) 
were investigated under identical conditions. Figure 2 presents titration data of 
the chitosan 100 kDa insulin complex.   
0
200
400
600
800
1000
1200
1400
0.1 0.5 0.9
Insulin Volume Added (ml)
Pa
rti
cl
e 
Si
ze
 (n
m
)
0
100
200
300
400
500
600
K
cp
s
 
 Figure 2. Evolution of particle size and Kcps value of chitosan 100 kDa-insulin complex 
versus insulin volume. (■) Size; (◆) Kcps. Chitosan 100 kDa solution (2 mg/ml) 
was titrated with insulin solution (1 mg/ml). Particle size and Kcps values of the 
PEC were monitored by dynamic light scattering.  
 
During the initial stages of titration, the system pH was below the 
isoelectric point of insulin. Hence, it was weakly negatively charged and 
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therefore only large aggregates were observed. They condensed to a more 
defined and compact structure with increasing insulin concentration until a 
critical point was reached, from where the particle size increased abruptly. This 
increase was accompanied by a slight Kcps decrease, implying either the 
redistribution of insulin in the polymer, or binding on the surface of the polymer. 
Therefore, this critical point was selected to calculate the optimal ratio between 
insulin and chitosan. After this critical point, aggregation occurred in one hour 
due to the significantly increased particle size. 
As reported previously (19), at the physiological pH of 7.4 human insulin 
carries two negative charges per molecule. As for chitosan, the protonation of 
the molecule’s amino groups can be represented by (20): 
Glc-NH3+ + H2O ↔ Glc-NH2 + H3O+ 
(1-α)               α       α 
pKa = pH + log (1-α)/ α 
where α is the fraction of unprotonated free amino-groups NH2. Since the pKa 
of chitosan is approximately 6.5, we can calculate the proportion of amino 
groups that are not positively charged based on the final system pH. Making the 
assumption that 24% of the primary amino groups of chitosan (calculation 
based on a final system pH 6.8) and all primary and quaternized amino groups 
of TMC are protonated at neutral pH, the polymer/insulin charge ratio (+/-) was 
calculated according to the mass of the components at critical points. It was 
found to be polymer structure dependent and was approximately 7:1, 3:1, 5:1, 
5:1 for chitosan 100 kDa, TMC 100 kDa, PEG(5k)40-g-TMC(100) and 
PEG(550)228-g-TMC(100) respectively. These results suggest that the 
stoichiometry of the complexes are primarily determined by the charge density 
of the polymers.  
It is also noteworthy that the size of the PECs was inversely proportional to 
the quantity of polymer added. Smaller PECs were formed at ≥ optimal 
polymer/insulin ratio, whereas larger complexes were obtained below this ratio 
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and flocculation occurred in a short period of time. Similarly, several groups 
found that for chitosan and other cationic polymers, an optimal charge ratio of 
polymer/DNA 5:1 was essential for the protection of nanocomplexes of 
appropriate size (21,22). This is in agreement with the theory of PEC formation 
(23). Generally, only highly charged polyelectrolytes with strong ionic groups 
favor a 1:1 stoichiometry of PEC (24), and this is not the case for chitosan and 
insulin. The stoichiometric ratios observed for different combinations of 
components may be understood on the basis of a mass action law, assuming a 
different degree of dissociation between polyions and counterions. PECs with 
an excess of polycation are more stable due to the repulsion of charged 
nanocomplexes in suspension. 
 
3.3 Effect of polymer concentration  
Taking chitosan 100 kDa as an example, the effect of polymer 
concentration on complex formation was investigated. Figure 3a shows that the 
transmittance of the mixture increased with insulin volume until equilibrium 
was achieved. Three phases can clearly be observed in Figure 3a. At insulin 
volumes < 0.3 ml (critical volume, Vc, the precise value depends on polymer 
concentration), fewer complexes were formed. Turbidity increased rather 
abruptly after Vc and a plateau was reached at a specific insulin volume, which 
can be denoted as Vp and considered as the end point of the titration. When 
considering chitosan 100 kDa, the endpoint is polymer concentration dependent 
and is approximately 0.8 ml and 1.1 ml for 1 mg/ml (aggregation in 5 minutes) 
and 2 mg/ml solutions, respectively. Additionally, it is supposed that 
polymer-insulin binding can alter the local electrostatic environment of 
ionizable amino acid residues and therefore, the pH change was also monitored 
throughout. Figure 3b shows the evolution of pH versus polymer concentration. 
Compared to the control group (acetate buffer pH 5.5), a large number of 
protons were released during the complex formation process and the proton 
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number was a function of polymer concentration. More protons were released at 
a higher concentration, as indicated by a lower pH value. Consequently, fewer 
complexes were formed due to decreased negative charge density of insulin at 
low pH. Another possibility explaination for the decreased complex 
concentration is that a proportion of the charged segments are shielded at high 
concentration due to the strong intermolecular interactions, as chitosan normally 
takes the shape of an extended random coil in solution.    
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Figure 3  (a) Turbidity evolution profiles as a function of insulin volume using different 
concentration of chitosan 100 kDa solutions. (◆) 1 mg/ml; (■) 2 mg/ml; (▲) 
4 mg/ml. 
     (b) pH evolution profiles as a function of insulin volume using different 
concentrated chitosan 100 kDa solutions.  
The PEC was prepared by the stepwise addition of insulin solution (1 mg/ml, pH 
8.5, 50 µl ) stepwise into 1 ml of various concentrated polymer solutions (pH 5.5). 
The transmittance of the mixture was measured at 460 nm and denoted as T. The 
pH of the mixture was measured simultaneously. 
 
3.4 Effect of system pH 
Since the most important factor that must be controlled during PEC 
formation process is pH, the relationship between pH value and transmittance 
was studied with chitosan and TMC, as depicted in Figure 4. An extremely good 
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correlation between pH and transmittance could be observed. Three regions can 
be defined in Figure 4. In region 1, columbic repulsive forces present between 
the positively charged polymer and the mainly positively charged insulin 
prohibited the complex formation. A sharp increase in turbidity was observed in 
region 2. In region 3, a saturation plateau appeared, which can be regarded as 
the endpoint of the titration. These regions can be considered as separate phases, 
with pHc representing the critical pH value for transition from region 1 to 
region 2 and pHe representing the equivalent pH value. For both chitosan and 
TMC, virtually no PEC was obtained at pH < 6.0. 
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Figure 4. Relationship between pH value and transmittance. 
(a) chitosan 100 kDa  (×) 1 mg/ml; (* ) 2 mg/ml; (●) 4 mg/ml 
(b) TMC 100 kDa     (×) 1mg/ml; (* ) 2mg/ml; (●) 4 mg/ml 
 
This is due to the fact that in order to form a PEC, both polymers have to be 
ionized and bear opposite charges. In the case presented here, the reaction can 
only proceed at pH values in the vicinity of the pKa interval of the two 
polymers (the pKa of chitosan is approximately 6.5, whilst the apparent pI of 
insulin is 6.4). It is also noted that the pHc value is polymer concentration 
independent, an observation that has previously been reported (25). In contrast, 
the pHe value varied with polymer structure. It was measured to be 
 102
Chapter 5 
approximately 6.5 for chitosan and 7.3 for TMC, which can be explained by the 
different charge properties of the polymers. 
However, as suggested by Kabanov (23), soluble PEC species in which the 
host polyelectrolyte component is a weak polyacid or a weak polybase can be 
compacted and precipitated by a pH change, i.e. suppressing ionization of 
single-stranded blocks. As chitosan is a weak polybase, the precipitation pH for 
chitosan-insulin complex and TMC-insulin complex was investigated. The 
values were approximately 7.5 and 10.0 for chitosan and TMC respectively. In 
this case, the system pH should be below the precipitation pH value to obtain 
soluble PEC. Additionally, at pH values < 5 or > 8, insulin degrades relatively 
rapidly (26). Consequently, the pH of the system should be controlled in the 
range of 6.5-8.0 depending on the polymer structure. 
 
3.5 Effect of polymer molecular weight and structure 
Since all interpolymer interactions are known to be critically dependent on 
the chain lengths of the interacting macromolecules (27), the complex 
formation process was studied with different MW chitosans and evolutions of 
transmittance (Figure 5a) and system pH (Figure 5b) were observed 
simultaneously. The critical insulin volume (Vc) for complex formation 
increased with chitosan MW, from approximately 300 µl for chitosan 50 kDa 
and 25 kDa to 500 µl for chitosan 400 kDa and 100 kDa. Slopes of the profiles 
in Figure 5a were calculated using data in the linear range, which were 0.071, 
0.084, 0.145, 0.141 for chitosan 400 kDa, 100 kDa, 50 kDa and 25 kDa, 
respectively. This data is regarded as binding constants between polymers and 
insulin. It is clear that the formation of chitosan-insulin soluble complexes was 
chitosan MW dependent, with chitosans exhibiting shorter chains being 
preferable for complexation. These findings can probably be explained by the 
fact that complex formation was mainly governed by kinetics which led to 
preferential binding with the shorter chains due to their greater flexibility. 
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However, no statistic differences were observed regarding the slope of chitosan 
50 kDa and chitosan 25 kDa (P > 0.05) or chitosan 400 kDa and chitosan 100 
kDa (P > 0.05). 
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Figure 5. (a) Effect of chitosan molecular weight on the formation of insulin complexes.  
(b) pH profiles as a function of insulin solution volume. 
(◆)chitosan 400 kDa,  (■)chitosan 100 kDa,  (▲) chitosan 50 kDa,  
(╳) chitosan 25 kDa,   (●) medium,         (+) medium +insulin. 
 
When compared to the control, binding between chitosan and insulin led to 
proton release by enhancing the dissolution constant, Ka, of the ionizable 
groups, with this process being chitosan MW dependent (Figure 5b). The 
particle sizes of the PECs decreased with decreasing molecular weight (376.4±
10.3 nm for chitosan 400 kDa compared to 182.3±2.9 nm for chitosan 25 kDa). 
A considerably decreased particle sizes were obtained from the PECs prepared 
with PEGylated TMC 100 kDa copolymers, compared to the homopolymer 
TMC 100 kDa (Table 1). This is probably a consequence of the hydrophilic 
polyethylene glycol forming a shell on the PEC surface, which subsequently 
promotes complex condensation. Zeta potentials of the PECs at optimal charge 
ratios were also measured, and have been listed in Table 1. All of the PECs are 
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positively charged, and the charge values are in the order of TMC > 
PEG(5k)40-g-TMC(100) > PEG(550)228-g-TMC(100) > chitosan. This implies 
that insulin was encapsulated in the polymers projecting their positively charged 
chains towards the external aqueous medium, which will subsequently increase 
the interaction with the negatively charged cell surface and facilitate insulin 
uptake. The use of copolymers PEGylated with different MW PEG allows 
variation of the positive surface charge density by changing the relative 
substitution ratio.  
 
Table 1. Properties and characteristics of the polymers and the PECs 
 
a DD degree of deacetylation, calculated by 1H NMR analysis. 
Polymer 
(kDa) 
DDa
(%) 
Substit
ution
(%)b 
Molecular 
weight   
(kDa)c 
Mass 
ratio 
Pol. 
/Ins.d 
PCS size 
(nm) 
AFM size 
(nm) 
Zeta-potentia
l (mv) 
Drug 
loading 
(%) 
Charge 
ratio(Po
l./Ins.)d 
Chitosan 400 85.1   2:1 376.4±10.3  13.6±0.3 89.7±2.1 7:1 
Chitosan 100 85.4   2:1 308.2±8.5 284.2 ± 37.5 8.8±0.4 87.3±2.4 7:1 
Chitosan 50 89.9   2:1 226.8±6.3  7.4±0.3 93.2±1.3 7:1 
Chitosan 25 86.2   2:1 182.3±2.9  6.4±1.2 94.2±1.1 7:1 
TMC 100  39.3b1 100 0.3:1 273.3±4.6 245.5 ± 26.4 22.9±1.8 81.4±2.1 3:1 
PEG(5k)40-g-TMC(100)  6.44 300 1:1 186.4±8.3 136.0 ± 14.1 21.0±2.2 94.8±1.1 5:1 
PEG(550)228-g-TMC(100)  36.7 225 1:1 224.6±2.3 215.5 ± 12.3 12.7±2.3 94.2±1.7 5:1 
b Calculation based on the primary amino group content in chitosan, b1 Degree of quaternization. 
c Calculation based on the composition of the copolymer. 
d Calculation based on the stoichiometric ratio optimized in Section 3.2. 
 
 
When compared with the labile insulin association of 10-85 % observed 
for chitosan nanoparticles prepared by ionic gelation (28,29), the insulin 
association efficiencies of the self-assembled nanocomplexes prepared here 
were high and stable, at approximately 90%. Additionally the complexes 
displayed a significantly decreased surface charge, with a zeta potential value of 
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8.8± 0.4 versus 27.1± 2.6 for chitosan 100 kDa self-assembled insulin 
nanocomplexes and chitosan 70 kDa insulin nanoparticles, respectively. The 
difference in particle size was marginal. However, the particle size distribution 
narrowed for the nanocomplexes (28,29). 
 
3.6  Complex stability 
3.6.1 Effect of polymer MW 
Maintaining the physico-chemical stability of the delivery vehicles is 
thought to be one of the essential requirements for obtaining in vivo activity. We 
began by investigating the influence of chitosan MW on complex stability. 
When the MW of chitosan was as high as 25 kDa, soluble PECs were obtained 
and kept stable for at least 8 hours. In contrast, large particle sizes (µm) were 
observed for the PECs prepared with chitosan 10 kDa and 5 kDa, with 
precipitation occurring within 1 h. This phenomenon is consistent with the 
theoretical prediction that suggests the stability of interpolymer complexes are 
critically dependent on the chain length, and for each system matrix an “ upper 
critical length” of oligomer chains exists, above which the complexes are found 
to be stable (30). Kabanov also reported that the solubility of PEC in aqueous 
media is determined by the relative length of oppositely charged polyions (23). 
A similar MW limitations were observed when different MW PEIs 
(polyethylenimine) were employed to complex DNA (31). Complexes of LMW 
PEI were not stable, even in the presence of extreme excesses of polycation 
(N/P 50). Huang et al. reported the same problem when preparing nanoparticles 
with chitosan 10 kDa by ionotropic gelation (32). 
 
3.6.2 Effect of ionic strength of the medium 
Some studies indicated that the addition of salt could affect the stability of 
the PEC. For example, it was reported that complexes formed by catalase and 
polyacrylic acid readily precipitated upon increases in NaCl concentration (27). 
 106
Chapter 5 
Reduced protein binding with increasing ionic strength was also observed in the 
lysozyme-PMAA system (27).    
In order to investigate the effect of salt on the chitosan-insulin interaction, 
the ionic strength of the solution was adjusted by adding sodium chloride. This 
was achieved by mixing various PECs with a series of concentrated sodium 
chloride solutions, and monitoring the integrity of the PECs immediately after 
mixing by dynamic light scattering. Since we found no apparent change in 
particle size, only the evolution of Kcps values are presented in Figure 6.  
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Figure 6. Effect of ionic strength on the dissociation of different structured polymer-insulin 
complexes. 
 
Dissociation clearly increased with increasing salt concentration, which is 
probably the result of reduced attraction between the oppositely charged 
polyelectrolytes by contribution to the counter-ion environment. The degree of 
influence was polymer structure dependent. This was particularly obvious for 
chitosan-insulin PECs, with a linear correlation (R = 0.995) being observed 
between the percent of Kcps remained and the ionic strength of the solution. 
With regard to TMC 100 kDa and PEGylated TMC 100 kDa insulin PECs, the 
influence appeared to be marginal when the ionic strength was < 50 mM, 
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probably as a consequence of the steric effect of methyl groups and 
polyethylene glycol segments. However, severe complex dissociation was 
observed at an ionic strength of 75 mM, irrespective of the PEC structure. This 
can be defined as a critical ionic strength (Ic) concerning the complex stability. 
 
3.6.3 Effect of temperature 
A number of different PECs were incubated at 20, 37, 50, 65℃ for 6 h, 
and were subsequently characterized at predetermined time intervals at room 
temperature. At elevated temperatures, more complexes were formed as 
indicated by the increased Kcps values. This increase was accompanied by a 
slight decrease in particle size (10-20%), independent of polymer structure. 
Figure 7 illustrates the influence of temperature on the properties of chitosan 
100 kDa insulin complexes. After 6 h incubation, Kcps values increased by 
100% at 65℃  (compared with the value at 20℃), and the particle size 
decreased by 20%. Thus, increases in temperature facilitate complex formation 
and compaction. This suggests that the reaction may be entropy driven in the 
same way polyanion-polycation complexation occurs, where the increase in 
entropy is associated with the release of small counterions initially bound to the 
polymers (27). On the other hand, high temperatures may have a profound 
influence on the kinetics of complex formation.  
 
 
 
 
 
 
 
Figure 7. Effect of temperature on the properties of chitosan100 kDa insulin complexes. 
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3.6.4 Properties of the complexes after lyophylization  
Chitosan-insulin complexes were susceptible to aggregation when stored 
at room temperature or at 4℃ over two days. In contrast, TMC and PEGylated 
TMC insulin complexes showed no indication of aggregation within one month 
at room temperature. This improvement in stability probably stems from the 
higher hydrophilicity of the modified polymer surface. We hypothesize that the 
surface coupling of PEG increases the hydrophilicity of the complexes and 
lowers their surface free energy, thereby enhancing their physical stability in 
aqueous media. The feasibility of preparing PECs by lyophylization was also 
investigated.  
Using sucrose and mannitol as lyoprotectants, properties of the complexes 
after lyophylization were investigated by dynamic light scattering. It was 
demonstrated that sucrose could protect the complexes from aggregation 
effectively at an appropriate sucrose/insulin ratio. On the contrary, aggregation 
could not be avoided even when the mannitol/insulin ratio was as high as 100:1 
(data not shown). The optimal sucrose/insulin ratio was polymer composition 
dependent. With regard to chitosan 100 kDa and PEG(550)228-g-TMC(100), 
aggregation was prevented when the ratio was above 10:1 with the optimal state 
occurring at 40:1. This ratio was accompanied by only marginal particle size 
increases. In contrast, the optimal ratio was approximately 100:1 for both 
PEG(5k)40-g-TMC(100) and PEG(5k)19-g-TMC(50) copolymers. The effect of 
sucrose/insulin ratio on the properties of chitosan 100 kDa insulin complexes 
and PEG(5k)40-g-TMC(100) insulin complexes after lyophylization are depicted 
in Figure 8.  
When considering that all copolymers employed during this study have 
similar graft ratios, this result implies that the interaction intensity between 
polymer and insulin is dependent upon polymer structure. Coupled PEG 5 kDa 
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in the copolymer probably shields a proportion of the positively charged groups 
on TMC and therefore weakens the interaction with insulin. In contrast, the 
chain length of PEG 550 Da is possibly too short to have considerable 
influence.  
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Figure 8. Particle size, Kcps value and polydispersity index of different polymer-insulin 
complexes as a function of sucrose/insulin ratio (a) chitosan 100 kDa-insulin 
complexes, (b) PEG(5k)40-g-TMC(100)-insulin complexes. 
 
3.7 Visualization of insulin complexes 
Compared to electron microscopy, atomic force microscopy (AFM) is a 
technique that permits the acquisition of images in a liquid environment, 
without drying or fixation of the sample. Additionally, tapping mode AFM 
allows the imaging of soft samples at high resolution without damaging the 
sample surface. AFM can also provide three-dimentional structure and 
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information of the analysed particles, which is a benefit not available with 
conventional light-scattering measurements (33). For size determination, all 
PECs were evaluated individually within a representative scan area (25 × 25 
µm). The particle size measurements obtained from AFM images were slight 
smaller but of the same magnitude as those obtained from dynamic light 
scattering data (Table 1). Figure 9a-9d shows an overview of different polymer 
insulin complexes at a scan size of (25 × 25 µm). In Figure 9a, excessive 
chitosan chains are observed and two subpopulations are found. The smaller 
fraction had an average diameter of approximately 180 nm, and the larger 
fraction showed size between 400 and 480 nm. The big particles might consist 
of two of the small ones. There was also a much smaller fraction of about 40-50 
nm. Similar to chitosan complex, also two fractions were found for TMC insulin 
complex, approximately 380 nm for larger particles and 100-180 nm for smaller 
ones (Figure 9b). In contrast, smaller particles with low polydispersity were 
observed for the PECs formed with the copolymers (Figure 9c, 9d). The insert 
(1x1 µm) of each image allows visualizing the surface morphology of the PECs 
clearly. It shows that the majority of particles were separated from one other, 
suggesting that these PECs were possibily stabilized against agglomeration.  
A general problem with soft objects such as complexes is to obtain 
accurate height information. Therefore, topographical images were subsequently 
captured for generating three-dimentional images of the PECs (Figure 9e,f). 
From such images it was clear that most of the complexes were spherical or sub 
spherical with a smooth surface devoid of cracks. Line scan size analysis further 
demonstrated that the complexes exhibited a good aspect ratio between height 
and diameter (Figure 9g).  
 
4. Conclusion 
Based on the results presented above, it is reasonable to conclude that the 
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interactions involved in PEC formation are predominantly electrostatic. The 
PEC formation process is influenced by a varity of parameters, including the 
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Figure 9.  Atomic force microscopy images of polymer-insulin complexes at optimized 
charge ratio. 
(a) Chitosan 100 kDa, (b) Trimethyl chitosan 100 kDa, (c) PEG(5k)40-g-TMC(100), 
(d) PEG(550)228-g-TMC(100), (e) Three-dimentional image of chitosan 100 kDa, (f) 
Three-dimensional image of PEG(550)228-g-TMC(100), (g) line scan size analysis of 
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PEG(550)228-g-TMC(100). The inserts are 1x1 µm for each image. 
 
system pH, sequence of mixing, polymer/protein ratio and concentration, 
polymer molecular weight and structure, ionic strength, etc. Amongst all of 
these parameters, the most important factor appears to be the system pH. The 
order of mixing is polymer property dependent. With regard to chitosan, due to 
its poor solubility at neutral pH, the insulin solution should be added to chitosan 
solution to avoid precipitation. In contrast, the mixing order appears to have a 
negligible influence for TMC and PEGylated TMC copolymers. The 
polymer/protein ratio needs to be optimized individually. When the MW of 
chitosan and its derivatives were ≥25 kDa, soluble insulin complexes in the 
size range of 200-400 nm with spherical or sub-spherical morphology can be 
readily obtained by simply mixing two components at a specific pH and charge 
ratio. All of the insulin complexes were successfully freeze-dried without 
influcing the complex properties, by using sucrose as a lyoprotectant. These 
studies have contributed much to the understanding of PEC formation and 
complexation with insulin. This work will be furthered by performing intranasal 
absorption studies in animal models.      
References 
 
1.  M. Tobio, A. Gref, A. Sanchez, R. Langer, M. Alonso, Stealth PLA-PEG nanoparticles as 
protein carriers for nasal administration, Pharm. Res. 15 (1998) 270-275.   
2.  M.C. Julienne, M.J. Alonso, J.L.G. Amoza, J.P. Benoit, Preparation of poly (D, 
L-Lactide/Glycolide) nanoparticles of controlled particle size distribution: application of 
experimental design, Drug Dev. Ind. Pharm. 10 (1992) 1063-1077. 
3.  H. Ibrahim, C. Bindschaedler, E. Doelker, P. Buri, R. Gurny, Aqueous nanodispersions 
prepared by a salting-out process, Int. J. Pharm. 87 (1992) 239-246. 
4.  J.C. Leroux, E. Allemann, E. Doelker, R. Gurny, New approach for the preparation of 
nanoparticles by an emulsification-diffusion method, Eur. J. Pharm. Biopharm. 41 (1995) 
14-18. 
5.  H. Mao, K. Roy, V.L. Troung-Le, K.A. Janes, K.Y. Lin, Y. Wang, J.T. August, K.W. 
 113
Nanocomplexes formation between chitosan derivatives and insulin 
Leong, Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and 
transfection efficiency, J. Controlled Rel. 70 (2001) 399-421. 
6.  P. Artursson, T. Lindmark, S.S. Davis, L. Illum, Effect of chitosan on the permeability of 
monolayers of intestinal epithelial cells (Caco-2), Pharm. Res. 11 (1994) 1358-1361. 
7.  A.K. Singla, M. Chawla, Chitosan: Some pharmaceutical and biological aspects-an 
update, J. Pharm. Pharmacol. 53 (2001) 1047-1067.  
8.  P. Erbacher, Chitosan-based vector/DNA complexes for gene delivery: biophysical 
characterization and transfection ability, Pharm. Res. 15 (1998) 1332-1339. 
9.  C.W. Richardson Simon, V.J. Kolbe Hanno, R. Duncan, Potential of low molecular mass 
chitosan as a DNA delivery system: biocompatibility, body distribution and ability to 
complexes and protect DNA, Int. J. Pharm. 178 (1999) 231-243. 
10.  R. Fernandez-Urrusuno, P. Calvo, C. Remunan-Lopez, J.L. Vila-Jato, M.J. Alonso, 
Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm. Res. 16 
(1999) 1576-1581. 
11.  L. Illum, N.F. Farraj, S.S. Davis, Chitosan as a novel nasal delivery system for peptide 
drugs, Pharm. Res. 11 (1994) 1186-1190. 
12. P. Calvo, C. Remunan-Lopez, J.L. Vila-Jato, M.J. Alonso, Novel hydrophilic 
chitosan-polyethylene oxide nanoparticles as protein carriers, J. Appl. Polym. Sci. 63 
(1997) 125-132. 
13.  A.M. Dyer, M. Hinchcliffe, P. Watts, J. Castile, I. Jabbal-Gill, R. Nankervis, A. Smith, L. 
Illum, Nasal delivery of insulin using novel chitosan based formulations: A comparative 
study in two animal models between simple chitosan formulations and chitosan 
nanoparticles, Pharm. Res. 19 (2002) 998-1008. 
14.  S. Mao, X. Shuai, F. Unger, M. Simon, D. Bi and T. Kissel, The depolymerization of 
chitosan: effects on physicochemical and biological properties, Int. J. Pharm. 281 (2004) 
45-54. 
15.  A.B. Sieval, M. Thanou, A.F. Kotze, J.C. Verhoef, J. Brussee, H.E. Junginger, 
Preparation and NMR characterization of highly substituted N-trimethyl chitosan 
chloride, Carbohydrate Polymers 36 (1998) 157-165. 
16.  S. Mao, X. Shuai, M. Wittar and T. Kissel, Poly (ethylene glycol)-graft-trimethyl 
chitosan block copolymers: synthesis, characterization and potential as water-soluble 
insulin carriers. (in preparation) 
17.  A. Tsuboi, T. Izumi, M. Hirata, J. Xia, P.L. Dubin, E. Kokufuta, Complexation of 
proteins with a strong polyanion in an aqueous salt-free system, Langmuir 12 (1996) 
 114 
Chapter 5 
6295-6303. 
18.  J.M. Park, B.B. Muhoberac, P.L. Dubin, J. Xia, Effects of protein charge heterogeneity 
in protein-polyelectrolyte complexation, Macromolecules 25 (1992) 290-295. 
19.  J. Brange, Galenics of insulin: The physio-chemical and pharmaceutical aspects of 
insulin and insulin preparations, Springer-Verlag, Berlin (1987) 1-103. 
20.  M.M. Beppu, C.C. Santana, Influence of calcification solution on in vitro chitosan 
mineralization, Mat. Res. 5 (2002) 47-50. 
21.  L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A.N. Fisher, and S.S. Davis, Chitosan as a novel 
nasal delivery system for vaccines, Adv. Drug Deliv. Rev. 51 (2001) 81-96. 
22.  M. Thanou, B.I. Florea, M.Geldof, H.E. Junginger, G. Borchard, Quaternized chitosan 
oligomers as novel gene delivery vectors in epithelial cell lines, Biomaterials 23 (2002) 
153-159. 
23.  V.A. Kabanov, Basic properties of soluble interpolyelectrolyte complexes applied to 
bioengineering and cell transformations, Macromolecular complexes in chemistry and 
biology, Springer-Verlag Berlin Heidelberg (1994) 151. 
24.  H. Dautzenberg, J. Koetz, K.J. Linow, B. Philipp and G. Rother, Static light scattering of 
polyelectrolyte complexes solutions, Macromolecular complexes in chemistry and 
biology, Springer-Verlag Berlin Heidelberg (1994) 119. 
25.  K.W. Mattison, I.J. Brittain and P.L. Dubin, Protein-Polyelectrolyte phase boundaries, 
Biotechnol. Progr. 11 (1995) 632-637. 
26.  J. Brange, L. Langkjaer, Chemical stability of insulin. 3. Influence of excipients, 
formulation, and pH, Acta Pharm. Nord. 4 (1992) 149-158. 
27.  E. Tsuchida and S. Takeoka, Interpolymer complexes and their ion-conduction, 
Macromolecular complexes in chemistry and biology, Springer-Verlag Berlin Heidelberg 
(1994) 183. 
28.  K.A. Janes, M.J. Alonso, Effect of polymer molecular weight on chitosan nanoparticles 
for peptide delivery, Proc. Int. Symp. Control. Rel. Bioact. Mater. 27 (2000) 8043. 
29.  Z. Ma, H. Yeoh, L. Lim, Formulation pH modulates the interaction of insulin with 
chitosan nanoparticles, J. Pharm. Sci. 91 (2002) 1396-1404. 
30.  N. Karibyants and H. Dautzenberg, Preferential binding with regard to chain length and 
chemical structure in the reactions of formation of quasi-soluble polyelectrolyte 
complexes, Langmuir 14 (1998) 4427-4434. 
31.  H. Petersen, K. Kunach, A.L. Martin, S. Stolnik, C.J. Roberts, M.C. Davies and T. 
Kissel, Star-Shaped poly (ethylene glycol)-block-polyethylenimine copolymers enhance 
 115
Nanocomplexes formation between chitosan derivatives and insulin 
DNA condensation of low molecular weight polyethylenimines, Biomacromolecules 3 
(2002) 926-936.  
32.  M. Huang, E. Khol, L. Lim, Uptake and cytotoxicity of chitosan molecules and 
nanoparticles: Effects of the molecular weight and degree of deacetylation, Pharm. Res. 
21 (2004) 344-353. 
33.  H.G. Shi, L. Farber, J.N. Michaels, A. Dickey, K.C. Thompson, S.D. Shelukar, P.N. 
Hurter, S.D. Reynolds, M.J. Kaufman, Characterization of crystalline drug nanoparticles 
using atomic force microscopy and complementary techniques, Pharm. Res. 20(2003) 
479-484. 
 116 
  
 
 
 
 
 
 
 
 
 
 
Chapter 6 
  
Uptake and transport of PEG-graft-trimethyl chitosan 
copolymer-insulin nanocomplexes in Caco-2 cell 
monolayers 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscript in preparation 
 
Chapter 6 
Abstract 
Purpose. The objective of this study was to evaluate the influence of chitosan 
and PEGylated trimethyl chitosan copolymer structure on the uptake and 
transport of insulin nanocomplexes and delineate the mechanisms.  
Methods. Self-assembled insulin nanocomplexes were prepared and 
characterized. Complex uptake in Caco-2 cells was quantified by measuring the 
cell-associated fluorescence and localized by confocal laser scanning 
microscopy using TRITC-labeled insulin. The transport of different insulin 
complexes through Caco-2 monolayers was then investigated.  
Results. All complexes were 200-400 nm in diameter, positively charged and 
displayed an insulin loading efficiency of approximately 90%. In vitro release 
of insulin from the complexes was dependent on the medium pH. Insulin uptake 
was enhanced by nanocomplex formation, and was incubation time, temperature 
and concentration dependent. Complex uptake in Caco-2 cells was inhibited by 
25.2±1.3%, 13.0±1.0% and 16.6±0.7% in the presence of cytochalasin D, 
sodium azide and 2,4-dinitrophenol respectively. The uptake mechanism was 
assumed to be adsorptive endocytosis. Additionally, the cell uptake efficiency 
was shown to be influenced by a combination of polymer molecular weight, 
viscosity and positive charge density. However, none of the nanocomplexes 
displayed improved transport properties when compared to insulin transport 
data after 2 h incubation with Caco-2 monolayers.  
Conclusions. Small, stable insulin nanocomplexes were formed using 
PEGylated trimethyl chitosan copolymers, which significantly enhanced the 
uptake of insulin in Caco-2 cells by adsorptive endocytosis. However, 
nanocomplexation did not appear to enhance insulin transport across cell 
monolayers.  
 
1. INTRODUCTION 
In order to maintain blood glucose levels at a near-physiological level and 
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thereby minimize long-term diabetic complications, the treatment of insulin- 
dependent diabetes requires up to four subcutaneous injections per day. To 
circumvent this tedious regimen of therapy, several attempts have been made to 
exploit mucosal surfaces for the delivery of macromolecular drugs, especially 
the nasal, pulmonary and oral mucosae (1). The nasal route has been a particular 
focus of recent research interests due to demonstrations of biologically active 
peptides, such as desmopressin, salmon calcitonin and corticotrophin, show 
significant absorption across the nasal mucosa (2). 
In fact, the nasal route has been recognized as an attractive alternative for 
the administration of insulin since 1922 (3). However, despite the promise of 
intranasal administration for the delivery of peptides, the efficacy of the nasal 
route for the absorption of large peptides, e.g. insulin, is low (4). Therefore, new 
nasal delivery systems to facilitate the enhancement of insulin absorption have 
been studied, including surfactants, protease inhibitors, and solutions of 
bioadhesive polymers or bioadhesive microspheres (5,6). Unfortunately, most 
chemical enhancers (surfactants, bile salts, fatty acids, etc.) induce irreversible 
damage, and irritate the nasal mucosa when used at efficacious concentrations 
(7). In contrast, nanoparticles and microparticles have been demonstrated to be 
the most promising macromolecular carriers (8,9).  
Unlike other absorption promoters, chitosan, a non-toxic and 
biocompatible cationic polysaccharide produced by partial deacetylation of 
chitin derived from naturally occurring crustacean shells, was reported to be 
able to open the tight junctions without damaging. The issues concerning the 
use of chitosan as a nasal delivery system have been discussed in the review by 
Illum et al. (10). Intranasal administration of chitosan insulin nanoparticles 
formed by a mild ionotropic gelation procedure has reportedly enhanced the 
nasal absorption of insulin to a greater extent than an aqueous solution of 
chitosan (11). The mechanism of action of chitosan is suggested to be a 
combination of bioadhesion and a transient widening of the tight junctions 
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between epithelial cells (12). However, this absorption enhancing ability was 
evident only at acidic condition (pH < 6.5), where most of the amino groups are 
protonated. To solve this problem, PEGylated trimethyl chitosan copolymers 
were synthesized in our laboratory in an attempt to increase the solubility of 
chitosan at physiological pH and improve the biocompatibility of trimethyl 
chitosan (TMC) (13). Insulin nanocomplexes were prepared with the 
copolymers by electrostatic interaction (14). We anticipate that by combining 
absorption enhancers, i.e., chitosan derivatives, and nanocomplex systems, 
intranasal absorption of insulin can be improved significantly. 
     The goal of this study is to evaluate the influence of chitosan and 
PEGylated TMC copolymer structure on the uptake and transport of insulin 
nanocomplexes and elucidate the mechanisms. Since several groups have 
suggested that Caco-2, a human colon adenocarcinoma cell line, functions as a 
suitable in vitro model to investigate particle uptake and intestinal permeability 
of drugs (15,16), in vitro quantification and elucidation of the uptake and 
transport of polymer-insulin complexes were performed with confluent Caco-2 
monolayers. Such monolayers form tight junctions, and exhibit similar 
properties to those in the intestinal and nasal epithelium.  
 
2. MATERIALS AND METHODS 
2.1 Polymers  
Chitosan (400 kDa) was purchased from Fluka (Steinheim, Germany) with 
a degree of deacetylation (DD) of 84.7% and depolymerized according to an 
oxidative degradation method to obtain chitosan 100 kDa and 50 kDa (17). 
PEGylated TMC copolymers were synthesized as described elsewhere (13). The 
following nomenclature was adopted for the copolymers: PEG(X)n-g-TMC(Y), 
where X denotes the molecular weight (MW) of PEG (polyethylene glycol) in 
Da, Y denotes the MW of TMC in kDa, and the subscript n represents the 
average number of PEG chains per TMC macromolecule of Y kDa.   
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2.2 Preparation and characterization of copolymer-insulin self-assembled 
nanocomplexes 
The complexes were prepared via self-aggregation, utilizing the 
electrostatic interaction between the polymers and insulin (Aventis Pharma AG, 
Germany) as a driving force. The process parameters were optimised and 
described in detail elsewhere (14). Briefly, complexes were prepared by mixing 
equal volumes of insulin and polymer solution at the desired ratio (Table 1) 
under gentle magnetic stirring, and incubated for a further 20 min at room 
temperature. Complex sizes and zeta potentials were obtained by using dynamic 
light scattering and Laser Doppler Anemometry (LDA) measurements as 
described in the literature (14). 
 
2.3 In vitro release studies 
 Insulin release was determined by incubating the complexes (100 µl) in 1.5 
ml Tris buffer pH 7.4 and acetate buffer pH 4.0 at 37℃. The concentration of 
the complex in the release media was adjusted in order to access sink conditions 
for insulin. At appropriate time intervals (30’, 45’, 1 h, 2 h, 4 h, 6 h) individual 
samples were centrifuged at 14000 rpm/min for 30 min and the amount of 
insulin released from the complexes was evaluated by HPLC as described 
elsewhere (14). 
 
2.4 Labeling of polymers and insulin 
Chitosan 100 kDa, PEG(5k)40-g-TMC(100) and PEG(5k)19-g-TMC(50) 
were labeled with Oregon Green carboxylic acid succinimidyl ester (Oregon 
Green 488, Molecular Probes, Eugene, OR, USA) following the previously 
described method (18). Insulin was labeled with TRITC 
(tetra-methyl-rhodamine isothiocyanat, Sigma, Taufkirchen, Germany). Briefly, 
insulin was dissolved at a concentration of 4.5 mg/ml in 0.1 M sodium 
bicarbonate buffer pH 9.3. A solution of TRITC (1 mg/ml) in dimethyl sulfoxide 
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(DMSO) was added dropwise under stirring (molar ratio of insulin: TRITC 
1:2.9) and the mixture was stirred for 18 h at 4℃ under light exclusion. The 
reaction was quenched with an excess of ammonium chloride, and stirred for a 
further 4 h. Purification was performed on a PD-10 desalting column 
(Amersham Pharmacia Biotech, Freiburg, Germany) with PBS (phosphate 
buffered salt solution) pH 7.4. 
 
2.5 Cell culture  
Mycoplasma-free Caco-2 cells were used at passage numbers 44-50 (HD, 
DKFZ, German Cancer Research Institute, Heidelberg, Germany) under 
conditions described previously (19). Cells were seeded at a density of 6*104 
cells/cm2 on 12-well cell culture plates or 6-well uncoated polycarbonate 
Transwell TM filter inserts (Costar, Bodenheim, Germany, 0.4 µm pore size, area; 
4.71 cm2) and cultivated over 21 days. The growth medium was changed every 
second day.  
 
2.6 Uptake Studies 
Cell uptake studies were performed with Caco-2 cell monolayers 
according to the method described in the literature (20). The uptake medium 
was 0.01 M Tris buffer, supplemented with 100 mM glucose, 1.17 mM CaCl2, 
1.03 mM MgCl2, pH 7.4. The cell lysate, obtained by solubilizing the cells with 
300 µl/well 2% SDS (pH 8.0), was measured for fluorescence with a LS 50B 
spectrometer (Perkin Elmer, Ueberlingen, Germany) at an excitation wavelength 
of 543 nm and an emission wavelength of 560 nm. Protein content was 
determined by BCA (bicinchoninic acid) assay according to the manufacture’s 
protocol (Promega, Mannheim, Germany). Uptake was expressed as the 
quantity of insulin associated with 1 mg of cellular protein (mean ± SD, n = 
3). To further evaluate the possibility of complex uptake occurring through an 
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active process, cells were preincubated with the metabolic inhibitors sodium 
azide (10 mM) and 2,4-dinitrophenol (0.2 mM), endocytosis inhibitors 
cytochalasin D (0.1 µg/ml) and nocodazole (1 µg/ml) (all from Sigma, 
Steinheim, Germany) for 30 min prior to complex application and throughout 
the 2 h uptake experiment. 
 
2.7 Confocal laser scanning microscopy (CLSM) 
Confocal laser scanning microscopy was utilized to visualize the 
internalization of insulin nanocomplexes. Caco-2 cells grown on glass cover 
slides for 7 days were treated with insulin, the polymers and the complexes 
(insulin concentration 250 µg/ml). After 2 h incubation at 37℃, cells were 
washed three times with ice-cold transport buffer, fixed with 3.7% 
paraformaldehyde in PBS pH 7.4 at room temperature for 30 min and 
counterstained with DAPI (4,6-diamidino-2-phenylindole, 0.2 µg/ml) for 20 min, 
both under light exclusion. For the samples without labeled polymer, the cells 
were counterstained with FITC (fluorescein isothiocyanate)-labeled wheat germ 
agglutinin (WGA, 0.01 µg/ml) for 30 min. Samples were embedded in 
FluorSaveTM Reagent (Calbiochem, Darmstadt, Germany) and imaged by 
CLSM (Zeiss Axiovert 100 M Microscope coupled to a Zeiss LSM 510 
scanning device, Jena, Germany) which was equipped with a Zeiss Neofluor 
40*/1.3 objective. Excitation wavelengths were 364 nm (long pass filter (LP) 
385 nm) for DAPI, 488 nm (LP 505 nm) for Oregon Green 488 and FITC, and 
543 nm (LP 567 nm) for TRITC (18,20). All images were recorded by using the 
multitracking mode in which each fluorescence channel was scanned 
individually. Additionally, trypan blue was post-incubated with cells for 1 min 
(400 µg/ml in 0.1 M citrate buffer, pH 4.4) after 2 h incubation with the 
complexes or polymers. 
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2.8 Transport across Caco-2 cell monolayers 
Transport studies were performed 21 days post-seeding. The integrity of 
the monolayers was checked by measuring the transepithelial electrical 
resistance (TEER) values in HBSS (Hank’s balanced salt solution) buffer pH 
7.4 before and after the experiment, as described previously (19,20). Only Cells 
with TEER value in the range of 250-350 Ωּcm2 were used for the transport 
studies. Briefly, filter inserts were rinsed with transport buffer pH 7.4 (the same 
as the uptake medium) and allowed to equilibrate at 37℃  for 15 min. 
Experiments were carried out by replacing the apical buffer (1.5 ml) with the 
samples (insulin 250 µg/ml) and the basolateral buffer with fresh transport 
buffer (2.5 ml). Every 20 min up to 2 h, 1.0 ml sample was collected from the 
basolateral chamber and replaced with fresh buffer. Each experiment was 
performed in triplicate. To study TEER reversibility, monolayers were rinsed 
with fresh transport buffer directly after the transport experiment and allowed to 
regenerate in fresh culture medium under culture conditions. After 24 h 
monolayer integrity was checked in HBSS buffer.  
 
2.9 Calculations and statistics 
  The apparent permeability coefficient (Papp) was calculated from 
concentration-time profiles using the following equation: 
]/[//1/ 0 scmCVAdtdCPapp ××=  
where dC/dt (µg/s) represents the flux across the monolayer, A (cm2) the surface 
area of the monolayer, V (cm3) the volume of the receiving chamber and C0 (µg) 
the initial concentration in the basolaterial compartment. The quantity of all 
cell-associated insulin was calculated by subtracting the amount transported and 
remained in the apical compartment from the initial amount. Results were 
expressed as mean value±SD of three experiments. Significance between the 
mean values was calculated using one-way ANOVA analysis (Origin 7.0 SRO, 
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Northampton, MA, USA). Probability values P < 0.05 were considered 
significant. 
 
3. RESULTS 
3.1 Physicochemical characteristics of polymers and complexes 
The properties of the polymers and the self-assembled insulin 
nanocomplexes are described in Table 1.  
 
Table 1. Properties and characteristics of the polymers and their 
complexes with insulin  
a DD degree of deacetylation, calculated by 1H NMR analysis. 
Polymers 
(kDa) 
DDa 
(%) 
Substitution 
(%)b 
Graft ratio 
(%)c 
Mass 
ratiod 
Size (nm) ξ (mv) Association 
efficiency 
(%) 
Charge 
ratio 
(Pol./Ins.)
Chitosan 400 85.1              2:1 376.4±10.3 13.6±0.3 89.7±2.1 7:1 
Chitosan 100 85.4   2:1 308.2±8.5 8.8±0.4 87.3±2.4 7:1 
Chitosan 50 86.2   2:1 226.8±6.3 7.4±0.3 93.2±1.3 7:1 
TMC 100  39.3b1  0.3:1 273.3±4.6 19.8±1.1 81.4±2.1 3:1 
TMC 50  39.6b1  0.3:1 236.6±1.3 21.4±0.3 86.3±3.2 3:1 
PEG(5k)40-g-TMC(100)  6.44 66.1±2.2 1:1 233.3±7.2 18.8±0.3   94.8±1.1 5:1 
PEG(550)228-g-TMC(100)  36.7 58.5±3.1 1:1 224.6±2.3 13.9±2.9 94.2±1.7 5:1 
PEG(5k)19-g-TMC(50)  6.13 64.9±1.7 1:1 203.9±7.2 15.0±1.2 90.4±4.4 5:1 
PEG(550)132-g-TMC(50)  37.4 59.2±3.0 1:1 220.3±5.5 16.4±1.9 94.7±3.3 5:1 
 b Calculated based on the primary amino group content in chitosan; b1 Degree of quaternization. 
c Calculated based on the composition of the copolymer by 1H NMR analysis. 
d Optimized polymer/insulin mass ratio for complexes preparation. 
 
All complexes had a size in the range of 200-400 nm, a positive surface 
charge and an insulin association efficiency (AE) of approximately 90%. The 
measured particle size of the complexes decreased with chitosan MW. In terms 
of the copolymer-insulin complexes, the size was comparable to that of small 
MW chitosan 50 kDa and TMC 50 kDa. The zeta potential of chitosan-insulin 
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complexes was approximately 2-fold lower than that of TMC and copolymers, 
and a slightly decreased zeta potential was observed for the copolymers 
compared to that of TMC. With a similar graft ratio, the zeta potential of 
PEG(550)228-g-TMC(100) copolymer was lower compared to that of 
PEG(5k)40-g-TMC(100) due to the increased substitution ratio. The optimal 
charge ratio between polymer and insulin was polymer structure dependent, it 
was 7:1 for chitosan, compared to 3:1 for TMC. 
Figure 1 exemplifies the release profiles of insulin from complexes 
formed with chitosan 100 kDa and PEG(5k)40-g-TMC(100). Similar profiles 
were achieved for the two complexes, showing a pH dependent insulin release. 
Almost all insulin was released in 30 min at pH 4.0. In contrast, less than 40% 
insulin was released at pH 7.4 in 6 h.  
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Figure 1. In vitro release of insulin from complexes at different pH.  
(a) Chitosan 100 kDa-insulin complexes.  
(b) PEG(5k)40-g-TMC(100)-insulin complexes. (◆) pH 4.0, (■) pH 7.4. 
 
3.2 Effect of polymer structure on complexes uptake in Caco-2 cells  
In order to study particulate uptake in vitro, the most common 
experimental approach is to use fluorescent-labelled particles. Then, particle 
uptake can be determined indirectly by quantitative extraction of the markers 
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from the cells. Moreover, particles labelled with fluorescent marker also provide 
visual evidence for cellular uptake. Therefore, TRITC-labelled insulin was used 
in this study. 
Based on the stability of the complexes, 0.01 M Tris buffer was selected 
for uptake studies. Ca2+ and Mg2+ were added to the buffer since they are 
essential for the tight junction function of the cells. In preliminary studies the 
chitosan-insulin complexes were found to be extremely ionic strength-sensitive 
(14), thus their stability was investigated in the Ca2+/ Mg2+ supplemented buffer. 
This revealed that the influence of Ca2+/ Mg2+ on complex dissociation was 
polymer structure dependent. Regarding chitosan-insulin complexes, 
dissociation appeared immediately after mixing. In contrast, TMC and 
PEGylated TMC insulin complexes remained stable for at least 6 h hours (data 
not shown). Therefore, the cell uptake experiments were performed in buffer 
without Ca2+/ Mg2+ for chitosan-insulin complexes.  
To facilitate their direct comparison, all chitosans and copolymers were 
investigated at 250 µg/ml (constant insulin concentration 125 µg/ml) except 
TMC (125 µg/ml), which is cytotoxic according to MTT assay. TMC displayed 
an IC50 (the concentration at which cell growth is inhibited by 50%) of 
approximately 100 µg/ml after 3 h incubation with L929 cells, compared to an 
IC50 > 500 µg/ml for all the copolymers investigated here. The uptake results 
after 2 h incubation with Caco-2 cells are shown in Figure 2. Compared to free 
insulin solution, all complexes improved insulin uptake significantly (P < 0.05), 
the extent of which depended on the polymer structure. The highest uptake was 
observed for TMC despite the lower concentration and comparable result was 
obtained for the copolymer PEG(5k)40-g-TMC(100). With regard to chitosan, 
insulin uptake efficiency was MW dependent, and two-fold uptake was 
observed for chitosans 100 kDa and 50 kDa, compared to chitosan 400 kDa. In 
terms of the other copolymers, similar results were obtained with 
PEG(550)228-g-TMC(100), PEG(550)132-g-TMC(50) and PEG(5k)19-g-TMC(50) 
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where uptake quantities were comparable to that of chitosan 50 kDa.  
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Figure 2. Uptake of polymer-insulin complexes as a function of polymer structure at 37℃ in 
Caco-2 cell line. Insulin (125 µg/ml) complexes were incubated with cells for 2 h. 
Error bars represent mean±SD ( n = 3).  
 
As can be seen in Figure 2, complexes uptake data correlated with zeta 
potential values. The observed high uptake efficiency of TMC 100 kDa and 
TMC 50 kDa were in line with their high positive charge, and negligible 
statistical difference was observed between each data set (P > 0.05). However, 
cytotoxicity of TMC could possibly be a cause for the high uptake efficiency. 
With similar graft ratios, the cell uptake efficiency of PEG(5k)40-g-TMC(100) 
insulin complexes, which was comparable to that of pure TMC, was 
significantly higher than that of PEG(550)228-g-TMC(100). This is probably a 
consequence of its relatively high positive charge, whereas the other copolymers 
had lower zeta potential and showed lower cellular uptake. Nevertheless, 
negligible statistical difference was observed between PEG(5k)19-g-TMC(50) 
and PEG(550)132-g-TMC(50) insulin complexes (P > 0.05). Based on the results 
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of uptake experiment, the PEG(5k)40-g-TMC(100) copolymer insulin complex 
was selected for following study. 
 
3.3 Mechanism of insulin complexes uptake 
3.3.1 Effect of polymer concentration 
Keeping the insulin concentration at 125 µg/ml, influence of the 
PEG(5k)40-g-TMC(100) copolymer concentration on complex uptake was 
studied and is shown in Figure 3(a). The insulin uptake increased with 
increasing polymer concentration. A 2.5-fold increase was measured when the 
polymer concentration increased from 125 to 500 µg/ml. Moreover, a linear 
relationship was established between uptake percentage and polymer 
concentration in the range studied. 
 
3.3.2 Effect of incubation time 
Keeping the PEG(5k)40-g-TMC(100) copolymer concentration at 125 µg/ml 
and insulin 125 µg/ml, the effect of incubation time on the uptake of insulin 
complexes was investigated and results are shown in Figure 3(b). The insulin 
uptake increased with incubation time and more than 4-fold uptake was 
observed by prolonging the incubation time from 0.5 h to 4 h. Additionally, 
insulin uptake correlated linearly with time for up to 4 h.  
 
3.3.3 Effect of insulin concentration and temperature 
Keeping the PEG(5k)40-g-TMC(100) copolymer concentration at 125 
µg/ml, the effect of insulin concentration was investigated by incubating Caco-2 
cells with the complexes for 2 h. Studies were carried out at both 37℃ and 4℃. 
The rate of uptake increased with insulin concentration and did not exhibit 
saturation in the range of 62.5-500 µg/ml (Figure 3c). The uptake amount 
increased 5-fold when the concentration increased from 62.5 to 500 µg/ml. 
However, the uptake efficiency decreased with increasing insulin concentration 
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and leveled off at 250 µg/ml at 37℃ (Figure 3d). At 4℃ the uptake efficiency 
was less than 3% irrespective of insulin concentration. 
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Figure 3. Effect of polymer concentration, insulin concentration, incubation time and 
temperature on complexes uptake in Caco-2 cell line. Error bars represent mean±
SD (n = 3). 
(a) Effect of PEG(5k)40-g-TMC(100) copolymer concentration on complexes 
uptake at 37℃. The concentration of insulin was 125 µg/ml. 
(b) Effect of incubation time on complex uptake at 37℃. Both the concentration of 
insulin and PEG(5k)40-g-TMC(100) copolymer used was 125 µg/ml. 
(c) Uptake amount versus insulin concentration. 
(d) Uptake efficiency versus insulin concentration. 
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Lowering the temperature from 37℃ to 4℃ abolished uptake of insulin 
complexes by approximately 70%, indicating that the uptake is temperature 
dependent. These results suggest that an energy-dependent endocytic process 
could be responsible for up to 70% of complexes uptake, and the other 30% 
attribute to physical adhesion or diffusion. 
 
3.3.4 Effect of inhibitors 
When the complexes were preincubated with either sodium azide or 
2,4-dinitrophenol for 30 min, complexes uptake were reduced by 13.0±1.0 % 
and 16.6±0.7 %, respectively compared to that of control (Figure 4). This 
observation suggests that the complex-induced increase in permeability of 
insulin was to some extent regulated by metabolic energy (cell viability, P < 
0.05). When the cells were preincubated with 0.1 µg/ml cytochalasin D, an  
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Figure 4. Effect of energy depletion and vesicle transport inhibitors on 
PEG(5k)40-g-TMC(100) copolymer insulin (125 µg/ml) complexes uptake. 
 
actin microfilament inhibitor, uptake was decreased by 25.2 ± 1.3 %, 
significantly different from that of sodium azide or 2,4-dinitrophenol (P < 0.05). 
In contrast, nocodazole, a microtubule inhibitor, caused only a slight reduction 
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in complex uptake of 9.7±0.5%. These data suggest that the internalization 
mechanism triggered by insulin complexes may be associated with the 
combined effect of microfilaments and microtubules of the cells. 
 
3.4 Visualization by confocal laser scanning microscopy 
To confirm the preliminary results indicating an endocytic uptake 
mechanism, confocal microscopy was employed to provide a direct evidence for 
complex localization. To distinguish between different cellular structures, cells 
were double stained with FITC-WGA (membrane, green) and DAPI (blue, 
nuclei). To investigate the uptake and intracellular localization of the complexes 
and the copolymers, both complexes and copolymers were fluorescent labeled. 
With regard to pure insulin solution, only a slight red fluorescence was observed 
(Figure 5D), probably due to passive diffusion via the transcellular route. 
Confocal microscopy shows that a small amount of polymers was taken up by 
the cells (Figure 5C). In contrast, a significantly higher internalization of 
cell-associated insulin was found for all investigated complexes compared to the 
insulin control.  
To test whether complexes dissociation occurred upon incubation with the 
cells, the samples were viewed under confocal microscopy after 2 h incubation. 
An exemplary image of PEG(5k)40-g-TMC(100)–insulin complexes is shown in 
Figure 5(A) by using blue, red and green filters and an overlay of the images 
showed perfect congruence of red and green dyes. A large amount of yellow 
color, resulting from the colocalization of green and red, was distributed within 
the cytoplasm, in small, rounded vesicles localized in the perinuclear area, on 
the nuclear membrane and on the apical cell membrane, indicating that the 
complexes were internalized into the cells without dissociation. A similar 
phenomenon was observed with the other labeled polymers. 
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Figure 5.  Confocal micrograph images of Caco-2 cell monolayers incubated with 
complexes, copolymer and insulin for 2 h at 37℃. PEG(5k)40-g-TMC(100) 
copolymer was labeled with Oregon Green 488, insulin was labeled with TRITC 
and nuclei were labeled with DAPI. 
(A) Incubated with PEG(5k)40-g-TMC(100) copolymer insulin complexes (a) blue 
filter, (b) green filter, (c) red filter, (d) overlay of a,b,c.  
(B) Incubated with PEG(5k)40-g-TMC(100) copolymer insulin complexes for 2 h 
and post incubated with trypan blue.  
(C) Incubated with PEG(5k)40-g-TMC(100) copolymer and post incubated with 
trypan blue. 
(D) Incubated with free insulin solution and post incubated with trypan blue. Cell 
membrane was labeled with FITC-WGA. 
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It is well known that chitosan and its derivatives are mucoadhesive. They 
can attach on the cell surface and cannot be washed away completely in some 
cases. To distinguish between membrane-associated and internalized complexes, 
trypan blue, a dye that was reported to inhibit extracellular fluorescence (21), 
was used. An exemplary image is shown in Figure 5(B), which represents 
vertical scans (XZ images) through the monolayers. Intracellular staining could 
be observed clearly in the images. Because viable cells excluded trypan blue 
molecules, the residual fluorescence implied the existence of a substantial 
amount of intracellular insulin complexes, rather than cell surface adsorption. 
Interestingly, it was noted that the complexes were mainly localized in the 
perinuclear region, suggesting endocytic uptake.  
Moreover, it was noted that complex uptake was heterogeneous and cell 
state dependent. For the cells in the stage of division (indicated by the 
morphology of the nucleus), the complexes uptake was more efficiently 
compared to non-dividing cells (data not shown). This result could be explained 
by the fact that, during cell division, the cell membrane opens transiently and 
the complexes can enter the cytoplasm. 
 
3.5 Transport studies 
3.5.1 Effect of calcium and magnesium in the transport buffer 
Due to the instability of chitosan-insulin complexes in the existence of 
Ca2+/ Mg2+, which is essential for the tight junction, uptake and transport of 
chitosan-insulin complexes were performed in the medium without Ca2+/ Mg2+. 
To figure out the influence of Ca2+/Mg2+, the transport of 
PEG(5k)40-g-TMC(100) copolymer-insulin complexes, which is stable 
irrespective of Ca2+/ Mg2+, was investigated in both case and Papp values were 
calculated, as shown in Figure 6(a).  
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Figure 6. (a) Apparent permeability coefficient (Papp) of different polymer-insulin 
nanocomplexes in Caco-2 cells during 120 min (n = 3). The concentration 
of insulin was 250 µg/ml. 
(b) Percentage of amount of insulin internalized/attached in Caco-2 cell 
monolayers after 2 h incubation. Each point represents the mean±SD of 
three experiments. 
 
No significant difference in Papp values was found in both cases (P > 0.05), 
implying that the influence of Ca2+/Mg2+ on the transport of copolymer 
PEG(5k)40-g-TMC(100) insulin complexes was marginal. In terms of tight 
junction, after 2 h incubation the TEER values decreased by 60% and 65% with 
and without Ca2+/Mg2+ respectively, compared to the medium. These values 
were reversible after 24 h. On the other hand, the amount of insulin remained in 
the apical compartment after 2 h incubation was measured and the amount of 
internalized or attached insulin was calculated, as shown in Figure 6(b). As we 
have demonstrated, complexes considerably enhanced insulin uptake in Caco-2 
cells, approximately 50% of insulin was attached or internalized in the cells, 3.5 
fold higher compared with free insulin, irrespective of Ca2+/Mg2+.  
 
 135
Chapter 6 
3.5.2 Effect of chitosan MW 
Transport of chitosan 100 kDa and 50 kDa insulin complexes was 
investigated in transport buffer without Ca2+/ Mg2+. Transport amount increased 
with incubation time and the Papp values were calculated and depicted in Figure 
6(a). No remarkable difference was found between each other (P > 0.05) and 
both of them were considerably lower compared with that of free insulin, which 
was transported through the cells two fold faster than these complexes. Instead 
of transport, large amount of insulin complexes (30-50%) were internalized or 
attached on cell monolayers (Figure 6b).  
 
3.5.3 Effect of TMC MW in the copolymers 
To elucidate the influence of TMC MW in the copolymers on the transport 
properties of insulin, two copolymers, PEG(5k)40-g-TMC(100) and 
PEG(5k)19-g-TMC(50) with similar PEGylation ratio, were employed. The 
results are depicted in Figure 6. In agreement with the cell uptake results, the 
Papp value of PEG(5k)40-g-TMC(100) insulin complexes was higher than that of 
PEG(5k)19-g-TMC(50), however not significantly different due to a high 
standard deviation (P > 0.05). PEG(5k)40-g-TMC(100) copolymer is 
advantageous compared to chitosan concerning transport (P < 0.05), but no 
difference was found between PEG(5k)19-g-TMC(50) copolymer and chitosan 
(P > 0.05). Compared to free insulin solution, only at the initial 40 minutes, 
PEG(5k)40-g-TMC(100) copolymer insulin complexes enhanced insulin 
transport remarkably, and the difference became marginal after 1 h and the Papp 
value was lower than insulin solution but no statistical difference (P > 0.05). 
Similar to chitosan insulin complexes, high internalization or attachment is the 
advantage of the complexes beyond insulin solution (Figure 6b).  
Additionally, TEER values were measured after 2 h incubation with the 
complexes. Significantly decreased TEER value indicated that the tight 
junctions between cells were opened. For chitosan 100 kDa and 50 kDa, TEER 
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decreased approximately 60% and no reversibility occurred after 24 h. In 
contrast, 60% and 40% TEER decrease was measured for the copolymers 
PEG(5k)40-g-TMC(100) and PEG(5k)19-g-TMC(50) and these were reversible. 
 
4. DISCUSSION 
In the current study, the cellular uptake and the permeability of chitosan 
derivatives insulin nanocomplexes were assessed. Despite the remarkably 
enhanced uptake, the permeation ability of the complex was low.  
In vitro release of insulin from the self-assembled nanocomplexes was pH 
dependent. At pH 4.0, both chitosan and insulin were positively charged, 
rending complexes dissociation due to electrostatic repulsion and therefore, 
complete insulin release. This is consistent with a previous report (11). In 
contrast, insulin release at pH 7.4 (Tris buffer) was slow compared to that from 
chitosan-insulin nanoparticles (phosphate buffer pH 7.4) (11). The fast release 
of insulin in pH 7.4 phosphate buffer can be contributed to the strong interaction 
between phosphoric and ammonium ion of chitosan (22) and insulin was 
substituted by the phosphoric, rendering a rapid release of insulin. In this case, 
phosphate buffer is not a proper medium for insulin release investigation from 
chitosan nanoparticles. Therefore, 0.01 M Tris buffer pH 7.4 was selected in this 
study based on the stability of the complexes. On the other hand, although 
copolymer PEG(5k)40-g-TMC(100) is completely soluble in the whole pH range, 
its insulin complexes kept stable at pH 7.4 for at least 6 h, indicated by the 
Tyndall phenomenon and precipitation at the bottom of the tube after 
centrifugation, suggesting that the developed insulin complexes may retain 
insulin on particles until uptake into mucosal membrane. Similar release 
profiles were observed for the other PEGylated TMC copolymer-insulin 
complexes, a rapid initial release in the first 30 min accompanied by a plateau 
after 1 h.   
Compared to insulin control, a significantly higher cell-associated insulin 
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was found for all investigated complexes. Insulin uptake efficiency was chitosan 
MW dependent, and two-fold uptake for chitosan 100 kDa and 50 kDa 
compared to chitosan 400 kDa. However, an inverse finding was reported by 
Huang et al. (23), indicating that higher MW is preferred regarding A549 
cellular uptake of chitosan nanoparticles. This discrepancy could be explained 
by the different cell line and different particle size employed. It is well known 
that cell uptake efficiency was particle size dependent and smaller size is 
preferable (24,25). The decreased particle size (226.8±6.3 versus 376.4±0.3 
for chitosan 50 kDa and 400 kDa respectively) could probably lead to enhanced 
uptake. In terms of the copolymers, PEG(5k)40-g-TMC(100) was more effective 
compared to PEG(5k)19-g-TMC(50) with the same graft ratio. Considering that 
they have comparable particle size, we assume that besides zeta potential 
difference(18.8±0.3 versus 15.0±1.2), polymer molecular weight may play an 
important role in the permeation ability and high molecular weight is preferred. 
Ranaldi et al. also observed this phenomenon (26). It was noted that, despite 
less positively charged at physiological pH, the cell uptake amount of chitosan 
insulin complexes was still higher than some of the copolymers. This can 
probably be explained by the mucoadhesive ability of chitosan, which 
prolonged the contact time with cell membrane. Besides, the absence of calcium 
and magnesium in the buffer may also be a cause for the high uptake. 
In addition, our findings demonstrated that uptake of insulin complexes by 
Caco-2 cell monolayers was dependent on time, temperature and loading 
concentration. Lowering the incubation temperature and energy level through 
the use of metabolic inhibitors reduced complex uptake remarkably, which 
demonstrates that uptake is an active process. This is in consistent with 
previously reports by Qaddoumi et al. with the uptake of 6-coumarin PLGA 
nanoparticles in rabbit conjunctival epithelial cells (27). Energy depletion was 
also found to reduce the opening of tight junctions in Caco-2 cells (28). 
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Treatment of Caco-2 cells with cytochalasin D, an actin inhibitor, reduced 
complexes uptake considerably, implying that uptake may be occurring by 
endocytosis. Nocodazole, a microtubule inhibitor, caused only slight reduction 
in complexes uptake. This is quite reasonable while microtubules are involved 
in vesicle transport but not in endocytosis, and vesicle transport is assumed to 
be a step after endocytic uptake (29). The reduction in complexes uptake as a 
result of energy depletion and application of endocytosis inhibitors suggest that 
adsorptive endocytosis is the main internalization mechanism of insulin 
complexes in Caco-2 cells. Additionally, the perinuclear localization of the 
insulin nanocomplexes under confocal microscopy corroborated the endocytosis 
uptake mechanism. Although there are contradictory reports in the literature 
concerning the ability of chitosan to be taken up by the cells physically (30), 
confocal microscopy did indicate that a small amount of polymers was taken up 
by the cells (Figure 5C). Similarly, Ranalidi et al. suggested the internalization 
of poly-L-lysine by fluorescent microscopy and assumed that polycations could 
be internalized by cells (28).  
As reported, the mechanism of chitosan to enhance the absorption of drug 
substance is a combination of mucoadhesion and a transient opening of the tight 
junctions in the mucosal cell membrane (30). The intactness of tight junction is 
linked to the presence of Ca2+/ Mg2+ ions (31). Reduction of extracellular Ca2+ 
concentration has been reported to result in an opening of tight junctions and 
consequently increased the paracellular permeability of epithelial cell 
monolayers (32). Similarly, Ranaldi et al. reported that the presence of calcium 
ions significantly reduced the permeability of Caco-2 cells by treatment with 
0.002% chitosan but no effect for Mg2+ (28). On the contrary, the promoting 
effect of another polycation, poly-l-Arginine, has been demonstrated in a 
calcium independent manner (33). The influence of Ca2+/Mg2+ on the transport 
was investigated with PEG(5k)40-g-TMC(100) copolymer-insulin complexes in 
both cases. It showed that their influence on the transport properties of 
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copolymer PEG(5k)40-g-TMC(100) insulin complexes was marginal and TEER 
value decreased to a comparable extent after 2 h incubation, implying that 
insulin complexes could not pass through the tight junction or at least 
paracellular transport was not the main pathway despite the ability of chitosan 
derivatives to open the tight junctions. This is reasonable. Although tight 
junctions are dynamic structure and can open and close to a certain degree, 
when needed, the mean size of the channels is in the order of less than 10 A°
and the transport of large molecules is considered more limited. Our previous 
study also demonstrated this point (20). It showed that after the incubation with 
a solution of FITC-BSA mixed with chitosan, the detected fluorescence was 
significantly lower as compared to chitosan nanoparticles (20). Similarly, if 
opening the tight junction is the main mechanism, a large amount of insulin 
should be measured in the basolaterial compartment, but it is not the case. So far, 
all the literature reported just demonstrated that chitosan derivatives can open 
the tight junction on a molecular level. No direct evidence was supplied, which 
demonstrated transport of drug substance through tight junction. We assume that 
endocytosis is the main mechanism for insulin complex transport. After taken 
up into the cytoplasma, the complex will be sorting into endo-lysosome. Due to 
the acid environment (pH 4.5-5.0) in the endo-lysosome, both the polymer and 
insulin are positively charged and complex will dissociate. Positively charged 
polymer will interact with the negatively charged vesicle membrane, leading to 
insulin release. In this case, endo-lysosome escape is a rate-limiting step for 
insulin transport. 
Similarly, Ma et al. reported that no measurable level of fluorescence was 
detected in the basolateral compartment after 4 h incubation with chitosan 
nanoparticles (34). Qaddoumi et al. also observed low transport value through 
cell monolayers with 6-coumarin-loaded nanoparticles (27). Recently, the 
pharmacologic responses of an insulin-chitosan (MW 205 kDa, DD 83%) 
solution formulation were shown to be significantly larger than those produced 
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by equivalent nanoparticle formulations in the rat and sheep models (35). This is 
in line with our predication with cell culture results. Therefore, the advantage of 
complexes or nanoparticles regarding enhancing drug prompt absorption, like 
insulin, was discredited. It is true that chitosan (CL110, CL210) nanoparticles 
(300-400 nm) has been shown to be able to increase nasal insulin absorption to 
a greater extent than chitosan solutions in rabbits (14), but the experiment was 
performed at pH 4.3 and the nanoparticles were highly positively charged. 
However, it should be mentioned that in this study, transport buffer was selected 
based on the stability of the complexes, which, on the other hand, will be a 
disadvantage for insulin release and transport. Confocal microscopy did 
demonstrate that there was still a large amount of insulin complexes existing in 
a intact state within the cells after 2 h incubation. Nevertheless, the efficacy of 
the insulin complexes needs be proved in vivo. 
Besides, for chitosan-insulin complexes, no TEER reversibility occurred 
ever after 24 h restoration. Ranaldi et al. observed the same phenomenon even 
with 0.01% chitosan (28). Shortage of calcium and magnesium as a cause could 
be ruled out, because TEER reversibility was observed after incubation with 
PEG(5k)40-g-TMC(100) copolymer insulin complexes in the same buffer. 
Probably due to the mucoadhesive properties of chitosan, it cannot be washed 
away completely and the amount left keeps opening the tight junction. 
 
5. Conclusion 
Self-assembled insulin nanocomplexes have been formed between insulin 
and chitosan derivatives. The complexes exhibit a small particle size and high 
loading efficiency. In vitro release of insulin was dependent on the medium pH. 
Encapsulation of insulin into complexes enhanced association with the Caco-2 
cell monolayers up to 3-fold when compared to free insulin solution. The cell 
uptake efficiency has been shown to be a combination of polymer molecular 
weight, viscosity and charge density. Uptake of insulin complexes was time, 
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concentration and temperature dependent and it increased linearly with time and 
polymer concentration. Co-incubation with metabolic inhibitors and endocytosis 
inhibitors prevented complex uptake. Based on the studies of uptake and 
confocal images, internalization of the complexes appears to occur via 
adsorptive endocytosis, an energy dependent process that is proceeded by 
non-specific interactions of the carrier with the cell membrane, electrostatic 
interactions between the positively charged complexes and negatively charged 
membrane and the mucoadhesive ability of the polymers. However, 
nanocomplexes did not appear to enhance insulin transport across cell 
monolayers at physiological pH. 
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Summary 
Recently, chitosan has been extensively investigated as a promising carrier 
in the field of drug delivery. To overcome its poor solubility at physiological pH 
and the cytotoxicity of trimethyl chitosan, PEGylated trimethyl chitosan 
copolymers were synthesized and characterized systemically for the first time 
and their potential as insulin carriers for intranasal administration were studied. 
The use of chitosan as an absorption enhancer and gene delivery vehicle is 
molecular weight (MW) dependent. Therefore, in Chapter 2, we utilized an 
oxidative depolymerization method to prepare and investigate different MW 
chitosans. The MW of the depolymerized chitosan was shown to be influenced 
by the initial concentration and source of chitosan. At constant initial 
concentrations, the MW decreased linearly with the chitosan/NaNO2 ratio and 
was found to be a function of the logarithm of the reaction time. Chitosan with 
larger MW was more sensitive to depolymerization. The physicochemical 
properties of the resulting polymer fractions were then characterized. Infrared 
and 1H NMR experiments were performed, and no structural changes were 
observed during depolymerization. In addition, the thermal properties of 
chitosan fragments were studied by thermal gravimetric analysis and it was 
found that the decomposition temperature was MW dependent. Chitosan with 
MW of 250-500 kDa showed a maximum degradation temperature of 
approximately 280℃, with low MW chitosan degrading at lower temperature, at 
220℃ and 180℃ for MW 25-100 kDa and MW 2.5-5 kDa respectively. 
Furthermore, the solubility of different MW chitosans was assayed as a function 
of pH. pH50 and cloud point pH were shown to increase with decreasing MW. 
As reports from the literature regarding the cytotoxicity of different MW 
chitosan are rarely in agreement, we performed our own study with MTT assay 
using L929 cell line recommended by USP 26. It showed that the cytotoxicity of 
chitosan was concentration dependent, but virtually molecular weight 
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independent. Chitosan 400 kDa showed an IC50 of 4200 µg/ml, whilst chitosan 
100-5 kDa displayed a figure of approximately 5000 µg/ml.  
In an attempt to improve the solubility of chitosan at physiological pH, we 
used a two-step method to synthesis a series of trimethyl chitosans (TMC) with 
substitution degree of 40% using the different MW chitosan obtained in chapter 
2 as starting material. However, TMC was demonstrated to be toxic. Therefore, 
PEGylated TMC copolymers were synthesized in Chapter 3 to improve the 
biocompatibility of TMC. Hydroxyl-terminated PEGs were converted to 
carboxyl-terminated intermediates by esterification with cyclic aliphatic 
anhydride, and then a series of copolymers with different degrees of substitution 
were obtained by grafting activated PEGs of different MW onto TMC via 
primary amino group reactions. The structure of the copolymers was 
characterized by infrared (FT-IR) and 1H, 13C nuclear magnetic resonance 
(NMR) spectroscopy. Successful coupling was demonstrated by gel permeation 
chromatography (GPC). Solubility experiments demonstrated that 
PEG-g-TMC(400) copolymers were completely water-soluble over the entire 
pH range (1-14) regardless of the PEG MW, even when the graft density was as 
low as 10%.   
In Chapter 4, the in vitro biocompatibility of PEGylated TMC copolymers 
was studied and compared with that of TMC. Using the MTT assay, the effect of 
TMC MW, PEGylation ratio, PEG and TMC MW in the copolymers, and 
complexation with insulin on the cytotoxicity of TMC was examined and the 
IC50 values were calculated accordingly with the L929 cell line. All of the 
polymers exhibited a time- and dose-dependent cytotoxic response that 
increased with MW. PEGylation decreased the cytotoxicity of TMC, to a great 
extent in the case of low MW TMC. According to cytotoxicity results, PEG 5 
kDa is preferable for PEGylation compared to PEG 550 Da at similar graft ratio. 
Complexation with insulin increased cell viability after 24 h incubation. 
Additionally we performed a LDH assay to measure the membrane damaging 
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effects of the copolymers on the basis of the results of the MTT assay. After 3 h 
incubation with 1 mg/ml copolymer solutions, less than 6% LDH release was 
measured for PEG(5k)40-g-TMC(100), PEG(5k)19-g-TMC(50) and 
PEG(550)228-g-TMC(100) copolymers, compared to approximately 50% for 
TMC 100 kDa, which is consistent with the conclusions from MTT assay. 
Moreover, the safety of the copolymers was corroborated by examining the 
morphological changes of the cells under inverted phase contrast microscopy. 
    Since chitosan and its derivatives are positively charged, and insulin is 
negatively charged at pH > PI, polyelectrolyte-protein complexes (PEC) 
formation process between chitosan derivatives and insulin were studied and 
factors influencing the process were investigated systemically. This work is 
presented in Chapter 5. Turbidimetric titration in combination with dynamic 
light scattering (DLS) and laser doppler anemometry were applied to study the 
preferential binding between insulin and chitosan derivatives. Morphology of 
the complexes was observed with atomic force microscopy (AFM). It was 
demonstrated that the complex formation process was pH dependent. Binding 
between chitosan derivatives and insulin took place only above critical pH 
(pHc), which was approximately 6.0 for all chitosan derivatives investigated. 
Soluble complexes in the size range of 200-500 nm, which displayed a spherical 
or subspherical shape with smooth surface, could be obtained at optimized 
polymer/insulin charge ratio when the final system pH was in the range of 
6.5-8.0, depending on polymer structure. Stability of the complex was polymer 
chain length dependent, and only when the MW of the polymer was ≥25 kDa 
complex precipitation was avoided. Increasing the ionic strength of the medium 
accelerated complex dissociation by reducing electrostatic interactions. 
Conversely, high temperatures facilitated complex formation and compaction. 
Chitosan trimethylation and PEGylation significantly improved the stability of 
the complexes. The complexes could be lyophilized using sucrose as a 
cryoprotector without affecting the complex properties. Moreover, it was 
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observed that a large number of protons were released during the complex 
formation process, indicating that the interactions enhanced the dissolution 
constant Ka of the ionizable groups on polymers. On the basis of these results 
we suggest that the interaction involved in the PEC formation was mainly 
electrostatic, involving the positively charged amino groups of chitosan and the 
negatively charged insulin above its isoelectric point. 
In Chapter 6, the uptake and transport of chitosan derivatives-insulin 
complexes in Caco-2 cells was studied and the mechanisms were delineated. All 
complexes were 200-400 nm in diameter, positively charged and displayed an 
insulin loading efficiency of approximately 90%. In vitro release of insulin from 
the complexes was dependent on the medium pH, and burst release occurred in 
1 h at pH 4.0. In contrast, less than 40% insulin was released at pH 7.4 in 6 h. 
Insulin uptake was enhanced by nanocomplex formation, and was incubation 
time, temperature and concentration dependent. Complex uptake in Caco-2 cells 
was inhibited significantly by cytochalasin D and marginally inhibited by 
metabolic inhibitors. The uptake mechanism was assumed to be adsorptive 
endocytosis. Additionally, the cell uptake efficiency was shown to be influenced 
by a combination of polymer molecular weight, viscosity and positive charge 
density. Complex internalization was further demonstrated by confocal 
microscopy. However, none of the nanocomplexes displayed improved transport 
properties when compared to insulin transport data after 2 h incubation with 
Caco-2 monolayers. In contrast, the complexes considerably enhanced insulin 
uptake or adhesion, with approximately 50% of insulin being attached or 
internalized in the cells after 2 h incubation, 3.5 fold higher compared with free 
insulin.  
In summary, PEGylated TMC copolymers of different MW were 
synthesized for the first time, and their cytotoxicity was characterized by MTT 
and LDH assay. The self-assembled PECs between polymer and insulin were 
prepared and characterized. Ability of the insulin nanocomplexes to enhance 
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intranasal delivery of insulin was evaluated with uptake and transport 
experiments in Caco-2 cells.  
 
Outlook 
   The transport results of the self-assembled PECs between chitosan 
copolymers and insulin in Caco-2 monolayers cast doubt on the ability of 
nanocomplexes to enhance insulin absorption in vivo. The release mechanism of 
insulin from the complexes in the subcellular compartment requires further 
investigation. Due to the difference between in vitro and in vivo conditions, the 
efficacy of the PEC for intranasal administration will be further investigated in 
vivo. Additionally, as a consequence of the decreased particle size, improved 
stability of the PEC prepared with the copolymers and the ability to be taken up 
by Caco-2 cells in an intact state, the bioavailability of the PEC via oral route 
will be subject to further investigation.  
   As a consequence of the sustained release characteristics of the complexes, 
and their enhanced uptake by the cells, we believe they will be promising 
intranasal delivery carriers for vaccines. They could also be used as carriers for 
anticancer drugs to target the central nervous system (CNS) by intranasal 
administration to avoid the blood brain barrier (BBB). 
   Preliminary experiments with the ethidium bromide assay demonstrated that 
the copolymers could condense DNA by complexation, with promising 
transfection capability already reported in cell culture experiments. Other 
investigations are currently ongoing. The relationship between polymer 
structure and transfection efficiency will be elucidated, and the promising 
complexes will be subsequently characterized in detail. 
We also believe that the biocompatibility and excellent solubility of the 
copolymers may make them ideal carriers for other peptides or proteins.
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